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ABSTRACT 
Christopher Mazzone: Contributions of Genetically Defined Cell Populations in the Extended Amygdala to 
Emotional Behavior 
(Under the direction of Thomas Kash) 
 
 Emotional disorders, including anxiety, remain pervasive and debilitating conditions throughout 
the world despite decades of progress in the development of pharmacological treatments. Limitations in 
treatment efficacy exist, in part, due to our lack of understanding of the precise neural pathways and 
mechanisms underlying emotional disorders. Here I focus on the extended amygdala, an area of the brain 
that has long been implicated in the regulation of emotional behaviors. In this dissertation work, I use 
combinatorial approaches to determine the cellular identity and receptors that contribute to anxiety so that 
we may better develop more selective drug treatments for emotional disorders. 
 In Chapter 2, I use Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) to 
manipulate G protein-coupled signaling pathways in a population of inhibitory cells of the bed nucleus of 
the stria terminalis (BNST), a component of the extended amygdala. This approach allowed us to identify 
that activation of Gq-coupled signaling pathways within inhibitory cells of the BNST is sufficient to induce 
an anxiety-like state in mice. I then identified endogenous Gq-coupled receptors expressed by inhibitory 
cells of the BNST, ultimately creating a list of potential candidate receptors for alleviating anxiety.  
 In Chapter 3, I further dissect BNST anxiety circuitry by focusing on the impact of serotonin on 
BNST corticotropin-releasing factor (CRF) expressing neurons. I show that the serotonergic input from the 
dorsal raphe (DR) nucleus to the BNST can induce both serotonin release and anxiety-like behavior. 
Using electrophysiological tools we found that serotonin produces opposing effects on membrane 
properties within BNST CRF neurons. Interestingly, selective serotonin reuptake inhibitors (SSRIs) are 
known to exacerbate learned fear responses and we found that inhibition of BNST CRF neurons is able to 
occlude the SSRI-induced enhancements of fear. These results highlight inhibition of BNST CRF neurons 
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as a potential therapeutic strategy for SSRI-induced increases in anxiety seen in patients during the early 
stages of SSRI-based therapies.  
 Together, these studies untangle part of the complex emotional circuits that may contribute to 
pathological emotional states and provide new therapeutic targets for the alleviation of both acute and 
SSRI-induced anxiety.   
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CHAPTER 1 INTRODUCTION 
1.1 Anxiety in Humans 
Anxiety disorders remain widely prevalent despite decades of research and pharmaceutical drug 
development. Each year, nearly 18% of the United States population can be diagnosed with an anxiety 
disorder, and lifetime prevalence affects nearly a third of the population (Kessler, 2005; Kessler et al., 
2007).These widespread chronic conditions are characterized by excessive fear and hypervigilance that 
can exert both high personal and economic costs (Whiteford et al., 2013; DiLuca & Olesen, 2014). 
Existing medical options for the treatment of anxiety-related conditions primarily focus on targeting the γ-
aminobutyric acid (GABA) and serotonin (5-HT) neurotransmitter systems through the actions of 
benzodiazepines and selective serotonin reuptake inhibitors (SSRIs), respectively. Other drug classes 
may be prescribed, such as 5-HT norepinephrine reuptake inhibitors, monoamine oxidase inhibitors 
(MAOIs), and tricyclic antidepressants, though benzodiazepines and SSRIs remain the first-line options 
(Griebel & Holmes, 2013). Unfortunately, side effect profiles or a reduction of drug efficacy mar the 
potential for long-term treatment of persistent anxiety disorders. For example, chronic treatment with 
benzodiazepines suffers from abuse potential, while SSRIs may take weeks of treatment before the 
alleviation of symptoms (O’brien, 2005; Hoffman & Mathew, 2008). This highlights the need to better 
understand the underlying neural circuitry for anxiety disorders so that we may better target and modulate 
the activity of defined cell types involved in the generation of anxiety states. 
In humans, functional magnetic resonance imaging (fMRI) studies have provided insights into the 
brain regions associated with anxiety-related conditions. Studies assessing the blood-oxygen-level 
dependent (BOLD) signal in patients with generalized anxiety disorder (GAD), social anxiety, or panic 
disorder (PD), have identified dysregulation in cortical areas, including the prefrontal cortex (PFC) and 
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anterior cingulate cortex (ACC) (Blair et al., 2008; Greenberg et al., 2013; Mochcovitch et al., 2014). 
Many studies have observed altered activity in subcortical structures as well, including the amygdala 
(Hoehn-Saric et al., 2004; Nitschke et al., 2009; Costafreda et al., 2008; Sergerie et al., 2008), however it 
should be noted that some studies have shown no differences, or a reduction, in amygdalar activity to 
emotional stimuli (Whalen et al., 2008; Etkin et al., 2010; Blair et al., 2008; Yassa et al., 2012).  
Interestingly, it has been proposed that in adult patients with GAD, there is reduced amygdala activity that 
correlates with enhanced activity in the bed nucleus of the stria terminalis (BNST), a component of the 
extended amygdala (Yassa et al., 2012). In keeping with this, previous studies have shown that BNST 
activity is elevated in humans during anxiety-evoking stimuli (Straube et al., 2007; Somerville et al., 2010; 
Avery et al., 2016). In one study, human patients with arachnophobia had elevated activity in the BNST 
that correlated with self-reports of anxiety following being told they would be presented with an image of a 
spider, while non-arachnophobic patients did not show elevated BNST activity during the same protocol 
(Straube et al., 2007). Similarly, in a study with human subjects without a diagnosed anxiety disorder, 
perceiving a spider to be near their feet elevated activity in the BNST in a proximity-dependent manner 
that correlated with self-reports of anxiety (Mobbs et al., 2010). Such studies have highlighted the BNST 
as a neural locus that is engaged during aversive emotional states. It is important to note that the small 
size of the BNST in humans makes it difficult to identify reactivity of discrete subregions, though recent 
advances in segmentation approaches may yield more discrete results (Theiss et al., 2016). 
Non-human primates also show similar increases in BNST activity during anxiety-evoking states. 
Changes in freezing behavior, a behavioral manifestation of anxiety and fear, correlated with BNST 
activity in rhesus macaques using positron emission tomography (PET) imaging (Kalin et al., 2005).  
These studies in humans and non-human primates highlight the BNST as a promising node in the 
regulation of anxiety. Although the BNST has been linked with anxiety in humans and non-human 
primates, the majority of the literature has used rodent models to characterize the involvement of brain 
nuclei and discrete cell populations in anxiety-related behavior, which we discuss below. 
1.2 Rodent Models of Anxiety- and Fear-Related Behavior 
While fMRI and PET imaging technologies allow for remarkable assessments of activity-driven 
changes in neural and metabolic function in humans, they unfortunately do not provide insights into the 
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specific contributions of discrete anatomical connections between brain nuclei or genetically defined cell 
populations to producing emotional states. We thus turn to animal models of emotional behavior to 
overcome these limitations and untangle the complex circuitry that governs emotion processing. 
Additional complexities arise given the subjectivity of emotional experiences and the controversial nature 
of associating animal behavior with human emotion (Anderson & Adolphs, 2014; LeDoux, 2012). 
Nonetheless, we can use emotional behavior in models organisms where the behavioral readout gives 
clues to the internal emotional state (Anderson & Adolphs, 2014).  
Importantly, a key aspect of an anxiety state is whether the emotional response can be defined as 
either trait or state anxiety. Trait anxiety refers to a non-evoked stable degree of anxiety, such as baseline 
anxiety levels, while state anxiety refers to anxiety experienced in a particular moment, especially 
following a stimulus (Lister, 1990). Due to the difficulty in assessing trait anxiety in animals, studies in 
rodents often capitalize on the state anxiety induced by exposure to novel environments. Generally, these 
tests involve a motivational conflict: the desire to explore the entirety of a novel environment versus 
remaining in safer aspects of the potentially threatening arena. One of the most common anxiety assays 
in rodents is the elevated plus maze (EPM). It consists of two intersecting platforms that create a plus-
shaped environment with four arms. Two of the arms are walled, thus generating two “safe” arms (walled) 
and two potentially threatening arms (open). When placed into the maze, a typical mouse will spend more 
time in the closed arms relative to the exposed open arms (Pellow et al., 1985). This general approach-
avoidance principle drives other exploratory-based anxiety assays as well. The light-dark box, for 
instance, features a two-compartment box with a well-lit “exposed” compartment, and one that is 
enclosed by dark walls. Similarly, an open field assay consists of a single large enclosed space, and the 
duration spent in the central area, as opposed to being near the walls, serves as an inverse measure of 
the degree of anxiety.  
Another assessment of anxiety-like behavior is the startle response to an unexpected stimulus. 
This is most commonly an acoustic stimulus in rodents. This acoustic startle response can be enhanced 
by a number of anxiogenic conditions, such as fear-potentiated, light-enhanced, and corticotropin 
releasing-factor (CRF)-enhanced startle (Davis et al., 2010). Fear-potentiated startle refers to the evoked 
startle amplitude in the presence of a conditioned stimulus (CS) that was previously paired with an 
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aversive unconditioned stimulus (US), which is most often a foot shock in rodents (Brown et al., 1951). It 
is important to note that in this assay, fear potentiates the existing startle response and is dependent on a 
learned conditioned fear. As described above, rodents are averse to bright lights. Taking advantage of 
this, the acoustic startle assay was modified to assess the effect of bright light exposure on the startle 
response, or light-enhanced startle (Walker & Michael Davis, 1997). Because light-enhanced startle 
capitalizes on an innate anxiogenic stimulus, it is independent of learning and thus allows probing of the 
effects of drugs selectively on an anxiety-dependent and not a learned fear-dependent behavior. In 
contrast to rodents, both humans and non-human primates show an enhanced startle response in dark 
environments. The magnitude of this dark-enhanced startle can be in exacerbated in human patients with 
post-traumatic stress disorder (PTSD) and rhesus monkeys separated from their mothers (Grillon et al., 
1997; Grillon et al., 1998; Parr et al., 2002). Thus, the amplitude of the acoustic startle response serves 
as an index anxiety. Lastly, in addition to both fear- and light-enhanced acoustic startle, the startle 
response can be potentiated by intracerebroventricular (ICV) infusion of corticotropin-releasing factor 
(CRF), a peptide involved in the stress response (Swerdlow et al., 1986). This is not an exhaustive list of 
assays designed to probe anxiety-related behavior. Others have adapted to include more motivated 
behaviors, such as novelty-induced suppression of feeding in which palatable food consumption is 
suppressed by a potentially threatening novel environment (Merali et al., 2003; Bodnoff et al., 1988). 
A critical aspect of behavioral assay design is whether it satisfies face, construct, and predicative 
validity. Face validity refers to the degree of similarity between the assayed phenotype and what is 
observed in the human state being modeled. For example, in the exploratory assays described above, a 
reduction in the time spent in the aversive zones is representative of avoidance of cues or contexts that 
trigger anxiety in people. To meet construct validity in animal models, the underlying biological 
mechanisms for the observed phenotype must be similar to those in humans. Construct validity is thus 
critical if an animal model is being used to identify potential circuits or therapeutic targets of interest for a 
given condition. Appropriate construct validity in rodent models of anxiety is what allows us to identify 
discrete neural circuits potentially involved in the generation of anxiety in humans. Lastly, the predicative 
validity of rodent models of anxiety-like behavior refers to the ability of the assay to screen therapeutic 
effects of pharmacological agents in humans. Thus, if an assay shows a compound is anxiolytic in 
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rodents, then the same compound should reduce anxiety in humans (Cryan & Holmes, 2005; Belzung & 
Griebel, 2001; Calhoon & Tye, 2015). However, drug side effect profiles may create potential caveats for 
the predictive efficacy of an assay. Benzodiazepines, for example, reduce anxiety in people, but also 
have sedative properties. As the anxiety assays described above are dependent on exploration of a novel 
environment, pharmacologically-induced sedation would produce a reduction in locomotor activity that is 
independent of anxiety. It is therefore crucial to interpret results of behavioral assays carefully, particularly 
with respect to changes in locomotion.  
1.3 Involvement of the Extended Amygdala in Anxiety and Fear 
 Decades of work using electrolytic lesioning, pharmacological manipulations, transgenic rodent 
lines, optogenetics, and chemogenetics have aided in untangling the neural circuits that drive anxiety and 
fear behavior (for review, see Calhoon & Tye, 2015; Adhikari, 2014; Janak & Tye, 2015). The results of 
these studies identified numerous brainwide networks that contribute to multiple components of anxiety 
and fear. Much work has implicated the prefrontal cortex, the basolateral amygdala (BLA), the 
hippocampus, and the extended amygdala, which consists of the CeA and the BNST (Alheid & Heimer, 
1988). In a pioneering study in rhesus macaques, aspiration of the amygdala reduced fear-related 
behavior and cue-related learning behavior (Weiskrantz, 1956). Similar results were later obtained 
through excitotoxic lesions of the amygdala that spared damage to fibers of passage, implicating the 
amygdala indeed played a role in the effect (Meunier et al., 1999). Human subjects with damage to the 
amygdala also show reductions in conditioned fear learning without impaired learning of declarative 
memories, thus highlighting the importance of amygdala in human fear (Bechara et al., 1995). Beyond 
humans and non-human primates, a wealth of studies in rodents further established that disruption of the 
BLA impairs fear and anxiety-related behavior (LeDoux, 2000; Shin & Liberzon, 2010; Janak & Tye, 
2015). As the BLA has direct projections to the extended amygdala, including the CeA and BNST, and 
the extended amygdala has direct projections to areas of the hypothalamus and brainstem known to be 
involved in anxiety, these regions and circuits became of high interest for the potential regulation of 
anxiety-related behavior.  
The extended amygdala was initially defined following early characterizations of the CeA and 
BNST that remarked on the similarities of these structures with respect to anatomical connectivity and 
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neurochemical makeup (Alheid & Heimer, 1988). To determine the unique contributions of the BNST and 
CeA to anxiety and fear behavior, seminal studies used electrolytic or pharmacological lesions to 
inactivate components of the extended amygdala nuclei during fear-related tasks (Davis et al., 1997; 
Walker et al., 2003; LeDoux et al., 1988; Gewirtz et al., 1998). In particular, lesions of the CeA abolished 
fear-potentiated startle, while BNST lesions had no effect (LeDoux et al., 1988; Lee & Davis, 1997; 
Hitchcock & Davis, 1991). Conversely, pharmacological inhibition of the BNST, but not CeA, blocked 
light-potentiated startle (Walker & M Davis, 1997). Pharmacological inhibition of the BLA, an upstream 
target of both the CeA and BNST, was sufficient to impair both fear-potentiated and light-potentiated 
acoustic startle (Walker & M Davis, 1997). These initial findings led to the theory that the BNST is not 
involved in shock-predicting cues (Walker et al., 2003). Together, these formative studies led to a model 
in which the CeA regulates fear (immediate predictable threats), while the BNST is involved in anxiety 
(ambiguous threats) (Walker et al., 2003).  
The drivers of anxiety and fear behavior are distinct between fear- and light-potentiated startle. In 
fear-potentiated startle a discrete cue predicts a temporally near aversive stimulus, while light-potentiated 
startle uses an innately anxiogenic stimulus to exacerbate startle responding. In other words, in one 
situation there is a cue predicting a known immediate threat, while in the other the threat is ambiguous 
and possibly nonexistent. In agreement with this, light-potentiated and fear-potentiated startle produce 
different effects on the duration of the startle increase following offset of the potentiating stimulus (De 
Jongh et al., 2003). Startle amplitude returns to baseline within seconds following offset of the conditioned 
stimulus in fear-potentiated startle, while startle amplitude remains elevated on the order of minutes in 
light-enhanced started (De Jongh et al., 2003). To better dissect the role of temporal proximity between a 
CS and US in engaging anxiety or fear behavior through BNST function, a critical study from Waddell et 
al. used a classic fear conditioning paradigm in which an auditory CS preceded a US of a foot shock 
(Waddell et al., 2006). BNST lesions did not disrupt the acquisition of conditioned fear learning when a 
short duration CS (1 minute) preceded a footshock, but impaired the acquisition of fear learning when a 
long-duration CS (10 minutes) preceded shock. This study further demonstrated that BNST lesions 
disrupt the reinstatement of fear responding and was sufficient to reduce anxiety-like behavior in the 
elevated plus maze (Waddell et al., 2006). It is important to consider that these findings do not entirely 
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dissociate the BNST and CeA functionally. Indeed, the CeA has direct projections to the BNST and 
lesions to the CeA can reduce CRF labeling in the BNST (Sakanaka et al., 1986). While the findings 
discussed above demonstrate that they are differentially engaged by select anxiety- or fear-provoking 
stimuli, the CeA and BNST are functionally interconnected and may serve feedback loops that contribute 
to broader circuit changes in activity. This interconnectivity is important to consider when assessing the 
modulatory roles various neurotransmitter and neuropeptide inputs have on BNST function (Kash et al., 
2015). 
1.4 Anatomical Characterization of the BNST 
Early observations that the BNST shared structural similarities with the CeA led to the idea of 
these structures forming an “extended amygdala” (Alheid & Heimer, 1988). In addition to structural 
parallels, the CeA and BNST were similar with respect to cellular morphology, anatomical connectivity, 
and cellular composition as determined by immunohistochemistry (Alheid & Heimer, 1988). As described 
above, decades of research has since dissected the unique contributions of the CeA and BNST to various 
fear-related and motivated behaviors to better distinguish the differences between these similar 
structures. However, discerning precisely how the BNST contributes to emotional behavior is made 
difficult by the structure’s diverse, and often reciprocal, projections throughout the brain (Figures 1.1 and 
1.2). The BNST receives glutamatergic projections from the medial prefrontal cortex, paraventricular 
thalamus, ventral hippocampus, and the BLA (Dong & Swanson, 2003; Hong Wei Dong et al., 2001; Kim 
et al., 2013). In addition to glutamatergic inputs, the BNST receives dopaminergic afferents from the 
ventral tegmental area (VTA) and the A10dc located in the periaqueductal gray (PAG) (Park et al., 2013; 
Hasue & Shammah-Lagnado, 2002; Meloni et al., 2006), serotonergic inputs from the dorsal raphe (DR) 
(Phelix et al., 1992), and noradrenergic inputs from the locus coeruleus (LC) and the nucleus of the 
solitary tract (NTS) (Forray et al., 2000; Park et al., 2009). The BNST also receives dense GABAergic and 
CRFergic inputs from the CeA (Sakanaka et al., 1986; Erb et al., 2001; Morin et al., 1999; Cummings et 
al., 1983; Silberman et al., 2013). The BNST sends direct projections to numerous nuclei throughout the 
brain, including areas of the hypothalamus, amygdala, VTA, PAG, DR, and parabrachial nucleus (PBN) 
that allow the BNST to modulate a diverse array of behaviors (Hong Wei Dong et al., 2001; Hong W. 
Dong et al., 2001; Choi et al., 2007; Kim et al., 2013).   
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Beyond having a complex connectivity architecture, the BNST itself can be subdivided into more 
than a dozen subnuclei in rodents. Early topographical tracing studies in rats aided to rigorously 
characterize the discrete connectivity differences between BNST subregions with respect to local and 
distal projections (Dong & Swanson, 2003; Dong et al., 2006; Dong & Swanson, 2006b; Dong & 
Swanson, 2004a; Hong Wei Dong et al., 2001; Dong & Swanson, 2006a; Dong & Swanson, 2004b; H W 
Dong et al., 2001). Although the exact number of subcompartments of the BNST remains controversial, it 
can be generally divided by its medial-lateral and anterior-posterior axes (Bota et al., 2012). Under this 
schematic, the anterior division can be divided into the following nuclei: anterolateral, anteromedial, oval, 
juxtacapsular, rhomboid, dorsomedial, fusiform, ventral, and magnocellular (Bota et al., 2012; Lebow & 
Chen, 2016). Conversely, the posterior compartments of the BNST consist of the principal, interfasicular, 
transverse (Lebow & Chen, 2016; Dong & Swanson, 2004a).  
1.5 Neuromodulation of BNST Function by Corticotropin-Releasing Factor and Serotonin 
Corticotropin-releasing factor (CRF) 
 CRF is the most studied neuropeptide within the BNST, and CRF overexpression is sufficient to 
induce anxiety-like behavior (Coste et al., 2001). Likewise, stress-inducing stimuli elevates expression of 
c-fos, an intermediate early gene, in CRF-expressing cells in of the paraventricular nucleus of the 
hypothalamus (PVN) and other brain nuclei (Ceccatelli et al., 1989). Originally viewed for its initiation of 
the HPA stress axis via release of CRF from neurons of the PVN, CRF expression has been observed in 
non-hypothalamic structures including the CeA and BNST (Heinrichs & Koob, 2004; Bale & Vale, 2004; 
Vale et al., 1981; Merchenthaler et al., 1982; Phelix & Paull, 1990; Cummings et al., 1983; Herman et al., 
2003). Further, CRF positive fibers within the BNST were found to be in close proximity to serotonergic 
fibers, highlighting the potential interplay between neurotransmitter and neuropeptide systems (Phelix et 
al., 1992). In agreement with this, a study demonstrated that exposure to a novel environment enhances 
intermediate early gene (IEG) c-fos expression in BNST CRF neurons, but this effect is absent in mice 
lacking the 5-HT2C receptor (Heisler et al., 2007). Adding to the complexity, BNST CRF neurons also 
express the neurotransmitter GABA (Dabrowska et al., 2013). ICV and systemic treatment with CRF has 
been shown to elevate stress-related behaviors, and stress exposure elevates CRF mRNA within the 
BNST (Dunn & Berridge, 1990; Funk et al., 2006). Of note, the density of CRF-expressing cells is largely 
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similar between mice and rats, though differences in CRF neuron density do exist (Wang et al., 2011).  
These data implicate the BNST, and the extended amygdala generally, as critical loci for CRF-mediated 
stress-induced behavior. 
Building upon this, intracerebroventricular (ICV) CRF enhances the startle response, which can 
be blocked by pharmacological lesions of the BNST using NMDA (Lee & Davis, 1997). Further, ICV α-
helical CRF, a CRF antagonist, is sufficient to blunt light-enhanced startle without altering fear-potentiated 
startle (De Jongh et al., 2003). Infusion of α-helical CRF directly into the BNST also blunts light-enhanced 
startle, indicating the BNST is a critical locus for anxiety-induced startle responding (Lee & Davis, 1997). 
As prior reports observed that cerebroventricular infusion of CRF could potentiate the acoustic startle 
response (Swerdlow et al., 1986), this finding further positioned the BNST as a critical component of the 
CRF-induced increase in anxiety. Importantly, CRF-enhanced startle persists despite lesioning of the 
paraventricular nucleus of the hypothalamus (PVN) (Liang et al., 1992). Together, these studies 
demonstrate that CRF-potentiated acoustic startle requires BNST CRF receptor activation and is 
independent of CRF-induced engagement of the hypothalamic-pituitary-adrenal (HPA) stress axis. 
Building upon this, a study assessing the involvement of the CeA and BNST in the expression of a 
learned cued fear identified that electrolytic lesions of the CeA disrupted expression of cued and 
contextual fear, while lesions of the BNST only disrupted the expression of contextual fear (Sullivan et al., 
2004). Corticosterone levels in this study paralleled the expression of learned fear, such that BNST 
lesions blunted context-induced increases in corticosterone (Sullivan et al., 2004).  
 Interestingly, CRF infusions to the BNST can induce reinstatement of cocaine seeking, while 
antagonism of CRF receptors in the BNST disrupts stress-induced drug seeking (Erb & Stewart, 1999; 
Wang et al., 2006). Interestingly, overexpression of CRF in the BNST using a lentiviral approach led to no 
changes in baseline anxiety behavior (Sink et al., 2013). Further, overexpression of CRF in the BNST 
prior to a startle conditioning task impairs acquisition of fear responding, while overexpression post 
training exacerbates fear behavior (Sink et al., 2013). These data highlight the complexities of CRF 
effects on anxiety and fear within the BNST.  
Part of the variance in behavioral response to CRF manipulations in the BNST may be attributed 
to the activation of CRF receptor subtypes. CRF binds to two types of G protein-coupled receptors: CRF-
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1 and CRF-2 (CRF1R and CRF2R, respectively) (Hauger et al., 2006; Chalmers et al., 1995; Lovenberg 
et al., 1995). Although both of these receptors are preferentially coupled to a Gs alpha subunit, activation 
of CRF1 and CRF2 receptors can produce differing responses within the BNST (Tran et al., 2014). Of 
note, however, CRF receptors are capable of binding other types of G proteins as well, including the Gq 
subunit (Grammatopoulos et al., 2001). CRF receptors may also be bound by the CRF-related urocortin 
(UCN) peptides UCN 1, UCN 2 (also called stresscopin-related peptide), and UCN 3 (also called 
stresscopin) (Vaughan et al., 1995; Reyes et al., 2001; Lewis et al., 2001). Availability of both CRF and 
UCN 1 can be reduced through interactions with CRF binding protein (CRF-BP), thus providing multiple 
means of modulating the activity of CRF receptors (Behan et al., 1995; Lewis et al., 2001; Seasholtz et 
al., 2002).  
In rats, infusion of CRF into the BNST was sufficient to induce anxiety-like behavior, while co-
administration of a CRF1R antagonist, but not a CRF2R antagonist, could block the CRF-induced 
increase in anxiety (Sahuque et al., 2006). In agreement with this, deletion of GABA(A)α1 receptors in 
CRF neurons increases anxiety-like behavior in a manner that can be blocked by CRF1R antagonism in 
the BNST (Gafford et al., 2012). Similarly, CRF1R is upregulated, while CRF2R is downregulated, in a rat 
model of PTSD, and lentiviral overexpression of CRF2R in PSTD-like rats is sufficient to blunt PTSD-
related fear behavior (Elharrar et al., 2013). However, CRF2R levels were increased in a mouse model of 
PTSD, while knockdown of CRFR2 in the BNST reduced the susceptibility of PTSD-related behavior 
(Lebow et al., 2012). CRF receptor expression differences in PTSD models could potentially result from 
differences in the types of stress exposure used to induce PTSD-like states. Regardless, the results from 
these studies implicate CRF receptor signaling in the BNST as a contributor to behavior during 
pathological states.  
The mechanistic underpinnings of these differences are complex. Within the BNST, CRF1R 
facilitates postsynaptic GABAergic signaling while also facilitating presynaptic glutamate release (Kash & 
Winder, 2006; Silberman et al., 2013). Given the diverse projections of the BNST, the localization of these 
effects is critical for the potential behavioral impact. CRF-induced enhancement of glutamatergic events 
in the BNST, for example, has been observed in VTA-projecting neurons (Silberman et al., 2013). This 
result is intriguing given that BNST projections to the VTA modulate anxiety and ethanol drinking behavior 
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(Jennings, Sparta, et al., 2013; Rinker et al., 2015). Interestingly, CRF depolarizes BNST neurons 
categorized as Type II, which are potentially BNST interneurons (Ide et al., 2013; Hammack et al., 2007). 
Additionally, CRF interacts with other neurotransmitter systems in the BNST as it has been shown that 
dopamine-induced increases in glutamatergic transmission in the BNST requires CRF1R activation (Kash 
et al., 2008). The source of CRF for both behavioral and electrophysiological effects remains unclear. As 
described above, the BNST contains both CRF-expressing cells and receives a dense CRF input from the 
CeA. Further dissection of local BNST microcircuits is required to fully assess the contributions of local 
CRF release to both behavior and synaptic events. 
Serotonin (5-hydroxytryptamine; 5-HT) 
 5-HT has long been implicated in emotion regulation, particularly depression, and many 
pharmaceutical treatments for affective disorders target the 5-HT system (Griebel & Holmes, 2013; 
Berger et al., 2009; Asan et al., 2013; Graeff, 2002; Jasinska et al., 2012; Wise et al., 1972). Unlike the 
broad brain-wide distribution of most neurotransmitter and neuropeptide systems, the majority of 
serotonergic cells are located in the DR nucleus (Fuxe, 1965). DR 5-HT neurons receive diverse inputs 
from forebrain and brainstem nuclei, thus allowing the 5-HT system to integrate inputs from throughout 
the brain (Pollak Dorocic et al., 2014). Likewise, DR 5-HT neurons project throughout the brain and 
regulate an array of biological and neuropsychological functions, including mood, sleep, appetite, and 
affect (Berger et al., 2009). In agreement with this, acute diet-induced reductions in tryptophan, the 
precursor for 5-HT, is sufficient to elevate anxiety-related startle in humans (Robinson et al., 2012). In 
rodents, DR 5-HT neurons are engaged by multiple types of stressful stimuli and can be directly activated 
by CRF (Hammack et al., 2002; Hammack et al., 2003; Kirby et al., 2000; Lowry et al., 2000). Elevated 
synaptic 5-HT release is also observed in the amygdala and PFC upon exposure to psychological threats 
(Kawahara et al., 1993). The cellular effects of 5-HT signaling occur through 5-HT binding of fourteen 
subtypes of 5-HT receptors (divided into classes of 5-HT1 – 5-HT7) that are localized to both pre- and 
postsynaptic membranes (Roth, 1994; Asan et al., 2013; Hannon & Hoyer, 2008; Barnes & Sharp, 1999). 
5-HT receptor subtypes are G protein-coupled receptors that bind various G alpha subunits with the 
exception of the ionotropic 5-HT3 receptor. This heterogeneity allows 5-HT to modulate pre- and 
postsynaptic function through the engagement of an array of G protein-mediated signaling cascades. The 
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family of 5-HT1 receptors preferentially bind Gi/o, thereby leading to reductions in cyclic AMP (cAMP) 
production and a hyperpolarization resulting from activation of inwardly rectifying potassium channels 
(Polter & Li, 2010). 5-HT1A receptor function can be divided into autoreceptor or heteroreceptor activity. 
As an autoreceptor, 5-HT1A receptors are located on presynaptic and somatodendritic membranes of 
serotonergic neurons of the raphe nucleus, ultimately reducing the firing of serotonergic neurons (Polter & 
Li, 2010). Conversely, postsynaptic localization of 5-HT1A heteroceptors function as the predominant 
inhibitory postsynaptic 5-HT receptor in the forebrain (Garcia-Garcia et al., 2014). This positions the 5-
HT1A receptor as a modulator of both the synaptic levels of 5-HT release and the magnitude of the 
postsynaptic response. Given this broad role for 5-HT1A receptor signaling, it is not surprising that 
disruption of 5-HT1A receptor function or expression alters numerous behavioral states. In contrast to the 
5-HT1A receptor, the 5-HT2 family of receptors preferentially couple to Gq subunits and have excitatory 
effects through activation of the phospholipase C (PLC) signaling pathways and inhibition of potassium 
channels (Polter & Li, 2010; Asan et al., 2013).  
   Behavioral pharmacology and genetic manipulation studies in rodents have identified 5-HT 
receptor involvement in mediating anxiety and fear-related behaviors. Numerous studies have identified 
the 5-HT2C receptor is involved in modulating anxiety-related behavior. Specifically, it was identified that 
antagonism of 5-HT2 signaling, through oral administration of a 5-HT2 family antagonist, reduced anxiety-
like behavior in mice tested on the elevated plus maze (Stutzmann et al., 1991). Similarly, agonism of the 
5-HT2C receptor using meta-cholorophenylpiperazine (mCPP) or 6-chloro-2[1-piperazinyl] pyrazine (MK-
212) induces anxiety-related behavior in rodents (Kennett et al., 1989; De Mello Cruz et al., 2005; Hackler 
et al., 2007). Antagonism of 5-HT2C receptors induces anxiety and panic-like episodes in both normal 
healthy subjects and in patients suffering from panic disorder (Charney et al., 1987). Adding to the role of 
5-HT in regulating emotional behavior, patients suffering from major depressive disorder (MDD) have 
reduced blood platelet levels of 5-HT and the 5-HT precursor L-trypotphan (Maurer-Spurej et al., 2007; 
Ogawa et al., 2014). These results, coupled with the clinical observations that drugs elevating 5-HT levels 
have remained the most effective treatments for depressive disorders, have contributed to the 5-HT 
hypothesis of depression disorders (Fakhoury, 2016). Further, the involvement of 5-HT receptors in 
mediating the effects of anxiety and depression is consistent with high clinical comorbidity of anxiety and 
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depression (Gorwood, 2004; Ballenger, 1999). It is thus unsurprising that pharmacological targeting of the 
5-HT system remains the most common form of clinical treatment for patients suffering emotional 
disorders. 
Selective serotonin reuptake inhibitors (SSRIs) are a first-line treatment for many anxiety and 
depressive disorders (Griebel & Holmes, 2013). Mechanistically, SSRIs act by elevating synaptic levels of 
5-HT through blockade of the serotonin reuptake transporter, which is localized to serotonergic neurons 
(Austin et al., 1994). While such results are in agreement with data showing 5-HT levels are reduced in 
patients diagnosed with MDD, this is not without caveats. Therapeutic benefits of SSRIs require multiple 
weeks of treatment, and acute responses to SSRIs can exacerbate anxiety, fear, and suicidal ideation in 
human patients (Grillon et al., 2007; Griebel & Holmes, 2013; Gorman et al., 1987; Fergusson et al., 
2005). Interestingly, the therapeutic benefits of chronic SSRI treatment are not limited to patients suffering 
from a psychiatric illness. Chronic SSRI treatment has been sufficient to reduce anxiety-related behavior 
in healthy patients (Grillon et al., 2009). This study further demonstrated that the therapeutic benefits of 
SSRI treatment in healthy subjects were limited to context-induced anxiety, and not cue-evoked fear 
behavior. The dissociation of context- and cue-evoked fear is of particular interest given the complex 
modulation of anxiety and fear responses within the extended amygdala. As the BNST is largely 
considered to mediate anxiety-related behaviors, it is possible the therapeutic benefits of SSRI treatment 
are mediated through changes in BNST function.  
Although it may seem counter-intuitive that initial response to SSRIs, and therefore elevated 
synaptic levels of 5-HT, can worsen symptoms of anxiety and depression, similar results have been 
widely observed in rodents (Burghardt et al., 2004; Mombereau et al., 2010; Burghardt et al., 2007; 
Ravinder et al., 2011; Belzung et al., 2001). As the acute aversive effects of SSRI administration increase 
anxiety and fear behavior, the extended amygdala has been an intriguing structure that could mediate 
these effects. Both the CeA and BNST receive serotonergic afferents from the DR nucleus (Commons et 
al., 2003). Of particular interest, serotonergic fibers in the BNST are present near CRF-expressing cells, 
and some serotonergic cells of the DR also express CRF (Commons et al., 2003; Phelix et al., 1992). In 
keeping with this, systemic administration of the 5-HT2C receptor agonist mCPP increases anxiety-like 
behavior and elevates c-fos expression in the BNST (Singewald et al., 2003).  To better probe the 
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underlying circuitry of 5-HT induced effects on anxiety, recent work has used behavioral pharmacology 
and site-directed infusion of drugs targeting 5-HT receptors to various brain areas.  
1.6 Optogenetic and Chemogenetic Tools for Modulating Discrete Neural Circuits 
 As detailed above, the neural circuits underlying emotional behavior are complex, interconnected, 
and composed of vastly heterogeneous cell types. We have begun to untangle these circuits through a 
wealth of behavioral studies employing the use of transgenic rodent lines, pharmacological or electrolytic 
lesions of discrete brain nuclei, or local pharmacological manipulations that have all provided useful 
insights into circuits that drive discrete behaviors. A caveat to these approaches, however, is the ability to 
directly modulate activity of cell types defined by anatomical connectivity or genetic identity within brain 
nuclei of interest. For example, while pharmacological inhibition of a brain nucleus is possible through 
cannulation and infusion of drugs targeting endogenous receptors, this approach is unable to selectively 
target cells that project to another nucleus of interest. This is critical, as recent studies using optogenetic 
approaches have demonstrated that both anatomical outputs or genetic identities of cell types within a 
nucleus contribute to the ultimate behavioral effect following activation (Kim et al., 2013; Jennings, 
Sparta, et al., 2013).  
 Optogenetics provides a temporally precise way of selectively activating or inhibiting neurons 
through optical activation of light-sensitive proteins that can directly influence action potential firing 
(Boyden et al., 2005; Deisseroth, 2011). Channelrhodopsin-2 (ChR2) is a light-sensitive protein naturally 
found in the algae Chlamydomanas reinhardtii that undergoes a conformational change upon stimulation 
with blue light that results in the influx of cations through the channel (Nagel et al., 2003; Zhang et al., 
2011). Similarly, light-sensitive GPCRs have been developed for optical manipulation of intracellular 
signaling (Airan et al., 2009). While ChR2 remains the most common optogenetic tool for stimulating cells, 
the optogenetic toolbox has grown to include inhibitory opsins, step-function opsins (SFOs), and an array 
of optically stimulated cation channels with various kinetic properties (Tye & Deisseroth, 2012; Klapoetke 
et al., 2014; Lin et al., 2009; Zhang et al., 2007; Chow et al., 2010; Berndt et al., 2009). Pioneering 
studies demonstrated that optical stimulation of genetically defined cell types in mice could induce action 
potential firing and alter behavior (Adamantidis et al., 2007; Tsai et al., 2009). Later work identified that 
implantation of optical fibers above ChR2-expressing axon terminals in downstream brain areas allowed 
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for in vivo stimulation of discrete neural projections (Tye et al., 2011). These landmark optogenetic 
studies demonstrated how light-sensitive opsins provide a precise way of manipulating discrete cell types 
and projections in vivo.  
In contrast to optogenetics, chemogenetics refers to the use of proteins that have been modified 
to bind previously unassociated compounds (Roth, 2016). In neuroscience, the most common 
chemogenetic tools are the Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) 
that are modified G protein-coupled receptors (GPCRs) that are coupled to the canonical G alpha 
subunits (Gs, Gi, and Gq) (Armbruster et al., 2007; Guettier et al., 2009). The original DREADD 
constructs are modified muscarinic receptors that are activated by the inert ligand clozapine n-oxide 
(CNO) (Armbruster et al., 2007). However, alternative ligands have also been discovered, including 
perlapine and compound 21 (Chen et al., 2015). An advantage of these compounds is that they avoid the 
back-metabolism of CNO to clozapine that occurs in humans (Jann et al., 1994).  While the most 
commonly used DREADD constructs are modified muscarinic receptors, additional DREADD variants 
exist, such as a modified κ-opioid receptor DREADD (KORD) that is exclusively activated by the inert 
compound salvinorin B (Vardy et al., 2015). Combination of DREADD constructs that are activated by 
discrete ligands allows for temporal modification of multiple discrete G protein-coupled signaling 
pathways, such as combining the use of the CNO activated hM3Dq receptor and the salvinorin B 
activated KORD (Vardy et al., 2015).  
Engagement of G proteins coupled to DREADDs can induce changes in membrane potential and 
can alter expression of intermediate early genes (Alexander et al., 2009; Nakajima et al., 2016). It is 
important to note that this approach differs from optogenetic strategies using light-gated ion channels, 
including ChR2, halorhodopsin, and archaerhodopsin, in that changes in cellular activity are downstream 
of the receptor manipulation. Light-gated ion channels allow for a direct means of altering ion influx or 
efflux, thus directly altering membrane potential and action potential firing within milliseconds, while G 
protein-coupled DREADDs require interaction with endogenous signaling cascades to induce changes in 
neuronal activity and excitability. However, while used less than chemogenetic tools, light-gated G 
protein-coupled receptors also exist, such as ChARGe, Rh-CT, and OptoXR (Zemelman et al., 2002; Oh 
et al., 2010; Airan et al., 2009).  
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While DREADD technology allows for the modulation of discrete G protein-coupled signaling 
pathways, it is important to consider the mechanism underlying DREADD-induced effects. Early 
assessments of hM3Dq DREADD receptor function observed that bath application of CNO induces a 
depolarization of CA1 pyramidal neurons, which is blocked in the presence of a PLC inhibitor, indicating 
that the depolarization observed required the canonical Gq-coupled signaling cascade (Alexander et al., 
2009). Further, activation of the hM3Dq DREADD induced an increase in action potential firing, verifying 
that Gq stimulation increases activity and action potential probability. This technology has also been 
extended to modulate activity of other cell types, including increasing Ca2 release of astrocytes, smooth 
muscle cells, and various others (Agulhon et al., 2013; Armbruster et al., 2007; Guettier et al., 2009; Roth, 
2016). Stimulation of Gq signaling with hM3Dq increases phosphorylation of ERK-1/2 in smooth muscle 
cells, highlighting the recruitment of endogenous second messenger systems (Armbruster et al., 2007). 
The inhibitory effects of the Gi-coupled hM4Di and KORD appear to occur through multiple classic 
signaling mechanisms. In part, hyperpolarization is mediated through the activation of G protein inward 
rectifying potassium (GIRK) channels by the Gβγ subunit (Armbruster et al., 2007). The hM4Di-induced 
hyperpolarization has been observed in multiple brain regions, including within the BNST (Pleil et al., 
2015). In addition to hyperpolarization effects, stimulation of Gi-coupled DREADD activity reduces 
neurotransmitter release probability and the frequency of postsynaptic currents (Stachniak et al., 2014; 
Vardy et al., 2015). Beyond acute cellular effects, recent evidence has demonstrated that ex vivo 
stimulation of Gi-DREADD expressing CA1 neurons can alter long-term forms of synaptic plasticity 
(López et al., 2016). It is likely that other mechanisms contribute to the reduction in synaptic release, 
including inhibition of presynaptic Ca2 channels and interactions with proteins involved with synaptic 
vesicle fusion (Gerachshenko et al., 2005; Blackmer et al., 2005). 
As with optogenetic approaches, DREADDs can be delivered to target cells using viral vectors 
that encode DREADD constructs. As DREADDs are activated by exogenous administration of CNO, 
many routes of administration are available depending on the experimental design. Acute systemic 
injections of CNO provide a temporally controlled stimulation of DREADDs, while chronic activation can 
be achieved through inclusion of CNO in home cage drinking water (Urban et al., 2015). CNO can also be 
locally infused both in somatic regions or at DREADD-expressing axon terminals to directly stimulate 
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distinct pathways (Rinker et al., 2015). DREADDs have been used to identify distinct GPCR-mediated 
signaling pathways involved in a number of behaviors, including feeding (Krashes et al., 2014; Krashes et 
al., 2011; Atasoy et al., 2012), reward (Chang et al., 2015; Ward et al., 2015), fear (Yau & McNally, 2015; 
López et al., 2016), pain (Peirs et al., 2015; Bourane et al., 2015), and depression (Urban et al., 2015). 
Further, a recent study identified that Gq- vs Gs-coupled DREADD activation differentially stimulates 
neurotransmitter and neuropeptide effects on feeding within the arcuate nucleus, respectively (Nakajima 
et al., 2016). Modulation of neural circuits using DREADDs is not limited to behavioral output. Studies 
coupling DREADD activation with positron emission tomography (PET) imaging have identified metabolic 
changes induced by DREADD activation throughout the brain (Michaelides et al., 2013; Anderson et al., 
2013; Urban et al., 2015). This combinatorial approach is referred to as DREADD Assisted Metabolic 
Mapping (DREAMM) (Michaelides et al., 2013). Chemogenetic approaches are particularly valuable given 
that the majority of pharmaceutical drugs developed target GPCRs, thus identification of these signaling 
pathways is valuable for future drug discovery (Rogan & Roth, 2011). 
1.7 Dissecting Contributions of Signaling within the BNST to Anxiety and Fear-Related Behavior 
 The heterogeneity of the BNST with respect to both neurotransmitter and neuropeptide content 
provides a wealth of opportunity for identifying new discrete circuits and signaling mechanisms that drive 
anxiety and fear behavior. Exciting recent discoveries have highlighted how discrete outputs of the BNST 
can produce opposing anxiety responses (Kim et al., 2013; Jennings, Sparta, et al., 2013), thus 
implicating the importance of these smaller projection-defined subpopulations of cells as targets for 
mediating particular affective states. These landmark studies used a combination of transgenic mouse 
lines with viral delivery of light-sensitive opsins to drive discrete projections of genetically defined cell 
types to identify select pathways that mediate the behavioral and autonomic components of anxiety. 
Interestingly, broad inhibition of the BNST with glutamate receptor antagonists reduced anxiety-like 
behavior, but optical stimulation and activation of multiple discrete BNST outputs reduced anxiety-like 
behavior. Further, optical stimulation of the BNST projection to the PBN had no effect on anxiety 
behavior, but did suppress respiration rate (Kim et al., 2013). Similarly, optical stimulation of GABAergic 
projections to the LH and VTA reduced anxiety-like behavior (Jennings, Rizzi, et al., 2013; Jennings, 
Sparta, et al., 2013; Kim et al., 2013). These findings are critical to untangling the behavioral and 
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emotional components modulated by extended amygdala circuitry. In this dissertation, I used a 
combination of optogenetic and chemogenetic strategies to identify both anatomical pathways and 
intracellular G protein-mediated signaling pathways that contribute to anxiety and fear within the BNST.   
 Discerning the circuits and cell types that drive various types of behavior will hopefully lead to the 
identification of cell populations to target for therapeutic manipulations. Although efforts are being made 
to use viral introduction of DREADDs in humans and non-human primates, we can still benefit from 
identifying endogenous GPCRs coupled to identified signaling pathways of interest. We touch on this 
approach in Chapter 2 where we used identification of a GPCR pathway in a genetically defined 
population of cells within the BNST to discern a potential target that may affect anxiety behavior. Further 
characterization of this cell type yielded endogenous receptors coupled to the same GPCR-mediated 
signaling pathway that affected anxiety, thus providing novel targets within the BNST for modulation of 
the anxious state. Building upon this, we also identify brain-wide changes in metabolic activity associated 
with this signaling pathway, leading to a possible measureable endophenotype that could be a predictor 
of activity in the brain during anxiety. Manipulations of one aspect of a circuit will produce changes in 
activity downstream, so we hope that metabolic mapping of network function can produce both a marker 
of the disease state and a readout of whether treatments are returning a network state to normal levels of 
activity.   
 It is important to also consider that modulation of circuits in rodents during the naïve state, by 
pharmacological, optogenetic, or chemogenetic means, is only one piece of the emotional circuit puzzle. 
As stress exposure and withdrawal from drugs of abuse is known to change activity of forebrain and 
limbic structures, we also need to identify how manipulation of circuits and signaling pathways under 
anxiety- and fear-inducing conditions affects subsequent behavior following stress or withdrawal. We 
consider this in Chapter 3 in a study in which we identify that activation of Gi-coupled signaling in BNST 
CRF neurons during fear learning does not affect subsequent fear expression, but is sufficient to block 
SSRI-induced enhancement of fear. This last point is of particular relevance for the potential therapeutic 
prevention of disorders such as PTSD, in which a devastatingly stressful event produces long-lasting 
changes in emotional circuitry that result in debilitating and exaggerated responses to previously 
innocuous environmental or internal stimuli. Perhaps targeted inhibition of cells identified to be critical in 
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producing the long-lasting changes in circuit function could blunt or prevent this development. Here we 
explore and discuss this possibility.   
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1.8 Figures 
 
Figure 1.1: Synaptic inputs to the BNST. The BNST receives an array of inputs from the throughout the 
brain. Colors indicate known types of neurotransmitter inputs. CeA, central nucleus of the amygdala; LH, 
lateral hypothalamus; PFC, prefrontal cortex; PVT, paraventricular nucleus of the thalamus; VTA, ventral 
tegmental area; LC, locus coeruleus; PAG, periaqueductal gray; DR, dorsal raphe nucleus; PBN, 
parabrachial nucleus; NTS, nucleus of the solitary tract; BLA, basolateral amygdala. 
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Figure 1.2: Synaptic outputs of the BNST. The BNST sends an array of projections to limbic and 
hindbrain structures. Colors indicate known types of neurotransmitter output. CeA, central nucleus of the 
amygdala; LH, lateral hypothalamus; PFC, prefrontal cortex; PVT, paraventricular nucleus of the 
thalamus; VTA, ventral tegmental area; LC, locus coeruleus; PAG, periaqueductal gray; DR, dorsal raphe 
nucleus; PBN, parabrachial nucleus; NTS, nucleus of the solitary tract; BLA, basolateral amygdala. 
  
 22  
 
 
 
 
CHAPTER 2 CHEMOGENETIC MODULATION OF Gq-COUPLED GPCR SIGNALING IN THE BNST 
INDUCES ANXIETY-RELATED BEHAVIOR1 
2.1 Historical Context 
Anxiety disorders, including generalized anxiety disorder (GAD), panic disorder, and social 
anxiety disorder, are prevalent neuropsychiatric conditions. Despite decades of research and the 
availability of diverse pharmacological treatment options, few treatments for these disorders remain 
effective long-term (Griebel & Holmes, 2013; Kessler, 2005; Kessler et al., 2007; Insel, 2012). In order to 
develop better therapies, it is important to understand the complex neural networks spanning cortical, 
limbic, and hindbrain nuclei that control both the behavioral and autonomic components of anxiety states 
(Calhoon & Tye, 2015). One brain region that has long been associated with modulating such states is 
the bed nucleus of the stria terminalis (BNST; recently reviewed in (Daniel & Rainnie, 2015; Lebow & 
Chen, 2016)). This ventral forebrain structure has a large population of GABAergic neurons and has 
reciprocal projections with numerous limbic and hindbrain nuclei (Sun & Cassell, 1993; Dong & Swanson, 
2004a; Dong & Swanson, 2006a). Such diverse connectivity allows the BNST to function as a critical 
relay center for regulating a range of emotional and motivational processes. In humans, the BNST has 
elevated activity during anticipatory threat, and in rodents, broad inhibition of the BNST reduces anxiety-
like behavior (Straube et al., 2007; Mobbs et al., 2010; Dean Mobbs et al., 2013; Somerville et al., 2010; 
Kim et al., 2013).  However, optogenetic activation of discrete BNST outputs can also reduce anxiety-like 
behavior, highlighting how BNST stimulation can have opposing regulatory processes (Kim et al., 2013; 
Jennings, Sparta, et al., 2013). Increased activity within the BNST is associated with elevated anxiety 
states in both humans (Straube et al., 2007; Somerville et al., 2010; Yassa et al., 2012) and non-human 
primates (A. S. Fox et al., 2008; Kalin et al., 2005), while lesioning or pharmacological inhibition of the 
BNST reduces anxiety-like behavior (Lee & Davis, 1997; Walker & M Davis, 1997; Waddell et al., 2006; 
                                                     
1 This chapter was previously published as an article in Molecular Psychiatry. Some minor adjustments 
have been made to accommodate dissertation formatting. The original citation is as follows: Mazzone, 
CM, et al., “Acute engagement of Gq-mediated signaling in the bed nucleus of the stria terminalis induces 
anxiety-like behavior.” Molecular Psychiatry. In press. 
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Kim et al., 2013). Thus, the BNST is an important nucleus in the regulation of anxiety and studies aimed 
at better understanding the role of the BNST in anxiety are important for the development of more 
effective therapeutics. 
In addition to complex anatomical connectivity, the BNST expresses an array of ionotropic 
channels and metabotropic G-protein coupled receptors (GPCRs) for both neurotransmitter and 
neuropeptidergic systems (Kash, 2012; Kash et al., 2015). Pharmacological and ex vivo slice 
electrophysiology studies have demonstrated that local infusion of GPCR ligands into the BNST can 
produce changes in anxiety-like behavior and synaptic function, but the broader effects of downstream 
network activity remain unknown (Khoshbouei et al., 2002; Walker, Miles, et al., 2009; Walker, Yang, et 
al., 2009; Hammack, Cheung, et al., 2009; Levita et al., 2004; J. H. Fox et al., 2008). Treatment with an 
α1-receptor antagonist, for example, can blunt stress-induced increases in anxiety, and restraint stress 
elevates norepinephrine release in the BNST (Khoshbouei et al., 2002). 5-HT2c knockout (KO) mice show 
blunted anxiety and reduced c-fos induction in corticotropin-releasing factor (CRF)-expressing cells of the 
BNST following an anxiogenic stimulus (Heisler et al., 2007). While these studies highlight the importance 
of GPCR-coupled signaling and anxiety within the BNST, they are unable to determine whether the 
effects are driven by pre- or postsynaptic mechanisms.  Here we provide the first characterization of the 
behavioral and network consequences following activation of Gq-mediated signaling within BNST VGAT-
expressing neurons using chemogenetic approaches. Further, we identify endogenous Gq-coupled GPCR 
expression in BNST VGAT neurons at the single cell level that may provide useful targets for modulating 
anxiety-like states.     
2.2 Methods 
Mice: All animals (>8 weeks old) were group housed on a 12 hour light cycle (lights on at 7 a.m.) with ad 
libitum access to rodent chow and water, unless described otherwise. VGAT-ires-Cre (VGAT-Cre) mice 
were provided by Dr. Bradford Lowell (Harvard University) and have been described previously (Vong et 
al., 2011). To isolate BNST VGAT neurons for single-cell qPCR and whole-cell patch clamp 
electrophysiology, VGAT-Cre mice were crossed with a Rosa26-floxed-stop-L10-GFP reporter line 
(VGAT-L10)(Krashes et al., 2014). Only male mice were used for behavioral, DREAMM, and single-cell 
profiling experiments. Male and female mice were used for electrophysiological recordings and in situ 
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hybridization experiments as described below. All procedures were conducted in accordance with the 
National Institutes of Health guidelines for animal research and with the approval of the Institutional 
Animal Care and Use Committee at the University of North Carolina at Chapel Hill.  For acoustic startle 
assessment, eight week old, male C57BL/6J mice (n = 16) were obtained from Jackson Laboratories in 
Bar Harbor, Maine. Mice were housed in groups of four in standard acrylic cages (24 cm (W) × 45cm (D) 
× 20cm (H)) located in an Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) approved conventional animal facility. Mice were maintained on a 12 h light/dark cycle (lights 
on at 07:00 h) with food and water available at all times. All procedures were approved by the University 
of Vermont Animal Care and Use Committee.  
Viruses and tracers: All AAV viruses were produced by the Gene Therapy Center Vector Core at the 
University of North Carolina at Chapel Hill and had titers of >1012 genome copies/mL. For chemogenetic 
manipulations, mice were bilaterally injected with 0.4-0.5 µl of rAAV8-hsyn-DIO-mCherry, rAAV8-hsyn-
DIO-hM3Dq-mCherry, rAAV8-hsyn-DIO-hM4Di-mCherry, or rAAV8-hsyn-DIO-rM3Ds.  
Stereotaxic injections: Adult mice (>8 weeks) were deeply anesthetized with 5% isoflurane (vol/vol) in 
oxygen and placed into a stereotactic frame (Kopf Instruments) while on a heated pad. Sedation was 
maintained at 1.5-2.5% isoflurane during surgery. Following 3 alternating swabs with betadine and 70% 
ethanol, an incision was made down the midline of the scalp, a burr hole was drilled above the target 
regions, and viruses were microinjected using a 1 µl Neuros Hamilton syringe at a rate of 100 nl/min. 
After infusion, the needle was left in place for at least an additional 5 minutes to allow for diffusion of the 
virus before being slowly withdrawn.  Injection coordinates for the BNST were (in mm: midline, Bregma, 
dorsal surface): ±0.9 – 1.10, 0.30, -4.35 (Paxinos & Franklin, 2008). Following surgery, all mice were 
returned to group housing. Mice were allowed to recover for at least 3 weeks prior to the start of 
experiments.  
BNST cannulation: Cannulae were obtained from Plastics One (Roanoke, VA). The cannulae used had 
a 22 gauge inner diameter and extended 5 mm below the 4mm pedestal. Injection cannulae had an inner 
diameter of 28 gauge and were 9.5 mm long and projected 0.5 mm beyond the guide cannula. Mice were 
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anesthetized using 2% Isoflurane and oxygen and then placed into a stereotaxic instrument (Steolting, 
Wood Dale, Illinois). The scalps of the mice were shaved and then scrubbed in alternate with 9% 
betadine and 95% ethyl alcohol. The scalp was opened using a cut along the midline and then the skull 
was lightly scraped with the edge of a scalpel blade to remove fascia. A small burr hole was drilled in the 
skull where each cannula was lowered. Coordinates were 0.3 mm anterior to Bregma, 2.6 mm lateral, and 
4.2 mm ventral. The cannulae were lowered at a 20 degree angle in order to avoid hitting the ventricles 
that lie dorsal and medial to the BNST. The same procedure was done for both the left and right BNST. 
After lowering both cannulae, they were affixed to the skull using glue (Loctite 454, Locktite, Westlake, 
OH) and a glue hardening accelerator (Loctite 7542).  Mice were given 0.05mg/kg of buprenorphine prior 
to being removed from the sterotaxic apparatus. The mice were allowed to recover under a heat lamp 
prior to being returned to their home cage and the colony room. Mice were monitored daily and received 3 
more doses of buprenorphine to help alleviate pain associated with the surgical procedure.  
Drugs: Tetrodotoxin (TTX) and picrotoxin were purchased from Abcam, while U73122, SR 141716A, and 
meta-Chlorophenylpiperazine (mCPP) were purchased from Tocris. Clozapine N-oxide (CNO) was 
generously provided by Dr. Bryan Roth (University of North Carolina). 
Electrophysiology: Mice were decapitated following deep isoflurane anesthesia, then brains were 
extracted and placed in ice-cold sucrose artificial cerebrospinal fluid (aCSF) containing (in mM) 194 
sucrose, 20 NaCl, 4.4 KCl, 2 CaCl2, 1 MgCl2, 1.2 NaH2PO4, 10.0 glucose, and 26.0 NaHCO3 saturated 
with 95% O2/5% CO2. Coronal sections of the BNST were sliced at 300 µm on a Leica 1200S vibratome 
at 0.07 mm/s. Slices were incubated in a heated holding chamber containing normal, oxygenated aCSF 
[(in mM): 124 NaCl, 4.4 KCl, 2 CaCl2, 1.2 MgSO4, 1 NaH2PO4, 10.0 glucose, and 26.0 NaHCO3] 
maintained at 32 ± 1˚C for at least 1 hour before recording. Slices were then transferred to a recording 
chamber (Warner Instruments), submerged in normal, oxygenated aCSF and maintained at 28-30˚C with 
a flow rate of 2 ml/min and allowed to incubate for 30 minutes. Female mice were used for recordings 
validating Gq DREADD function and Long-term depression (LTD) experiments, while male and female 
mice were used to verify hM4Di-induced hyperpolarization in response to CNO. Neurons of the BNST 
were visualized using infrared differential interference contrast (DIC) video-enhanced microscopy 
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(Olympus) and DREADD-expressing cells were identified by mCherry fluorescence. Whole-cell patch 
clamp recordings were made in current clamp mode with a potassium gluconate-based intracellular 
solution [(in mM): 135 K-gluconate, 5 NaCl, 2 MgCl2, 10 HEPES, 0.6 EGTA, 4 Na2ATP, 0.4 Na2GTP, pH 
7.3, 289–292mOsmol]. To record CNO-induced depolarization of Gq-DREADD expressing VGAT neurons 
in the presence of 0.5 µM TTX, 10 µM CNO was bath applied for 5 minutes after a four-minute baseline. 
The CNO-induced depolarization was calculated as the difference between the resting membrane 
potential (RMP) during the last 2 minutes of CNO application and the RMP 2 minutes before CNO 
reached the bath.  To assess the effects of phospholipase C (PLC) inhibition on CNO-induced 
depolarization, 10 µM U73122 was present in the bath throughout recordings. Similar recordings were 
obtained in Gi-DREADD expressing cells without TTX present in the bath. In Gi-DREADD-expressing 
cells, the rheobase, which was defined as the minimal amount of current required to elicit an action 
potential using a current ramp, was obtained using the potassium gluconate internal described above 
both before and following 5 minutes of bath application of 10 µM CNO. One cell was identified as an 
outlier by the Grubbs’ test (alpha set to 0.01) and was excluded from the rheobase dataset. To assess the 
effects of Gq-DREADD activation in BNST VGAT neurons on LTD, whole cell voltage clamp recordings 
were obtained using a cesium-gluconate internal [(in mM): 117 Cs-gluconate, 20 HEPES, 15.2 EGTA, 83 
TEA, 40 MgCl2, 200 Na2ATP, 20 Na2GTP, pH 7.31, 292 mOsmol] with the cell clamped at -70 mV 
throughout the recording period. All experiments were performed with 25 µM picrotoxin, or picrotoxin plus 
5 µM SR 141716A, present in the bath. To record evoked excitatory postsynaptic currents (EPSCs), a 
bipolar Ni-chrome stimulated electrode was placed in the dorsal BNST and dorsal to the recorded neuron. 
EPSCs were evoked at a frequency of 0.167 Hz using either voltage or current pulses. Evoked 
experiments were analyzed in Clampfit 10.5 (Molecular Devices Sunnyvale, CA). All evoked responses 
were normalized to the average EPSC amplitude during the first 50 sweeps (5 mins) before CNO 
application. Each data point consists of a 60 second (6 sweep) average of evoked responses. In all 
experiments, signals were digitized at 10-20 kHz and filtered at 3 kHz using a Multiclamp 700B amplifier. 
Behavioral Assays: Mice used for behavioral studies were habituated to handling for two days beginning 
three days prior to the first behavioral test. All behavioral testing was done during the light cycle, and 
there was at least 48 hours between test sessions. For chemogenetic manipulations, mice were 
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transported to a holding cabinet adjacent to the behavioral testing room to habituate for at least 30 
minutes before being pretreated with CNO (3.0 mg/kg, i.p.) unless stated otherwise. All behavior testing 
began 30 minutes after CNO treatment. Experimenters were blind to mouse treatment during testing. 
Equipment was cleaned with a damp cloth between mouse trials. Sessions were video recorded and 
analyzed using EthoVision software (Noldus Information Technologies). Elevated Plus Maze: Mice were 
placed into the center of an elevated plus maze and allowed to explore for a 5 minute session.  Light 
levels in the open arms were ~14 lux. The probability of an open arm entry was calculated as the number 
of open arm entries divided by the total number of arm entries (open + closed). Open Field: Mice were 
placed into the corner of a white Plexiglas open field arena (20 x 20 x 10 cm) and allowed to freely 
explore for 30 minutes. The center of the open field was defined as the central 25% of the arena. Light 
levels were ~14 lux. In one behavioral cohort, 5 mice were excluded due to a malfunctioning camera in 
one of the boxes (1 mCherry, 3 Gq, 1 Gi). Light-Dark: Mice were placed into the dark side of a two-
compartment box containing a dark side (black walls with lid) and a light side (clear Plexiglas walls, no lid) 
and were allowed to freely explore for 15 minutes. The two sides were connected by a central small 
opening in the walls of the enclosed side. Light levels in the light side were ~300 lux in the center. 
Acoustic startle: mCPP HCl (Tocris, Ellisville, MO) was mixed fresh on the morning that behavioral testing 
took place. mCPP was mixed with artificial cerebral spinal fluid (aCSF) at 1 µg/.5 µl. Animals were 
randomly assigned to receive mCPP or vehicle with the flip of a coin.  Mice received either vehicle or 
mCPP infusions using the injection cannula connected with polyethelene tubing to a 10ul micro syringe 
(Hamilton, Reno, NV).  Infusions were performed with a mechanical infusion pump (KD Scientific, 
Holliston, MA) at a rate of 0.25ul/minute for 2 minutes for a total volume of .5ul per side. The injector 
cannulae were left in place for an additional 2 minutes to aid in diffusion of the drug into the target area.  
Behavioral testing took place immediately after infusion. The startle tests were conducted in eight sound 
attenuating cubicles measuring 58 cm (W) × 32 cm (D) × 55 cm (H). Each cubicle was lined with black, 
sound absorbing foam with no internal source of light. Each cubicle contained a stabilimeter device 
consisting of a load cell platform onto which the behavioral chamber was mounted (MED-ASR-PRO1, 
Med-Associates, Georgia, VT). The chamber was constructed from clear acrylic, cylindrical in shape, 12.5 
cm in length, with an inner diameter of 5 cm. The floor of the chamber consisted of a removable grid 
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composed of 6 steel rods 3.2 mm in diameter, and spaced 6.4 mm apart. Startle responses were 
transduced by the load cell, amplified, and digitized over a range of 0–4096 units. Startle amplitude was 
defined as the largest peak to trough value within 100 ms after the onset of the startle stimulus. After a 
five-minute acclimation period, mice were presented with the first of 30 startle stimulus alone trials. The 
startle stimulus was comprised of white noise bursts lasting for 20 milliseconds.  Ten stimuli of each 
intensity level (95, 100, and 105 dB) were presented in a pseudo-random order (the constraint being that 
each intensity occur within each block of 3 trials) with an inter-trial interval (ITI) of 60 s. Data collection 
and the control and sequencing of all stimuli were controlled by Med-Associates startle reflex hardware 
and software. Raw startle scores were converted into a percent change score based on the average 
startle response in vehicle treated mice. 
Placement Verification and Histology: All mice used for behavioral and anatomical tracing experiments 
were anesthetized with Avertin and transcardially perfused with 30 ml of ice-cold 0.01M PBS followed by 
30 ml of ice-cold 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS). Brains were extracted 
and stored in 4% PFA for 24 hours at 4°C before being rinsed twice with PBS and stored in 30% 
sucrose/PBS until the brains sank. 45 µm slices were obtained on a Leica VT1000S and stored in 50/50 
PBS/Glycerol at -20°C. DREADD-containing sections were mounted on slides, allowed to dry, 
coverslipped with VectaShield (Vector Labs, Burlingame, CA), and stored in the dark at 4°C.  Viral 
injection sites were verified on either a Zeiss Axio Zoom.V16 microscope or Zeiss 800 confocal 
microscope. For the acoustic startle study, mice were euthanized using pentobarbital (SleepAway, Fort 
Dodge Drug Company, Fort Dodge, IA) and were immediately perfused transcardially using 0.9% saline 
followed by 10% neutral buffered formalin. Brains were saved in 10% neutral buffered formalin and 
coronal sections were obtained on a cryostat at 50-60um. Slices were stained with cresyl violet for 
cannula placement verification.  
DREADD-Assisted Metabolic Mapping (DREAMM): Male VGAT-Cre mice expressing a DIO-hM3Dq-
mCherry in the BNST were fasted overnight. The next morning mice were injected with either vehicle or 
CNO (3 mg/kg, i.p.) and 5 minutes later were injected with [18F]fluorodeoxyglucose (FDG) (~250 µCi, i.p.) 
and placed individually in a mouse home cage (each mouse was scanned twice). 35-40 minutes after the 
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FDG injection mice were anesthetized with 1.5% isoflurane, placed in a prone position on the bed of an 
Inveon microPET scanner (Siemens Medical Solutions, Malvern, PA) and scanned using a 20 min static 
acquisition protocol. These time points were chosen to align with those used for behavioral testing. All 
scans were reconstructed using the maximum a posteriori (MAP) algorithm. After reconstruction, images 
were spatially processed and normalized using the Pixel-wise Modeling software suite (PMOD) (PMOD 
Inc., Zurich, Switzerland) to a mouse brain MRI template (Michaelides et al., 2010) . Normalized scans 
were then analyzed using statistical parametric mapping (SPM) as previously described (Urban et al., 
2015) .  All SPM contrasts consisted of paired t-tests within each group (e.g. VEH>CNO, VEH<CNO) and 
were evaluated at p=0.01. Only clusters of at least 100 contiguous voxels were reported. 
FACS and Single-Cell qPCR: Single-cell suspension preparation: On two separate experimental runs, 
brains from one adult male VGAT-ires-Cre:Rosa26-floxed-stop-L10-GFP and one adult male mouse 
lacking either Cre or L10-GFP expression, were extracted following deep isoflurane anesthesia. The 
brains were blocked on ice to obtain a 1 mm thick coronal section containing BNST. The BNST was then 
isolated from the rest of the section using razor blades and was then finely minced with razor blades 
before being transferred to 1 ml of ice-cold Hibernate A (HA-if, Brain Bits). The samples were centrifuged 
for 2 minutes at 110 x g at 4°C, the supernatant removed, and the pellets resuspended in 1 ml of 
Accutase (SCR005, Millipore) and triturated up and down 4 times before digesting the tissue for 1 hour at 
4°C with end-over-end mixing. Following digestion, the tissue was centrifuged for 2 minutes at 960 x g at 
4°C, the supernatant was removed, and the pellets were resuspended in 0.6 ml of ice-cold Hibernate A. 
The samples then underwent a series of trituration steps using fire-polished glass pipettes with 
successively smaller diameters (1.3, 0.8, and 0.4 mm) that consisted of triturating up and down 10 times 
followed by placing the tube on ice for 2 minutes to allow undissociated debris to settle before collecting 
the supernatants and resuspending the undissociated debris with 0.6 ml of Hibernate A. The 
supernatants were pooled after each trituration step. Three additional trituration steps were carried out 
with a 0.4 mm diameter glass pipette resulting in pooled samples of dissociated cells with a volume of 
~3.6 ml. These samples were then filtered with 100 µm and 40 µm cell strainers (Falcon brand, BD 
Biosciences) before being used for FACS. Single-cell isolation and qPCR:   Cells expressing VGAT-ires-
Cre:Rosa26-floxed-stop-L10a-GFP were isolated by Fluorescence Activated Cell Sorting (FACS) using a 
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Sony SH800 FACS instrument (Sony Biotechnology, San Jose, CA). Multimers were excluded using a 
Forward-Scatter Area (FSC-A) versus Forward-Scatter Height (FSC-H) gating strategy. Dead cells were 
excluded using SYTOX Blue Live/Dead stain (S34857; Thermo-Fisher Scientific, USA). Gating windows 
were adjusted to only include events present in the GFP+ sample relative to the GFP- control brain. ~8-
9,000 VGAT-ires-Cre:Rosa26-floxed-stop-L10a-GFP cells were sorted into 20 µl of Optimem with the 
apoptotic inhibitor Y-27632 (Cat. #S1049, Selleck Chemical) diluted to 1:1000.  Eight µl of the cell 
suspension (~4000 cells) was added to 2 µl of C1 resuspension buffer (Fluidigm, South San Francisco).  
Five µl of this cell suspension was added to a 17-25 µm Fluidigm C1 Integrated Fluidics Chip (IFC). 
Specific target amplification (STA) was performed on the C1 instrument according to manufacturer’s 
specifications. The STA for each cell was interrogated for target gene (See Table 1 for Taqman probe 
information) expression levels by qPCR on a 192.24 IFC using the Fluidigm Biomark HD instrument 
according to that standard Fluidigm protocols. 
Double Fluorescence in situ hybridization (FISH): For validation of the VGAT-Cre line and comparison 
of VGAT and GPCR cellular colocalization, mice were anesthetized using isoflurane, rapidly decapitated, 
and brains rapidly extracted. Female VGAT-Cre mice were used for Slc32a1/Cre comparisons, while 
male C57Bl/6 mice were used for comparisons of Slc32a1 and GPCR expression. Immediately after 
removal, brains were placed on a square of aluminum foil on dry ice to freeze. Brains were then placed in 
a -80°C freezer for no more than 1 week before slicing. 12 µm slices containing the BNST were obtained 
on a Leica CM3050S cryostat (Germany) and placed directly on coverslips. FISH was performed using 
the Affymetrix ViewRNA 2-Plex Tissue Assay Kit with custom probes for Slc32a1 (VGAT), Grm5, Chrm1, 
Htr2c, Adra1a, Adra1b, and Cre designed by Affymetrix (Santa Clara, CA). Slides were coverslipped with 
SouthernBiotech DAPI Fluoromount-G. (Birmingham, AL). 3x5 tiled z stack (8 optical sections comprising 
10.57 µm total) were obtained on a Zeiss 800 confocal microscope. All images were preprocessed with 
stitching and maximum intensity projection. For quantification of Slc32a1 and GPCR probe colocalization, 
8-9 BNST images from 3 mice were hand counted using the cell counter plugin in FIJI (ImageJ) by a 
scorer blinded to the probes used. For validation of the VGAT-Cre line, 3 BNST images from 3 mice were 
analyzed. For all studies, cells were classified into three groups: probe 1+, probe 2+, or probe 1 and 2 +. 
Only cells positive for a probe were considered.  
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Group assignment: No specific method of randomization was used to assign groups. Whenever 
possible, mice from the same litter were randomly split across treatments to minimize differences in age.  
Inclusion/exclusion criteria: Pre-established criteria for excluding mice or cells from analysis included 
1) missed injections or a lack of viral expression, 2) equipment failures during testing, 3) statistical outliers 
as determined by Grubbs’ test. Specific instances of exclusion are described above. 
Sample size: Sample sizes were based on the expected variances from previous behavioral, 
electrophysiological, and in situ hybridization experiments. For behavioral experiments, we targeted 6-10 
mice per group. For electrophysiological experiments, we aimed for 5-10 cells from 3-6 mice. The one 
exception was 4 cells from 2 mice used for testing Gq-induced depolarization in the presence of the PLC 
inhibitor U73122. 
Statistics: Data are presented as means ± SEM. For comparisons with only two groups, p values were 
calculated using two-tailed paired or unpaired t-tests as described in the figure legends, unless specified 
otherwise. In cases where the data were not normally distributed, a Mann-Whitney test was performed as 
listed in the figure legends. Comparisons across more than two groups were made using a one-way 
Analysis of Variance (ANOVA). When an ANOVA was used, data met the assumptions of equality in 
variance. A Tukey’s posttest was performed following significance with an ANOVA. Differences were 
considered significant at p values below 0.05. All data were analyzed with GraphPad Prism 6 software. 
Figures were assembled using Adobe Illustrator. 
2.3 Results 
Selectively targeting GABAergic neurons in the BNST 
The BNST consists primarily of GABAergic neurons (Sun & Cassell, 1993), but also contains a 
population of vesicular glutamate transporter 2 (vGlut2)-and vesicular glutamate transporter 3 (vGlut3)-
expressing glutamatergic neurons in the ventral BNST (vBNST) (Hur & Zaborszky, 2005; Poulin et al., 
2009; Kudo et al., 2012). As prior reports show that stimulation of glutamatergic and GABAergic BNST 
outputs can evoke opposing behavioral states, we selectively targeted GABAergic BNST neurons using 
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stereotaxic delivery of adeno-associated viruses (AAVs) encoding Cre-inducible DREADDs to the BNST 
of VGAT-ires-Cre (VGAT-Cre) mice (Jennings, Sparta, et al., 2013) (Figure 2.1a). Injection of these viral 
constructs encoding a control mCherry fluorophore, hM3Dq-mCherry, or hM4Di-mCherry produced robust 
expression in both the dorsal and ventral regions of the BNST (Figure 2.1b). Importantly, we did not 
observe DREADD expression in Cre-negative littermates injected with the Cre-inducible hM3Dq (see 
Figure 2.5 f). Additionally, we validated that Cre expression was limited to VGAT-expressing cells using in 
situ hybridization and observed that 99.1% of cells expressing Cre were positive for Slc32a1 (VGAT) 
mRNA (Figure 2.2).  These data demonstrate that we were able to anatomically isolate BNST GABAergic 
cells for chemogenetic manipulations. To confirm functional DREADD expression, we recorded from 
hM3Dq-expressing BNST neurons using ex vivo whole cell slice electrophysiology (Figure 2.1c). Bath 
application of 10 µM CNO in the presence of TTX produced a 2.12 ± 0.35 mV depolarization in hM3Dq-
mCherry expressing BNST VGAT neurons (Figure 2.1 d-e), consistent with previous reports (Krashes et 
al., 2011; Alexander et al., 2009; Yiu et al., 2014).  Bath application of the PLC inhibitor U73122 (10 µM) 
significantly reduced the CNO-induced depolarization (Figure 2.1 d-e). As PLC is a known downstream 
target of Gq activation, these data highlight that CNO-induced depolarization following activation of 
hM3Dq receptors involve canonical Gq-mediated signaling pathways. In the absence of TTX, 50% (3/6) of 
hM3Dq expressing neurons began firing action potentials within 5 minutes of 10 µM CNO application, 
while the remaining neurons showed an average depolarization of 1.69 ± 0.24 mV (data not shown). 
Activation of Gq-coupled receptors can also result in an LTD of postsynaptic excitatory currents (Grueter 
et al., 2006; McElligott et al., 2010; McElligott & Winder, 2008). To assess if activation of hM3Dq activity 
within BNST VGAT neurons is sufficient to produce LTD, we recorded electrically evoked EPSCs during 
and following bath application of 10 µM CNO. There was a rapid and sustained reduction in EPSC 
amplitude relative to baseline that persisted for at least 25 minutes after washout of CNO, which was not 
observed in cells from non-DREADD expressing mice (Figure 2.1 f-h). Furthermore, antagonism of the 
cannabinoid receptor 1 (CB1R) with SR141716A (5 µM) blocked hM3Dq-induced LTD (Figure 2.1 f-h). In 
opposition to our observations with hM3Dq activation, stimulation of the hM4Di receptor was sufficient to 
induce a hyperpolarization and increase the amount of current required to elicit an action potential, thus 
indicating opposing actions of hM3Dq versus hM4Di signaling events (Figure 2.1 i-l).  
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Acute chemogenetic activation of BNST VGAT neurons induces anxiety-like behavior 
To determine how engagement of Gq-coupled and Gi-coupled signaling in BNST VGAT neurons 
affects acute anxiety-like behavior, we injected Cre-inducible hM3Dq or hM4Di constructs into the BNST 
of VGAT-ires-Cre mice with a Cre-inducible mCherry used as a control. Mice were treated with CNO (3.0 
mg/kg) 30 minutes before testing to allow time for DREADD-induced changes in activity (Figure 2.3 a). In 
the elevated plus maze (EPM, Figure 2.3 b), DREADD activation did not alter locomotor activity, but 
hM3Dq-expressing mice spent less time in the open arms and had a significantly reduced likelihood of 
entering an open arm. In the open field, neither the hM3Dq-expressing nor the hM4Di-expressing group 
showed changes in distance traveled (Figure 2.3 e, left), time spent in the center of the open field, or 
latency to enter the center of the open field (Figure 2.3 e, center and right, respectively). In the light-dark 
test, only the hM3Dq-expressing mice spent less time in the light compartment and made fewer entrances 
to the light side (Figure 2.3 f). Separately, we observed that acute activation of Gs-coupled signaling using 
the rM3Ds DREADD construct did not change anxiety in the same assays relative to mCherry controls 
(Figure 2.4). These results indicate that acute engagement of Gq-coupled, but neither Gi- nor Gs-coupled, 
signaling in BNST VGAT neurons is sufficient to generate an anxiety-like state in specific contexts.   
Metabolic mapping of BNST VGAT hM3Dq-evoked activity reveals broad circuit engagement 
The BNST sends projections to many structures involved with reward, anxiety, and the regulation 
of autonomic function (Dong & Swanson, 2004a; Kim et al., 2013). Injection of a Cre-inducible mCherry to 
the BNST of a VGAT-Cre mouse (Figure 2.5 a) showed direct projections of BNST VGAT fibers to these 
established regions, including the ventral tegmental area (VTA), locus coeruleus (LC), or parabrachial 
nucleus (PBN) (Figure 2.5 b). Given that we observed increases in anxiety-like behavior following the 
activation of Gq-coupled DREADDs in BNST VGAT neurons, we hypothesized that engagement of Gq-
mediated signaling within BNST VGAT neurons could produce extensive changes in network dynamics in 
these downstream targets. We used DREADD-assisted metabolic mapping (DREAMM) (Michaelides et 
al., 2013; Anderson et al., 2013) to assess how activation of hM3Dq receptors in BNST VGAT neurons 
alters network activity.  VGAT-Cre mice expressing DIO-hM3Dq in the BNST underwent two imaging 
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sessions following both vehicle and CNO pre-treatment.  Five minutes after this pre-treatment, mice were 
injected with [18F]fluorodeoxyglucose (FDG) before being anesthetized with isoflurane 25 minutes later 
and undergoing scanning (Figure 2.5 c). Mice with hM3Dq expression in the BNST (Figure 2.5 d) showed 
increases in FDG uptake in the BNST, ventral tegmental area (VTA), the locus coeruleus (LC), and the 
parabrachial nucleus (PBN) (Figure 2.5 e). Interestingly, we also observed elevated FDG uptake in the 
medial prefrontal cortex (mPFC), somatosensory cortex, and the central nucleus of the amygdala (CeA). 
Cre-negative littermates injected with a DIO-hM3Dq-mCherry lacked DREADD expression and showed 
negligible CNO-induced changes in FDG uptake in these regions (Figure 2.5 f-g).  
Single-cell profiling of BNST VGAT cells highlights endogenous transcription of Gq-coupled 
GPCRs 
As we observed robust changes in anxiety-like behavior following activation of Gq signaling in 
hM3Dq-expressing, but neither hM4Di- nor rM3Ds-expressing BNST VGAT neurons, we sought a greater 
understanding of the range of endogenous Gq-coupled receptors expressed within these cells. To isolate 
this population, the BNST was dissected from VGAT-Cre mice crossed with a flox-stop L10-EGFP 
reporter line. After creating a single-cell suspension, we isolated EGFP positive cells using fluorescence-
activated cell sorting (FACS), then captured sorted cells using a Fluidigm C1 microfluidics chip. Captured 
cells were lysed and used for single-cell quantitative polymerase chain reaction (qPCR) with probes 
targeting Slc32a1 (VGAT), Map2 (a neuronal marker), Gad1 and Gad2 (GABA markers), and an array of 
Gq-coupled receptors (Figure 2.6 a-b). We were able to capture 163 cells from two samples collected 
from two individual mice run on two separate chips. Our a priori exclusion criteria removed from analysis 
any cells negative for VGAT (13/163), Map2 (0/163), or both Gad1 and Gad2 (1/163), resulting in 149 
remaining cells. Interestingly, none of the excluded cells were positive for Slc17a6 (vGlut2), and only 1 
cell was positive for Slc17a8 (vGlut3). Of the remaining 149 cells, we observed that greater than 50% of 
captured cells expressed transcripts for the Gq-coupled receptors Grm5 (93.3%), Ntsr2 (85.2%), Chrm1 
(71.1%), Htr2c (55.7%), or Grm1 (50.3%) (Figure 2.6 c). We next used fluorescence in situ hybridization 
(FISH) to validate our qPCR findings by examining colocalization of mRNA for VGAT and various GPCRs 
(Figure 2.6 d-i). In agreement with the microfluidics approach, we observed a similar distribution of the 
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probed GPCRs in VGAT mRNA positive cells (Figure 2.6 i). Together, these results reveal an array of 
endogenous Gq-coupled receptors expressed within a genetically defined cell population in the BNST.  
Infusion of a 5-HT2CR agonist in the BNST increases anxiety-like behavior 
Of the identified endogenous Gq-coupled receptors identified in BNST VGAT neurons, we 
selected the 5-HT2CR for further analysis. The 5-HT system is known to be involved in anxiety and other 
affective-related behaviors, including within the BNST (Burghardt et al., 2004; Ravinder et al., 2013; 
Marcinkiewcz et al., 2016) . We implanted cannulae over the BNST and locally infused the 5-HT2CR 
agonist mCPP immediately before testing in an acoustic startle task. Briefly, mice were placed on an 
accelerometer in a sound-attenuated chamber then presented with short noise burst. The magnitude of 
the startle served as an index of anxiety-like behavior. Bilateral infusion of mCPP (1 µg) into the BNST 
reliably increased acoustic startle responding relative to vehicle treated controls, thus indicating that 
activation of this Gq-coupled receptor leads to an increase in anxiety-like behavior (Figure 2.7).  
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2.4 Discussion 
Existing pharmacological options for anxiety disorders remain ineffective in many patients and are 
often accompanied by undesirable side effects (Griebel & Holmes, 2013; Insel, 2012). Therapeutic 
difficulties arise, in part, due to the incomplete understanding of cell populations and brain circuits 
involved in mediating the desirable effects of drug treatments. Advances in optogenetic and 
chemogenetic techniques have revealed how stimulation of specific cell types within a structure can drive 
pathological behavior.  However, many of these studies to date have focused on well-known anatomical 
pathways, and few have capitalized on discovery-based tools to identify novel endogenous modulators of 
function.  Here we use a chemogenetic strategy to probe the role of GPCR signaling within a genetically 
defined cell population involved in anxiety-like behavior. We show that engagement of Gq-mediated 
signaling in BNST VGAT-expressing neurons induces anxiety-like behavior, while acute activation of both 
Gi and Gs signaling is insufficient to change anxiety-like responses in the assays tested. DREAMM 
imaging analysis following activation of Gq-DREADD signaling in BNST VGAT neurons showed enhanced 
activity in brain areas including the VTA, LC, and PBN. Furthermore, we used a discovery-based 
approach to identify potential novel GPCR regulators of this cell population.  These results not only 
provide an anatomical framework for anxiety-like behavior, but a conceptual framework to parse out novel 
GPCR regulators of circuit function and behavior.  
While hM3Dq-treated VGAT-Cre mice showed increased anxiety-like behavior, it is interesting 
that we did not see reductions in anxiety-like behavior following activation of hM4Di signaling in BNST 
VGAT neurons, particularly in light of previous work showing that pharmacological or optical inhibition of 
the BNST reduces anxiety behavior (Kim et al., 2013). At rest, the BNST has low levels of activity, and it 
is possible that the environment for our assays was not sufficient to engage BNST activity. As the hM4Di 
DREADD produced a hyperpolarizing inhibitory effect (Figure 2.1), suppressing activity of the BNST in 
these contexts may be insufficient to further reduce anxiety-like behavior. It would be interesting to repeat 
these experiments with activation of hM4Di DREADDs during a stressor that is known to increase BNST 
activity (foot shock, restraint, etc.) immediately before anxiety testing. Alternatively, similar experiments 
could be performed under brighter lighting conditions, as previous work has shown that open field 
exposure under bright lights (~600 lux) increases c-fos expression in the BNST (Heisler et al., 2007). We 
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also did not see changes in anxiety-like behavior following manipulation of Gs-coupled signaling. While 
both Gq- and Gs-coupled receptors have excitatory effects, a recent study identified that activation of Gq- 
and Gs-coupled DREADDs in agouti-related peptide (AgRP) neurons of the hypothalamus promoted 
feeding behavior through independent mechanisms, and that only Gs DREADD activation promoted AgRP 
release (Nakajima et al., 2016). As the BNST expresses an array of peptides, including corticotropin-
releasing factor (CRF) and neuropeptide Y (NPY) that are known to produce opposing behavioral 
responses, it is possible that potential stimulation of peptide release in BNST VGAT neurons using the 
Gs-coupled DREADD occludes the effect of activation of these individual peptide receptors alone (Pleil et 
al., 2015; Kash & Winder, 2006; Valdez & Koob, 2004; Heilig, 2004; Heilig & Koob, 2007).  
In addition to observing Gq-induced changes in behavior, our ex vivo slice electrophysiology 
recordings identified that activation of hM3Dq receptors in BNST VGAT neurons produced stimulatory 
depolarizing effects capable of increasing action potential firing that were accompanied by an LTD-like 
reduction of evoked EPSCs that persisted at least 25 minutes following washout of CNO. These changes 
are in agreement with previous studies demonstrating that bath application of agonists for the Gq-coupled 
α1-adrenergic receptor or group I metabotropic glutamate receptors induces LTD in the BNST (Grueter et 
al., 2006; McElligott et al., 2010; McElligott & Winder, 2008). Similarly, in the CA1 region of the 
hippocampus, stimulation of Gq-coupled DREADDs alters long-term plasticity, including LTD and long-
term potentiation (LTP) as assessed by field recordings (López et al., 2016). It is important to note, 
however, that while Gq-induced LTD has been observed in the BNST, we are currently unable to 
selectively antagonize the hM3Dq receptor following LTD induction to confirm the observed changes in 
synaptic plasticity are independent of CNO remaining bound to the DREADD receptor. Interestingly, we 
observed that the hM3Dq-induced reductions in EPSC amplitude involved CB1R-dependent activity, in 
agreement with previous long-term plasticity reports indicating CB1R-dependent reductions in evoked 
EPSC amplitude in the BNST (Grueter et al., 2006; Glangetas et al., 2013).  
  Our results from DREAMM analysis point to changes in metabolic activity throughout brain 
regions previously associated with anxiety pathology, including the mPFC, CeA, VTA, PBN, and the 
somatosensory cortex (Calhoon & Tye, 2015; Sehlmeyer et al., 2009; Nagai et al., 2007; Shackman & 
Fox, 2016; Gungor & Paré, 2016). Of note, we observed no reductions in regional metabolic activity 
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following CNO treatment. Other studies assessing brain glucose metabolism during periods of anxiety 
have also observed enhanced metabolic activity in subcortical and limbic regions across species 
including rats, monkeys, and humans (A. S. Fox et al., 2008; Shackman et al., 2013; Awwad et al., 2015; 
M. L. Liu et al., 2012). Importantly, FDG uptake represents increased glucose uptake and would therefore 
also be observed in active presynaptic terminals (Michaelides et al., 2013). Therefore, the exclusive 
increase in activity may reflect both enhanced presynaptic activity of BNST GABAergic afferents and 
increased local activity resulting from polysynaptic disinhibition. In agreement with this, previous work has 
shown that GABAergic BNST projections to the VTA innervate GABAergic VTA neurons (Jennings, 
Sparta, et al., 2013). However, the BNST to VTA projection is unlikely to account for the anxiogenic 
phenotype reported here as that study demonstrated that optogenetic stimulation results in anxiolysis. 
Nonetheless, given that stimulation of Gq-mediated signaling in BNST VGAT neurons was sufficient to 
induce anxiety, the observed changes in metabolic activity throughout the brain may highlight a potential 
biomarker for pathological anxiety. 
While the results reported here reflect acute activation of BNST VGAT neurons and 
corresponding increases in anxiety, changes in BNST neuronal activity have been observed under other 
models of pathological anxiety. For example, we recently found that BNST neurons exhibited increased 
excitability following chronic alcohol exposure, and that elevated BNST excitability correlated with 
increased anxiety-like behavior (Pleil et al., 2016). Moreover, we previously found that the increase in 
excitability was associated with excessive 5-HT2CR mediated signaling (Marcinkiewcz et al., 2015), and 
here we identify that an agonist of 5-HT2CR in the BNST increases anxiety-like startle responding. The 
approach outlined in this study provides a framework for identifying GPCRs that may be differentially 
altered during anxiety states. Additionally, the application of whole brain imaging using these genetic 
approaches provides a robust and reproducible approach for connecting cellular signaling events to broad 
patterns of activity. Identification of brain-wide network activity patterns is especially important as this 
provides a point of translation for human studies. For example, the new Research Domain Criteria 
(RDoC) system proposed by the National Institute of Mental Health as a means for understanding brain 
disorders, suggests that identifying the circuit elements associated with specific endophenotypes across 
multiple disorders can provide insight into treatment. One such RDoC construct is potential threat or 
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anxiety.  Our work highlights a whole brain metabolic map that could potentially serve as a biomarker for 
heterogeneous populations of patients suffering from conditions co-morbid with anxiety disorders and 
identifies potential receptor targets that may drive this endophenotype. Our results presented here in the 
naive state lay the foundation for future work to assess how the development of pathological anxiety 
states, such as anxiety associated with withdrawal from chronic alcohol exposure, changes GPCR 
expression patterns in BNST VGAT neuron and correspondingly changes metabolic brain-wide activity 
patterns.  
  
 40  
 
2.5 Figures 
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Figure 2.1: Select modulation of BNST VGAT neurons using DREADDs. (a) Stereotaxic 
delivery of viruses encoding a Cre-inducible mCherry or DREADD (hM3Dq or hM4Di) into 
the BNST of VGAT-Cre mice. (b) Representative sections showing expression of a Cre-
inducible mCherry (left), hM3Dq (middle), or hM4Di (right). Scale bars indicate 500 µm. (c) 
Schematic of ex vivo slice electrophysiology in hM3Dq-mCherry-expressing BNST neurons 
in the presence of CNO. (d) Representative traces from an hM3Dq-expressing BNST VGAT 
neuron depolarized by bath application of 10 µM CNO in the presence of TTX, but not in the 
presence of the PLC inhibitor U73122.  (e) Average change in resting membrane potential 
during the last 2 minutes of CNO application in ACSF + TTX with and without U73122 
(right). N: ACSF, 6 cells from 4 mice; ACSF + U73122, 4 cells from two mice. . **, p<0.01, 
Mann Whitney test. Error bars indicate SEM. (f) Time course of hM3Dq-induced reduction 
in evoked EPSCs is blocked by CB1R antagonist SR 141716A (g) Representative 
superimposed average evoked responses of the five minutes before CNO bath application 
(solid trace) and 20 to 25 minutes of washout (dotted line). (h) Mean evoked EPSC 
amplitude during minutes 30-35 (20-25 minutes of washout). F(2,10)=10.36, p=0.0037. 
*p<0.05, Tukey’s multiple comparison test; **p<0.01 Tukey’s multiple comparison test. (i) 
Schematic of ex vivo slice electrophysiology in hM4Di-mCherry-expressing BNST neurons 
in the presence of CNO. (j) Representative tracing showing hyperpolarization of hM4Di-
mCherry-expressing BNST neuron in the presence of 10 µM CNO. (k) Mean 
hyperpolarization induced by 10 µM CNO. **p<0.01, one-sample t-test. N: 10 cells from 6 
mice. (l) Mean change in rheobase following bath CNO application. **p<0.01, one-sample t-
test. N: 5 cells from 4 mice. 
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Figure 2.2: Validation of VGAT-Cre mouse in the BNST. (a) In situ hybridization for Vgat, Cre, 
and Dapi. Scale bar: 500 µM. Inset shows magnified section with representative cells 
demonstrating Cre only cells (green arrow), Vgat only cells (red arrows), and cells positive for both 
Cre and Vgat (yellow arrows). Scale bar: 100 µM. (b) Percent of BNST cells positive for Cre only, 
Vgat only, or both Cre and Vgat. N: 3 images from 3 mice. 
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Figure 2.3: Chemogenetic activation of BNST VGAT neurons increases anxiety-like 
behavior. (a) Behavioral assay design. VGAT-Cre mice expressing DIO-mCherry, DIO-hM3Dq, or 
DIO-hM4Di in the BNST were injected with 3.0 mg/kg CNO 30 minutes before being tested in 
exploratory assays. (b) Elevated plus maze (EPM). (c) Distance traveled (left; F(2,23)=1.413, 
p=0.26), time in open arms (middle; F(2,23)=3.894, p<0.05, One-Way ANOVA and Tukey’s post-hoc 
test) and probability of an open arm entry (right; F(2,23)=6.305, p<0.01, One-Way ANOVA, p<0.05, 
Tukey’s post-hoc test) during a 5 minute EPM session. N: 8 mcherry, 9 hM3Dq, 9 hM4Di). (d) 
Averaged heat maps showing time spent in open and closed arms for mCherry (left), hM3Dq 
(center), and hM4Di (right) expressing mice. (e) Open field. Distance traveled (left; F(2,18)=0.2503, 
p=0.78, One-Way ANOVA. N: 7 mCherry, 6 hM3Dq, 8 hM4Di), time in the center (middle; 
F(2,18)=0.5538, p=0.58. N: 7 mCherry, 6 hM3Dq, 8 hM4Di), and latency to enter the center (right; 
F(2,22) = 0.3674, p=0.6967. N: 8 mCherry, 9 hM3Dq, 8 hM4Di) during a 30 minute open field 
session. (f) Light-dark box. Time in (left; F(2,23)=5.266,  p<0.05, One-Way ANOVA, p<0.05, Tukey’s 
post-hoc test) and entrances to (right; F(2,23)=3.629, p<0.05), One-Way ANOVA, p<0.05, Tukey’s 
post-hoc test) the light compartment during a 15 minute session. N: 8 mCherry, 9 hM3Dq, 9 
hM4Di. *p <0.05 relative to mCherry, # p<0.05 relative to hM4Di, Tukey’s post hoc test. Error bars 
indicate SEM. 
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Figure 2.4: Chemogenetic activation of Gs signaling in BNST VGAT neurons does not alter 
anxiety-like behavior. (a) Schematic of viral injection (left) and representative expression of rM3Ds in the 
BNST of a VGAT-Cre mouse (right). (b) VGAT-Cre mice expressing DIO-mCherry or DIO-rM3Ds in the 
BNST were injected with 3.0 mg/kg CNO 30 minutes before being tested in exploratory assays. (c) 
Elevated plus maze. (d) Distance traveled (left; p=0.8551, unpaired t-test), time in open arms (middle; 
p=0.4393, unpaired t-test) and probability of an open arm entry (right; p=0.7082, unpaired-test) during a 5 
minute EPM session. (e) Open field. (f) Distance traveled (left; p=0.8289, unpaired t-test), time in the 
center (middle; p=0.4136, unpaired t-test), and latency to enter the center (right; p=0.5161, unpaired t-
test) during a 30 minute open field session. (g) Light-dark box. (h) Time in (left; p=0.5552, unpaired t-test) 
and entrances to (right; p=0.4332, unpaired t-test) the light compartment during a 15 minute session. N: 7 
mCherry, 8 rM3Ds. Error bars indicate SEM.  
 
 
 45  
 
 
Figure 2.5: Metabolic mapping of downstream activity following CNO-induced activation of 
hM3Dq in BNST VGAT neurons. (a) Injection of a DIO-mCherry to the BNST of a VGAT-Cre to label 
projection fibers. (b) mCherry fluorescence observed in the BNST injection site (left) and fluorescent 
fibers in the VTA (middle) and PBN/LC (right). Scale bars: 1 mm. (c) µPET imaging timeline. Mice 
were injected with vehicle or CNO and five minutes later injected with FDG. 25 minutes later mice 
were anesthetized with isoflurane and placed on the scanning bed for a 20 minute scanning session. 
(d) Representative image of a DIO-hM3Dq-mCherry BNST injection site. (e) Increased FDG uptake in 
areas corresponding to the BNST (left) VTA (middle) and PBN/LC (right) following activation of hM3Dq 
in BNST VGAT neurons. (f) Representative injection of a DIO-hM3Dq-mCherry to a Cre-negative 
control mouse. (g) No change in FDG uptake in the BNST (left), VTA (middle), or PBN/LC (right) from 
Cre-negative mice injected with a DIO-hM3Dq-mCherry to the BNST. N: 4 mice per group. A.c.: 
anterior commissure.  
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Figure 2.6: Single-cell qPCR analysis reveals Gq-coupled GPCRs in BNST VGAT cells. (a) BNST 
tissue was dissected from a VGAT-Cre x L10-EGFP mouse and dissociated to create a single-cell 
suspension. Following FACS, individual EGFP-positive cells were captured on a C1 chip and used for 
single-cell qPCR with probes targeting Gq-coupled receptors. (b) Heat map depicting delta Ct values 
of individual probes from 149 cells positive for Slc32a1, Map2, and Gad1 and/or Gad2. Values are 
normalized to RN18S. (c) Percent of cells expressing transcripts for each Gq-coupled GPCR. (d-h) 
Representative fluorescent in situ hybridization sections for assessing colocalization of VGAT mRNA 
and mRNA for mGluR5 (d), M1mAchR (e), 5-HT2CR (f), α1-AR (g), α1-BR (h). Scale bar: 100 µm. (i) 
Percent of VGAT mRNA positive cells expressing various GPCR transcripts. Error bars indicate SEM. 
Gene (Protein): Grm5 (MGLUR5), Ntsr2 (NTSR2), Chrm1 (CHRM1), Htr2c (HTR2C), Grm1 (mGluR1), 
Adra1a (α1-AR), Tacr1 (TACR1), Htr2a (5-HT2AR), Chrm3 (M3 mAChR), Calcr (CT), Oxtr (OXTR), 
Chrm5 (M5 mAChR), Adra1b (α1-BR), Ntsr1 (NTSR1), Adra1d (α1-DR), Npsr1 (NPSR1), 
Gpr171(GPR171), Cckar (CCKAR), Htr2b (5-HT2BR), Avpr1b (AVPR1B). 
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Figure 2.7: Local infusion of mCPP to the BNST increases acoustic startle. (a) Mice 
with cannulae inserted over the BNST received an infusion of 1 µg mCPP and were 
immediately placed in the acoustic startle chamber. Following a 5 minute habituation 
period, mice were presented with 30 startle stimuli. (b) Mice treated with mCPP showed 
an exacerbated acoustic startle response (t(14) = 3.015, p = 0.0093). N: 7 vehicle, 9 
mCPP. **p<0.01, unpaired t-test. Error bars indicate SEM.   
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 Table 1: Taqman probes used for single-cell qPCR 
Gene name Taqman Probe Number 
Slc32a Mm00494138_m1 
Map2 Mm00485231_m1 
Gad1 Mm00725661_s1 
Gad2 Mm00484623_m1 
RN18S Mm04277571_s1 
Grm5 Mm00690332_m1 
Ntsr2 Mm00435426_m1 
Chrm1 Mm00432509_s1 
Htr2c Mm00434127_m1 
Grm1 Mm00810231_s1 
Adra1a Mm00442668_m1 
Tacr1 Mm00436892_m1 
Htr2a Mm00555764_m1 
Chrm3 Mm00446300_s1 
Calcr Mm00432282_m1 
Oxtr Mm01182684_m1 
Chrm5 Mm01701883_s1 
Adra1b Mm00431685_m1 
Ntsr1 Mm00444459_m1 
Adra1d Mm01328600_m1 
Npsr1 Mm00558817_m1 
GPR171 Mm02620738_s1 
Cckar Mm00438060_m1 
Htr2b Mm00434123_m1 
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Avpr1b Mm01700416_m1 
Slc17a6 Mm00499876_m1 
Slc17a8 Mm00805413_m1 
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CHAPTER 3 SEROTONIN SYSTEM INVOLVEMENT IN ANXIETY AND FEAR RELATED BEHAVIOR 
IN THE EXTENDED AMYGDALA1 
3.1 Overview of findings 
Serotonin (also known as 5-hydroxytryptamine; 5-HT) is a neurotransmitter that has an essential 
role in the regulation of emotion. However, the precise circuits have not yet been defined through which 
aversive states are orchestrated by 5-HT. Here we show that 5-HT from the dorsal raphe nucleus (5-
HTDRN) enhances fear and anxiety and activates a subpopulation of corticotropin-releasing factor (CRF) 
neurons in the bed nucleus of the stria terminalis (CRFBNST) in mice.  Specifically, 5-HTDRN projections to 
the BNST, via actions at 5-HT2C receptors (5-HT2CRs), engage a CRFBNST inhibitory microcircuit that 
silences anxiolytic BNST outputs to the ventral tegmental area (VTA) and lateral hypothalamus (LH). 
Furthermore, we demonstrate that this CRFBNST inhibitory circuit underlies aversive behavior following 
acute exposure to selective serotonin reuptake inhibitors (SSRIs). This early aversive effect is mediated 
via the corticotrophin releasing factor type 1 receptor (CRF1R, also known as CRHR1), given that CRF1R 
antagonism is sufficient to prevent acute SSRI-induced enhancements in aversive learning. These results 
reveal an essential 5-HTDRN →CRFBNST circuit governing fear and anxiety, and provide a potential 
mechanistic explanation for the clinical observation of early adverse events to SSRI treatment in some 
patients with anxiety disorders(Gorman et al., 1987; Westenberg & den Boer, 1989).   
3.2 Methods 
Mice:  Mice were used in all experiments. For experiments involving Cre lines, mice were crossed for 
several generations to C57 mice before using. All wild-type mice were C57BL/6 mice obtained from The 
Jackson Laboratory (Bar Harbor, ME). For all behavior experiments except those involving Htr2cCre mice, 
male mice ranging in age from 8-16 weeks were used. Female Htr2cCre mice were used in chemogenetic 
                                                     
1 This chapter was previously published as an article in Nature. Some minor adjustments have been 
made to accommodate dissertation formatting. The original citation is as follows: Marcinkiewcz*, C. A., 
Mazzone*, C. M., et al. (2016). Serotonin engages an anxiety and fear-promoting circuit in the extended 
amygdala. Nature, 537 (7618), 97–101. * denotes co-first authorship. 
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manipulations. Both male and female mice aged 6-20 weeks were used for slice electrophysiology and 
anatomical tracing experiments. All behavioral studies or tissue collection for ex vivo slice 
electrophysiology were performed during the light cycle. 
All behavioral experiments in Htr2ccre mice were conducted at the University of Aberdeen and in 
accordance with the United Kingdom Animals (Scientific Procedures) Act of 1986.  All in vivo 
electrophysiology experiments were conducted in accordance with all rules and regulations at the 
National Institute for Alcohol Abuse and Alcoholism at the National Institutes of Health.  All other 
procedures were conducted in accordance with the National Institutes of Health guidelines for animal 
research and with the approval of the Institutional Animal Care and Use Committee at the University of 
North Carolina at Chapel Hill. 
All animals were group housed on a 12 hour light cycle (lights on at 7 a.m.) with ad libitum access 
to rodent chow and water, unless described otherwise. CRF-ires-Cre (Crfcre) were provided by Dr. 
Bradford Lowell (Harvard University) and were previously described(Krashes et al., 2014). C57BL/6J mice 
were obtained from the Jackson Laboratory (Bar Harbor, ME). To visualize CRF-expressing neurons, 
CrfCre mice were crossed with either an Ai9 or a cre-inducible L10-GFP reporter line (Jackson 
Laboratory)(Clarke, 1993) to produce CRF-Ai9 or CRF-L10GFP progeny, referred to throughout the 
manuscript as CRF-reporters. SertCre mice (from GENSAT) were a generous gift from Dr. Bryan Roth. 
Htr2cCre mice were supplied by Dr. Lora Heisler and are described in detail elsewhere(Burke et al., 2016). 
Male mice were used for in vivo optogenetic behavioral experiments and for assessing the 
involvement of BNST CRF neurons on fluoxetine-induced enhancement of fear. Female 5-HT2C-Cre mice 
were used in chemogenetic manipulations. Both male and female mice were used for slice 
electrophysiology and anatomical tracing experiments. All behavioral studies or tissue collection for ex 
vivo slice electrophysiology were performed during the light cycle.  
Viruses and tracers: All AAV viruses except INTRSECT constructs were produced by the Gene Therapy 
Center Vector Core at the University of North Carolina at Chapel Hill and had titers of >1012 genome 
copies/mL. For ex vivo and in vivo optical experiments, mice were injected with rAAV5-ef1α-DIO-
hChR2(H134R)-eYFP or rAAV5-ef1α-DIO-eYFP as a control. Red IX retrobeads (Lumafluor) were used 
to fluorescently label LH - and VTA-projecting BNST neurons during ex vivo slice electrophysiology 
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recordings.  The retrograde tracer Fluoro-Gold (Fluorochrome) was used for anatomical mapping.  
Choleratoxin B (CTB) 555  and CTB 657 retrograde tracers (Invitrogen; C34776, and C34778, 
respectively) diluted to 0.5% (w/v) in sterile PBS were used per injection site for anatomical mapping of 
collateral projections from BNST to LH and VTA. For chemogenetic manipulations, mice were injected 
with 400 nl of rAAV8-hsyn-DIO-hM3D(Gq)-mCherry, rAAV8-hsyn-DIO-hM4D(Gi)-mCherry, or rAAV8-
hsyn-DIO-mCherry bilaterally.  HSV-hEF1α-mCherry, HSV-ef1α-LSL1-mCherry-IRES-flpo, and HSV-
ef1α-IRES-Cre (supplied by Rachel Neve at the McGovern Institute for Brain Research at MIT) were 
injected bilaterally into the VTA and LH at a volume of 500500 nL per sitesite. The INTRSECT construct 
AAVdj-hSyn-Con/Foff-hChR2(H134R)-EYFP was infused at 500 nl per side into the BNST. All AAV 
constructs had viral titers >1012 genome particles/ml. 
Stereotaxic injections: All surgeries were conducted using aseptic technique. Adult mice (2-5 months) 
were deeply anesthetized with 5% isoflurane (vol/vol) in oxygen and placed into a stereotactic frame 
(Kopf Instruments) while on a heated pad. Sedation was maintained at 1.5-2.5% isoflurane during 
surgery. An incision was made down the midline of the scalp and a craniotomy was performed above the 
target regions and viruses and fluorescent tracers were microinjected using a Neuros Hamilton syringe at 
a rate of 100 nl/min. After infusion, the needle was left in place for 10 minutes to allow for diffusion of the 
virus before the needle was slowly withdrawn.  Injection coordinates (in mm, midline, Bregma, dorsal 
surface): BNST (±1.00, 0.30, -4.35), LH (±0.9 to 1.10, -1.7, -5.00 to -5.2), VTA (-0.3, -2.9, -4.6), DR (0.0, -
4.65, -3.2 with a 23ᵒ angle of approach). When using retrobeads, injection volumes into the LH and VTA 
were 300 nl and 400 nl, respectively. Fluorogold injection volumes were 200 nl per target site. CTB 
volumes were 200200 nL per target site. An optical fiber was implanted in the BNST (±1.00, 0.20, -4.15) 
at a 10ᵒ angle for in vivo photostimulation studies. After fiber implantation, dental cement was used to 
adhere the ferrule to the skull. Following surgery, all mice returned to group housing. Mice were allowed 
to recover for at least 3 weeks before being used for chemogenetic behavioral studies, or 6 weeks for in 
vivo optogenetic studies.  
Drugs: RS 102221, 5-HT and mCPP were from Tocris (Bristol, UK). For electrophysiology experiments, 
RS 102221 was made up to 100 mM in DMSO and then diluted to a final concentration of 5 µM in aCSF. 
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5-HT and mCPP were stocked at 10 and 20 mM, respectively, in ddH2O and diluted to their final 
concentations in aCSF. For electrophysiology experiments, clozapine-N-oxide (CNO; from Dr. Bryan 
Roth) was stocked at 100 mM in DMSO and diluted to 10 µM in aCSF. For behavior experiments, CNO 
was dissolved in 0.5% DMSO (in 0.9% saline) to a concentration of 0.1 mg/ml or 0.3 mg/ml and injected 
at 10 ml/kg for a final concentration of 1 or 3 mg/kg, i.p. Fluoxetine (Sigma) was made up in 0.9% NaCl to 
a concentration of 1 mg/ml and then injected at 10 ml/kg for a final concentration of 10 mg/kg, i.p. 
In vivo Electrophysiological Procedures  
Surgical Procedures: Mice were anesthetized with 2% Isoflurane (Baxter Healthcare, Deerfield, IL) and 
implanted with 2x8 electrode (35um tungsten) micro-arrays (Innovative Neurophysiology Inc, Durham, 
NC) targeted at the BNST (ML: 0.8 mm, AP: ± 0.5 mm , and DV: -4.15 mm relative to Bregma). Following 
surgery, mice were singly housed and allowed at least one week to recover prior to behavioral testing. 
Fear Conditioning: Fear conditioning took place in 27 × 27 × 11cm conditioning chambers (Med 
Associates, St. Albans, VT), with a metal-rod floor (Context A) and scented with 1% vanilla. Mice received 
5 parings of a pure tone CS with a .6mA foot shock.  24 h following conditioning, mice underwent a CS 
recall test (10 presentations of the CS alone, 5 sec ITI), which was conducted in a Plexiglas cylinder 
(20cm diameter) and scented with 1% acetic acid (Context B). Stimulus presentations for both tests were 
controlled by MedPC (Med Associates Inc, St. Albans, VT). Cameras were mounted overhead for 
recording freezing behavior, which was scored automatically using CinePlex Behavioral Research 
System software (Plexon Inc, Dallas, TX).  
Electrophysiological recording and single unit analysis: Electrophysiological recording took place during 
both fear conditioning and CS recall tests. Individual units were identified and recorded using Omniplex 
Neural Data Acquisition System (Plexon Inc, Dallas, TX).  Neural data was sorted using Offline Sorter 
(Plexon Inc, Dallas, TX).  Waveforms were isolated manually, using principal component analysis. To be 
included in the analyses, spikes had to exhibit a refractory period of at least 1 ms.  Autocorrelograms from 
simultaneously recorded units were examined to ensure that no cell was counted twice. Single units were 
analyzed by generating perievent histograms (3 sec bins) of firing rates from 30 sec prior to CS onset 
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until 30 sec after CS offset (NeuroExplorer 5.0, Nex Technologies, Madison, AL). Firing rates were 
normalized to baseline (30 sec prior to CS onset) using z-score transformation. Analysis included a total 
of 139 cells over three days of recording. Data reported for raw firing rates include only putative principal 
neurons (<10Hz). The formula for computing the suppression ratio was (average freezing rate) / (average 
freezing rate + average movement rate). Each cell was calculated individually. A value of .5 = no change 
in rate). 
Ex vivo Slice Electrophysiology: Brains were sectioned at 0.07 (mm/s) on a Leica 1200S vibratome to 
obtain 300 µm coronal slices of the BNST, which were incubated in a heated holding chamber containing 
normal, oxygenated aCSF (in mM:124 NaCl, 4.4 KCl, 2 CaCl2, 1.2 MgSO4, 1 NaH2PO4, 10.0 glucose, and 
26.0 NaHCO3) maintained at 30 ± 1˚C for at least 1 hour before recording. Slices were transferred to a 
recording chamber (Warner Instruments) submerged in normal, oxygenated aCSF maintained at 28-30˚C 
at a flow rate of 2 ml/min. Neurons of the BNST were visualized using infrared differential interference 
contrast (DIC) video-enhanced microscopy (Olympus). Borosilicate electrodes were pulled with a 
Flaming-Brown micropipette puller (Sutter Instruments) and had a pipette resistance between 3-6 MΩ. 
Signals were acquired via a Multiclamp 700B ampliﬁer, digitized at 10 kHz and analyzed with Clampfit 
10.3 software (Molecular Devices, Sunnyvale, CA, USA). 
Light-evoked action potentials: In SertCre or CrfCre mice, fluorescently labeled neurons expressing ChR2 
were visualized and stimulated with a blue (470 nm) LED using a 1 Hz, 2 Hz, 5 Hz, 10 Hz, and 20 Hz 
stimulation protocol with a pulse width of 0.5 ms.  Evoked action potentials were recorded in current 
clamp mode using a potassium gluconate based internal solution (in mM: 135 K+ gluconate, 5 NaCl, 2 
MgCl2, 10 HEPES, 0.6 EGTA, 4 Na2ATP, 0.4 Na2GTP, pH 7.3, 285–290 mOsmol). 
Light-evoked synaptic transmission: In CrfCre mice with ChR2 in the BNST and retrograde tracer beads in 
the VTA or LH, we visualized non-ChR2-expressing, beaded neurons using green (532 nm) LED. 
Recordings were conducted in voltage clamp mode using a cesium-methansulfonate (Cs-Meth) based 
internal solution (in mM: 135 cesium methanesulfonate, 10 KCl, 1 MgCl2, 0.2 EGTA, 2 QX-314, 4 MgATP, 
0.3 GTP, 20 phosphocreatine, pH 7.3, 285–290 mOsmol) so that we could detect EPSCs (-55 mV) and 
IPSCs (+10 mV) in the same neuron. After confirming the absence of a light-evoked EPSC signal, we 
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measured light-evoked IPSCs during a single, 5 ms light pulse of 470 nm. In a subset of these 
experiments, SR95531 (GABAzine, 10 µM) was bath applied for 10 minutes to block IPSCs. 
Drug effects in CRFBNST neurons: Crf-reporter mice were injected with retrograde tracer beads into the 
VTA (ML -0.5, AP -2.9, DV -4.6). We then recorded from beaded (VTA-projecting) and non-beaded (non-
projecting) CRF neurons in the BNST. Acute drug effects were determined in current clamp mode in the 
presence of TTX using a potassium gluconate-based internal solution. After a 5-minute stable baseline 
was established, 5HT (10 µM) or mCPP (20 µM) was bath applied for 10 minutes while recording 
changes in membrane potential. The difference in membrane potential between baseline and drug 
application at peak effect (delta or Δ MP) was later determined. In a subset of mCPP experiments, slices 
were incubated with RS 102221 (5 µM) for at least 20 minutes before experiments began. 
Synaptic transmission: Spontaneous inhibitory postsynaptic currents (sIPSCs) were assessed in voltage 
clamp using a potassium-chloride gluconate-based intracellular solution (in mM: 70 KCl, 65 K+-gluconate, 
5 NaCl, 10 HEPES, 0.5 EGTA, 4 ATP, 0.4 GTP,  pH 7.2, 285–290 mOsmol). IPSCs were 
pharmacologically isolated by adding kynurenic acid (3 mM) to the aCSF to block AMPA and NMDA 
receptor-dependent postsynaptic currents. The amplitude and frequency of sIPSCs were determined from 
2 minute recording episodes at -70 mV. The baseline was averaged from the 4 minutes preceding the 
application of 5-HT (10 µM) or mCPP (10 µM) for 10 minutes. In a subset of these experiments, RS 
102221 (5 µM) was added to the aCSF and slices were incubated in this drug solution for at least 20 
minutes before experiments began. For miniature IPSCs (mIPSCs), TTX was included in the aCSF to 
block network activity. 
In SertCre::ChR2BNST mice with retrograde tracer beads in the VTA, sIPSCs were recorded as 
described above. After achieving a stable baseline, a 10 s, 20 Hz photostimulation was applied.  
For assessment of spontaneous excitatory postsynaptic currents (sEPSCs), a cesium gluconate-
based intracellular solution was used (in mM:  135 Cs+-gluconate, 5 NaCl, 10 HEPES, 
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0.6 EGTA, 4 ATP, 0.4 GTP, pH 7.2, 290–295 mOsmol). AMPAR-mediated EPSCs were 
pharmacologically isolated by adding 25 μM picrotoxin to the aCSF. sEPSC recordings were acquired in 2 
minute recording blocks at -70 mV. 
Fast-scan cyclic voltammetry (FSCV): Electrodes were fabricated as previously described and cut to 
50-100 um in length(Bath et al., 2000). Animal and slice preparation were as described above for 
electrophysiology and slices were perfused on the rig in ACSF. Using a custom built potentiostat 
(University of Washington Seattle), 5-HT recordings were made in the BNST using TarHeel CV written in 
lab view (National Instruments). Briefly a triangular waveform (-0.1 V to 1.3 V with a 10% phase shift at 
1000 V/s, vs. Ag/AgCl) was applied to the carbon fiber electrode at a rate of 10 Hz. Slices were optically 
stimulated with 20 5-ms blue (490 nm) light pulses at a rate of 20 Hz down the submerged 40x objective. 
10 cyclic voltammograms were averaged prior to optical stimulation for background subtraction.  
Voltammograms were digitally smoothed one time with a fast Fourier transform following data collection 
and analyzed with HDCV (UNC Chapel Hill). Fluoxetine (10 µM) was bath applied following a stable 
baseline  (20 minutes).  
Behavioral Assays:  
For chemogenetic manipulations, mice were transported to a holding cabinet adjacent to the 
behavioral testing room to habituate for at least 30 minutes before being pretreated with CNO (3 mg/kg, 
i.p. for CrfCre mice and 1 mg/kg, i.p. for Htr2CCre mice). All behavior testing began 45 minutes following 
CNO treatment, with the exception of fear conditioning training, which occurred 30 minutes after a CNO 
injection. When assessing the effect of fluoxetine on fear conditioning, fluoxetine (10 mg/kg, i.p.), or 
vehicle, was administered 1 hour before training (30 minutes before CNO treatment). For optogenetic 
manipulations, mice received bilateral stimulation (473 nm, ~10 mW, 5 ms pulses, 20 Hz) when specified. 
Unless specified, all equipment was cleaned with a damp cloth between mouse trials. All sessions were 
video recorded and analyzed using EthoVision software (Noldus Information Technologies) except where 
noted.  
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Elevated Plus Maze: Mice were placed in the center of an elevated plus maze and allowed to explore 
during a 5 minute session.  Light levels in the open arms were ~14 lux. During optogenetic manipulations 
mice received bilateral stimulation during the entire 5 minute session. Mice that left the maze were 
excluded from analysis (n= 2 control, 1 ChR2 from optogenetic experiments). 
Open Field: Mice were placed into the corner of a white Plexiglas open field arena (25 x 25 x 25 cm) and 
allowed to freely explore for 30 minutes. The center of the open field was defined as the central 25% of 
the arena. For optogenetic studies the 30 minute session was divided into three 10-minute epochs 
consisting of stimulation off, stimulation on, and stimulation off periods. 
Novelty-Induced Suppression of Feeding: 48 hours prior to testing mice were provided with access to a 
single piece of Froot Loops cereal (Kellogg’s) in their home cage. 24 hours prior to testing, home cage 
chow was removed and mouse body weights were recorded. Water remained available ad lib. Beginning 
at least one hour before testing mice transferred to new clean cages so they were singly housed for the 
test session and body weights were recorded. During the test session mice were placed into an arena 
(25x25x25 cm) that contained a single Froot Loop on top of a piece of circular filter paper. Mice were 
monitored by a live observer and the latency for the mouse to begin eating the pellet was measured, 
allowing up to 10 minutes. All mice began eating within this time. Following the initiation of feeding, mice 
were removed from the arena and placed back into their home cages. Mice were then provided with 10 
minutes of access to a pre-weighed amount of Froot Loops™ for a post-test feeding session. After this 10 
minute post-test, the remaining Froot Loops were weighed and mice were returned to ad lib home cage 
chow. Mice were returned to group housing at the end of this session. For optogenetic experiments, mice 
received constant 20 Hz optical stimulation during both the latency to feed assay and the 10 minute post-
test. During optogenetic experiments, one control mouse did not feed during the 10 minute NSF session 
and was excluded from the results. 
Home cage feeding: SertCre mice were food deprived for 24 hours. On the day of the experiment, mice 
were acclimated to the behavior room for 1 hour. A single preweighed food pellet was placed in the home 
cage and the mice were allowed to eat for 10 minutes during optogenetic stimulation. At the end of the 
experimental session, the pellet was removed and weighed and mice were given ad lib access to food.  
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Htr2CCre mice were acclimated in metabolic chambers (TSE Systems, Germany) for 2 days before the start 
of the recordings. After acclimation, mice were food deprived for 24 hours. Following fasting, mice 
received an IP injection of CNO 30 minutes before food presented again. Mice were recorded for 12 
hours with the following measurements being taken every 30 minutes: water intake, food intake, 
ambulatory activity (in X and Z axes), and gas exchange (O2 and CO2) (using the TSE LabMaster system, 
Germany). Energy expenditure was calculated according to the manufacturer’s guidelines (PhenoMaster 
Software, TSE Systems).  
Fear Conditioning: We used a three day protocol to assess both cued and contextual fear recall. On the 
first day, mice were placed into a fear conditioning chamber (Med Associates) that contained a grid floor 
and was cleaned with a scented paper towel (19.5% EtOH, 79.5% H2O, 1% vanilla). After a 3 minute 
baseline period, mice were exposed to a 30 second tone (3 KHz, 80 dB) that co-terminated with a 2 
second scrambled foot shock (0.6 mA). A total of 5 tone-shock pairings were delivered with a random 
inter-tone interval (ITI) of 60-120 seconds. For optogenetic studies, light stimulation occurred only during 
the 30-second tones of this session. Following delivery of the last foot shock, mice remained in the 
conditioning chamber for a two minute consolidation period. 24 hours later, mice were placed into a 
separate conditioning box (Med Associates) that contained a white Plexiglas floor, a striped pattern on the 
walls, and was cleaned and scented with a 70% EtOH solution. After a 3 minute baseline period, mice 
were presented with 10 tones (30 seconds, 3 KHz, 80 dB) with a 5 second ITI. Mice remained in the 
chamber after the last tone for a two-minute consolidation period. 24 hours later (48 hours after training), 
mice were returned to the original training chamber for 5 minutes. For each session, freezing behavior 
was hand-scored every 5 seconds by a trained observer blinded to experimental treatment as described 
previously(Hefner et al., 2008). Freezing was defined as a lack of movement except as required for 
respiration.  
Immunohistochemistry and histology: All mice used for behavioral and anatomical tracing experiments 
were anesthetized with Avertin and transcardially perfused with 30 ml of ice-cold 0.01M PBS followed by 
30 ml of ice-cold 4% paraformaldehyde (PFA) in PBS. Brains were extracted and stored in 4% PFA for 24 
hours at 4°C before being rinsed twice with PBS and stored in 30% sucrose/PBS until the brains sank. 45 
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µm slices were obtained on a Leica VT100S and stored in 50/50 PBS/Glycerol at -20°C. DREADD or 
ChR2-containing sections were mounted on slides, allowed to dry, coverslipped with VectaShield (Vector 
Labs, Burlingame, CA), and stored in the dark at 4°C.  
Tryptophan hydroxylase/Fluorogold/cfos triple labeling We stained free-floating dorsal raphe sections 
using indirect immunofluorescence sequentially for first tryptophan hydroxylase (TPH) and Fluoro-
Gold(FG) and then c-fos. For TPH/FG, we washed sections 3X for 5 min with 0.01 M PBS, permeabilized 
them for 30 min in 0.5% Triton/0.01 M PBS, and washed the sections again 2X with 0.01 M PBS. We 
blocked the sections for 1 hour in 0.1% Triton/0.01 M PBS containing 10%(v/v) Normal Donkey Serum 
and 1%(w/v) Bovine Serum Albumin (BSA). We then added primary antibodies (1:500 Mouse anti-TPH 
[Sigma Aldrich T0678] and 1:3000 Guinea Pig anti-Fluoro Gold [Protos Biotech NM101]) to blocking 
buffer and incubated the sections overnight at 4 degrees C. The next day, we washed the sections 3X for 
5 min with 0.01 M PBS, then incubated them with 1:500 with Alexa Fluor 647-conjugated Donkey anti-
mouse and Alexa Fluor 488-conjugated Donkey anti-guinea pig secondary antibodies for 2 hr at RT, and 
washed the sections 4X for 5 min with 0.01 M PBS. We then proceeded directly to the c-fos tyramide 
signal amplification based immunofluorescent staining. We permeabilized the sections in 50% methanol 
for 30 min, then quenched endogenous peroxidase activity in 3% hydrogen peroxide for 5 min. Followed 
by two 10 min washes in 0.01 M PBS, we blocked the sections in PBS containing 0.3% Triton X-100 and 
1.0 % BSA for 1 hour. c-fos primary antibody (Santa Cruz Biotechnology - sc-52) was added to sections 
at 1:3000 and sections were incubated for 48 hours at 4 degrees. On day 3, we washed the sections in 
TNT buffer (0.1 M Tris-HCl pH 7.5, 0.15 M NaCl, 0.05% Tween-20) for 10 min, blocked in TNB buffer (0.1 
M Tris-HCl pH 7.5, 0.15 M NaCl, 0.5% Blocking reagent – PerkinElmer FP1020) buffer for 30 min. We 
then incubated the sections in secondary antibody (Goat anti-rabbit HRP-conjugated- PerkinElmer) 1:200 
in TNB buffer for 30 min., washed the sections in TNT buffer 4X for 5 min, and then incubated the 
sections in Cy3 dye diluted in TSA amplification diluents for 10 min. We washed the sections 2X in TNT 
buffer, mounted them on microscope slides. We coverslipped the slides using Vectashield mounting 
medium.  We acquired 4-5 2x4 tiled z-stack(5 optical slices comprising 7 µm total) images of the dorsal 
raphe from each naïve and shock mouse on a Zeiss 800 Upright confocal microscope. Scanning 
parameters and laser power were matched between groups. Images were preprocessed using stitching 
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and maximum intensity projection and then analyzed using an advanced processing module in Zeiss Zen 
Blue that allows nested analysis of multiple segmented fluorescent channels within parent classes. 
Double and triple-labeled cells were validated in a semi-automated fashion. At least 4 sections per mouse 
were counted in this way. One mouse was identified as a significant outlier in the Shock group and was 
excluded from further analysis. 
SertCre::ChR2, and CrfIntrsect-ChR2 validation: To verify expression of ChR2-expressing fibers in the BNST 
originating from DR serotonergic neurons, 300 µm slices used for ex vivo electrophysiological recordings 
containing the DR and BNST were stored in 4% paraformaldehyde at 4°C for 24 hours before being 
rinsed with PBS, mounted, and coverslipped with Vectashield mounting medium. Images showing eYFP 
fluorescence from the DR and BNST were obtained on a Zeiss 800 upright confocal microscope using a 
10x objective and tiled z stacks. To validate the INTRSECT construct, mice received injections of HSV-
hEF1α-mCherry or HSV-ef1α-LSL1-mCherry-IRES-flpo to both the LH and VTA bilaterally (N=4 and 5, 
respectively). Both groups received AAVDJ-hSyn-Cre-on/Flp-off-hChR2(H134R)-EYFP to the BNST 
bilaterally. Six weeks following injection, mice were perfused and tissue was collected as described 
above. To visualize YFP expression in the BNST of CrfCre::IntrsectBNST mice, free floating slices containing 
the BNST were rinsed three times with PBS for 5 minutes each. Slices were then incubated in 50% 
methanol for 30 minutes then incubated in 3% hydrogen peroxide for 5 minutes. Following three 10-
minute washes in PBS, slices were incubated in 0.5% Triton X-100 for 30 minutes followed by a 10 
minute PBS wash. Slices were blocked in 10% normal donkey serum/0.1% Triton X-100 for 1 hour, and 
then they were incubated overnight at 4°C with a primary chicken anti-GFP antibody (GFP-1020, Aves) at 
1:500 in blocking solution. Following primary incubation, slices were rinsed three times with 0.01M PBS 
for 10 minutes each and incubated with a fluorescent secondary antibody (AlexaFluor 488 Donkey anti-
chicken) at 1:200 in PBS for 2 hours at room temperature. Slices were then rinsed with four 10-minute 
PBS washes before being mounted onto glass slides and coverslipped with Vectashield with DAPI. A 3x4 
tiled z stack (7 optical sections comprising 35 µm total) image from both the left and right hemispheres of 
the BNST was obtained at 20x magnification using a Zeiss 800 upright confocal microscope. Scanning 
parameters and laser power were matched between groups. Images were preprocessed using stitching 
and maximum intensity projection. The number of fluorescent cells in the dorsal and ventral aspects of 
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the BNST were counted by a blinded scorer using the cell counter plug-in in FIJI (ImageJ). Each 
hemisphere was considered independently per mouse. One mouse in the flp-expressing group was a 
significant outlier for number of cells expressed in a ventral BNST hemisphere (ROUT, Q=0.1%) and all 
data from that mouse were excluded.   
Choleratoxin retrograde tracer studies in CRF reporter mice: 3 male CRF-L10a reporter mice were 
injected with 200 nl of CTB 555 and CTB 647 bilaterally to the LH and VTA, respectively, as described 
above. 5 days following injection, mice were perfused as described above, the brains were extracted, and 
were stored in 4% paraformaldehyde for 24 hours at 4°C before being rinsed with PBS and transferred to 
30% sucrose until the brains sank. 45 µm sections containing the BNST were collected as described 
above. Sections containing the BNST were mounted on glass slides and coverslipped using Vectashield. 
An image from the left and right hemispheres of a medial section of the BNST was obtained on a Zeiss 
800 upright microscope using a 20x objective and 3x5 tiled z stacks (5 optical slices comprising 7 µm 
total). Images were preprocessed using stitching and maximum intensity projection, and were then 
analyzed using the cell counter function in FIJI (ImageJ). Only cells positive for GFP (putative CRF 
neurons) were considered. Cells were scored exclusively as either 555+ only (LH-projecting), 647+ only 
(VTA-projecting), 555+ and 647+ (projecting to both LH and VTA), or 555- and 647- (unlabeled; neither 
LH- nor VTA- projecting). The total number of CRF neurons scored was calculated as the sum of all four 
groups, and percentages of each type were calculated from this value. Each hemisphere was scored and 
plotted independently (N=6 images from 3 mice), and the dorsal and ventral BNST were considered 
separately. The average values were plotted as pie charts (ED 9). 
Double Fluorescence in situ hybridization (FISH): For validation of 2C-cre line and comparison of 
CRF/2C mRNA cellular colocalization, mice were anesthetized using isoflurane, rapidly decapitated, and 
brains rapidly extracted. Immediately after removal, the brains were placed on a square of aluminum foil 
on dry ice to freeze. Brains were then placed in a -80°C freezer for no more than 1 week before slicing. 
12 µm slices were made of the BNST on a Leica CM3050S cryostat (Germany) and placed directly on 
coverslips. FISH was performed using the Affymetrix ViewRNA 2-Plex Tissue Assay Kit with custom 
probes for CRF, 5-HT2C, and Cre designed by Affymetrix (Santa Clara, CA). Slides were coverslipped 
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with SouthernBiotech DAPI Fluoromount-G. (Birmingham, AL). 3x5 tiled z stack (15 optical sections 
comprising 14 µm total) images of the entire 12 µm slice were obtained on a Zeiss 780 confocal 
microscope for assessment of CRF/2C colocalization. A single-plane 40x tiled image of a CRF/2C slice 
was obtained on a Zeiss 800 upright confocal microscope for the magnified image shown in Extended 
Data 6b, right.  3x5 tiled z stack (7 optical sections comprising 18 µm) images of 2C/Cre slices were 
obtained on a Zeiss 800 upright confocal microscope for the 2C/Cre validation. All images were 
preprocessed with stitching and maximum intensity projection. An image of the BNST from 3 mice in each 
condition was hand counted for each study using the cell counter plugin in FIJI (ImageJ). Cells were 
classified into three groups: probe 1+, probe 2+, or probe 1 and 2 +. Only cells positive for a probe were 
considered. Results are plotted as average classified percentages across the three images.  
Group assignment: No specific method of randomization was used to assign groups. Animals were 
assigned to experimental groups so as to minimize the influence of other variables such as age or sex on 
the outcome.  
Inclusion/exclusion criteria: Pre-established criteria for excluding mice from behavioral analysis 
included 1) missed injections, 2) anomalies during behavioral testing, such as mice falling off the elevated 
plus maze, 3) damage to or loss of optical fibers, 4) statistical outliers, as determined by the Grubb’s test.  
Sample size: A power analysis was used to determine the ideal sample size for behavior experiments. 
Assuming a normal distribution, a 20% change in mean and 15% variation, we determined that we would 
need 8 mice per group. In some cases, mice were excluded due to missed injections or lost optical fibers 
resulting in fewer than 8 mice per group. For electrophysiology experiments, we aimed for 5-7 cells from 
3-4 mice.  
Statistics: Data are presented as means ± SEM. For comparisons with only two groups, p values were 
calculated using paired or unpaired t-tests as described in the figure legends. Comparisons across more 
than two groups were made using a one-way ANOVA, and a two-way ANOVA was used when there was 
more than one independent variable. A Bonferonni posttest was used following significance with an 
ANOVA. In cases in which ANOVA was used, the data met the assumptions of equality of variance and 
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independence of cases. If the condition of equal variances was not met, Welch’s correction was used. 
Some of the sample groups were too small to detect normality (<8 samples) but parametric tests were 
used because nonparametric tests lack sufficient power to detect differences in small samples (Graphpad 
Statistics Guide – www.graphpad.com). The standard error of the mean is indicated by error bars for each 
group of data. Differences were considered significant at p values below 0.05. All data were analyzed with 
GraphPad Prism software. 
3.3 Results 
Electrophysiological interrogation of 5-HT inputs from the DR to the BNST  
In view of multiple converging lines of evidence pinpointing 5-HT as a critical neuromodulator of 
pathological fear learning (Burghardt et al., 2007; Ravinder et al., 2013), we first interrogated the 
endogenous recruitment of the 5-HTDRN→BNST circuit by an aversive footshock stimulus. Using fluorogold to 
retrogradely label BNST-projecting 5-HT neurons in the DRN, we found that c-fos, an immediate early 
gene indicative of in vivo neuronal activation, was significantly elevated in 5-HTDRN→BNST neurons after 
footshock (Figure 3.1a-f). Using in vivo electrophysiology, we then probed the neuronal dynamics of the 
BNST during fear conditioning and recall and found evidence for engagement during both conditioning 
and recall (Figure 3.2).  
To decipher the role of this 5-HTDRN→BNST circuit in aversive behavior, Channelrhodopsin2 (ChR2)-
eYFP was selectively expressed in 5-HTDRN neurons through the delivery of a Cre-inducible viral vector in 
mice expressing Cre recombinase under the control of a serotonin transporter promoter (SertCre) for both 
in vivo and ex vivo analysis. We observed eYFP+ (5-HT) cell bodies in the DRN and eYFP+ fibers in both 
the dorsal and ventral aspects of the BNST (SertCre::ChR2DRN→BNST), confirming a direct projection of 5-HT 
neurons originating in the DRN to the BNST (Figure 3.1g-h)(Phelix et al., 1992). Optical stimulation of 
these fibers in BNST slices evoked 5-HT release, as measured by fast-scan cyclic voltammetry (FSCV) 
(Figure 3.1i-j). Furthermore, bath application of the SSRI fluoxetine reliably decreased the rate of 5-HT 
reuptake, confirming that photostimulation of SERT+ terminals in the BNST originating from the DRN 
induces 5-HT release (Figure 3.1k-l).  
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Stimulation of 5-HT inputs to the BNST increases anxiety and fear learning 
We next examined whether this 5-HTDRN→BNST circuit is functionally relevant for fear and anxiety-
like behavior.  To investigate this, SertCre::ChR2DRN→BNST mice were implanted with bilateral optical fibers 
and photostimulated in the BNST (473 nm, 20 Hz) using a standard tone-shock fear conditioning 
paradigm. Optogenetic stimulation of this pathway was paired with a tone that co-terminated with a 
scrambled footshock. Cued fear was assessed 24 hours after, and contextual fear 48 hours after, the 
initial fear acquisition session (Figure 3.1m-n). While no changes were observed during fear acquisition, 
both cued and contextual fear recall were significantly heightened in photostimulated 
SertCre::ChR2DRN→BNST mice (Figure 3.1o-q).  We next assessed anxiety-like behavior using well-
characterized assays, the elevated plus maze (EPM) and novelty-suppressed feeding (NSF) tests. Upon 
stimulation with light, SertCre::ChR2DRN→BNST mice exhibited enhanced anxiety-like behavior in both the 
EPM and NSF (Figure 3.1r-s and Figure 3.3a-b). Importantly, photostimulation did not induce 
hypolocomotion in the EPM or open field tests nor did it alter home-cage feeding, thus confirming that 
hypophagia in the NSF assay was due to anxiety and not a reduction in appetitive drive (Figure 3.3c-e).  
One potential explanation of these results is that terminal stimulation in the BNST produces antidromic 
spikes in DRN cell bodies that release 5-HT in other brain regions, which could be also be driving these 
behaviors. In light of this, we probed the mechanism more deeply using converging approaches. 
Characterization of 5-HT actions on BNST CRF neurons and contributions of the 5-HT2C receptor 
to anxiety 
To determine a receptor target through which 5-HT is signaling in the BNST, we then examined 
the impact of optogenetically evoked 5-HTDRN release on postsynaptic neuronal excitability and found a 
3.05 ± 0.59 mV depolarization that was blocked by a 5-HT2CR antagonist (Figure 3.1t-u). In contrast to 
previous reports demonstrating co-release of 5-HT and glutamate from DRN projections to the nucleus 
accumbens(Liu et al., 2014), we did not observe any time-locked light-evoked EPSCs in the BNST (data 
not shown). These results indicate that 5-HTDRN→BNST projections have a predominantly excitatory effect 
that is dependent on 5-HT2CR signaling. To examine the role of 5-HT2CR containing neurons in anxiety-
like behavior, we next took advantage of a Htr2cCre mouse line (Figure 3.4a-b)(Burke et al., 2016). Using 
Designer Receptors Exclusively Activated by Designer Drugs (DREADDs)(Armbruster et al., 2007), we 
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found that activation of Gq signaling in 5-HT2CR-expressing neurons in the BNST significantly delayed the 
onset of feeding in the NSF assay without impacting home cage feeding behavior (Figure 3.4c-g), thus 
phenocopying the effect observed with 5-HTDRN→BNST fiber stimulation during NSF. Taken together, these 
results provide converging evidence that activation of 5-HTDRN→BNST inputs elicits anxiety-like behavior via 
5-HT2CR signaling.  
We then considered the neurochemical phenotype of these target 5-HTDRN→5-HT2CRBNST neurons 
and hypothesized that 5-HT via 5-HT2CR modulates the activity of neurons expressing the neuropeptide 
CRF.  This hypothesis was based upon a previous analysis of 5-HT2CR knockout mice, which exhibit an 
anxiolytic phenotype associated with a reduction of c-fos in CRFBNST neurons(Heisler et al., 2007). 
Initially, using CRF reporter mice to a priori select CRF neurons for recordings, we found a 
heterogeneous 5HT-induced response of CRFBNST (Figure 3.5a), with only a subset demonstrating a 
depolarization.  Consistent with this, double fluorescence in situ hybridization revealed that only a subset 
of  CRF neurons within the dorsal BNST (~70%) and ventral BNST  (~43%%) express 5-HT2CRs (Figure 
3.5b-d). 
Dissection of BNST CRF neuron projections to the LH and VTA 
While CRF signaling within the BNST is classically associated with anxiety-like behavior(Olive et 
al., 2002; Huang et al., 2010), more recent studies using circuit-based tools have found that optogenetic 
stimulation of GABAergic projections (which include CRFBNST neurons) to the VTA are 
anxiolytic(Jennings, Sparta, et al., 2013). This led us to hypothesize the existence of functionally distinct 
subsets of CRFBNST neurons that gate different behaviors and are differentially sensitive to 5HT. We used 
fluorescent retrograde tracer beads to label CRFBNST neurons as VTA-projecting or non-VTA-projecting 
(Figure 3.6a) and found that VTA-projecting CRF neurons (CRFBNST→VTA neurons) were hyperpolarized by 
an average of 5.73 ± 1.24 mV and non-VTA-projecting CRF neurons were depolarized by an average of 
2.74 ± 0.39 mV during 5-HT bath application. Moreover, the excitatory response to 5-HT in non-VTA-
projecting CRF neurons was reversed in the presence of a 5-HT2C receptor antagonist (Figure 3.6b). 
Furthermore, all CRFBNST→VTA neurons were non-responsive to the 5-HT2R agonist meta-
Chlorophenylpiperazine (mCPP), while all non-VTA projecting CRF neurons were depolarized by mCPP 
by an average of 3.78 ± 1.17 mV (Figure 3.5e-h). These findings suggest an anatomically distinct 
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response to 5-HT by different subsets of CRFBNST neurons.  The subset of CRFBNST neurons expressing 5-
HT2CRs do not project to the VTA and are depolarized by 5-HT, whereas the CRFBNST→VTA neurons are 
hyperpolarized by 5-HT, via actions at another 5-HT receptor. 
To determine if this 5-HT-dependent mechanism extended to other anxiolytic efferents, we 
injected retrograde tracer beads into the lateral hypothalamus (LH) of CRF reporter mice and found 5-HT 
had similar bidirectional effects on non-LH and LH projecting CRFBNST neurons (Figure 3.7a-c). Noting the 
functional similarities between these two populations, we used retrograde tracing to determine that 
roughly ~58% of CRFBNST neurons have projections to the LH or VTA (Figure 3.7d-f). Notably, ~20-31% of 
these CRFBNST output neurons form parallel projections to these structures.   
In light of recent reports that CRFBNST neurons are exclusively GABAergic(Dabrowska et al., 
2011), we hypothesized that non-VTA-projecting CRFBNST neurons may locally inhibit BNST→VTA 
neurons to promote fear and anxiety. To test this hypothesis, we injected CrfCre mice with a Cre-inducible 
ChR2 into the BNST and retrograde tracer beads into the VTA. We then recorded light-evoked IPSCs 
from non-ChR2 (ChR2-negative, retrograde tracer-positive) VTA-projecting BNST neurons (Figure 3.6c). 
Photostimulation produced action potentials in CRFBNST neurons and light-evoked IPSCs in non-ChR2 
VTA-projecting neurons, indicating that CRFBNST neurons form local GABAergic synapses with BNST 
neurons that project to the VTA.  Repeating these same experiments in CrfCRE::ChR2BNST mice with 
retrograde tracer beads in the LH, we found that we could light-evoke GABA currents in LH projecting 
neurons as well (Figure 3.7g-i). Moreover, we observed that 5-HT increased GABAergic transmission on 
to BNST→VTA projecting neurons in a tetrodotoxin and 5-HT2CR antagonist dependent manner (Figure 
3.6d-f and Figure 3.7j-n).  Similar effects of 5-HT on GABAergic transmission were found in BNST→LH 
projecting neurons (Figure 3.7o-v). Furthermore, slice recordings in a CRF reporter line indicates that 5-
HT does not increase GABAergic transmission on to the general population of CRFBNST neurons nor does 
it directly excite non-CRF VTA projecting neurons (Figure 3.8). The 5-HT2R agonist mCPP also increased 
GABAergic but not glutamatergic transmission in the BNST (Figure 3.9).  Finally, to test if optically evoked 
5-HT can inhibit BNST outputs to the VTA, we performed slice recordings in the BNST of 
SertCre::ChR2DRN→BNST mice and found that brief photostimulation of 5-HT terminals in the BNST increased 
sIPSCs on to VTA projecting BNST neurons in a manner similar to bath applied 5-HT (Figure 3.10a-c). 
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Together, these experiments indicate that CRFBNST neurons inhibit at least two major BNST outputs to the 
VTA and LH that are reported to be anxiolytic (Kim et al., 2013; Jennings, Sparta, et al., 2013), providing 
mechanistic insight into the aversive actions of 5-HT signaling in the BNST. 
We next took advantage of an intersectional strategy for direct visualization of these non 
projecting, putatively local CRFBNST neurons(Fenno et al., 2014). By coupling retrograde Cre-dependence 
flpases (HSV-LSL1-mCherry-IRES-flpo) in the VTA and LH with INTRSECT(Creon/flpoff)-Chr2-eYFP in the 
BNST of Crfcre mice (CrfCre::Intrsect-ChR2BNST mice), we were able to genetically isolate non-VTA/LH 
projecting CRF neurons in the BNST. We also infused Cre-dependent HSV-mCherry vector in a subset of 
CrfCre::Intrsect-ChR2BNST mice as a control. In HSV-flp infused CrfCre::Intrsect-ChR2BNST mice, we 
observed a significant reduction in YFP+ cells in the ventral BNST (Figure 3.10d-f), indicating that a large 
proportion of VTA and LH-projecting CRFBNST neurons are located in the ventral BNST. We also found 
that 5-HT robustly depolarized these CrfCre::Intrsect-ChR2BNST neurons compared to CRF neurons at 
large (Figure 3.6g-i). Furthermore, we observed light evoked IPSCs in the BNST of CrfCre::Intrsect-
ChR2BNST mice, confirming local GABA release from these neurons (Figure 3.10g).  These results support 
the existence of a separate population of local CRFBNST neurons that is excited by 5-HT and increases 
local GABAergic transmission in the BNST, distinct from a population of CRFBNST neurons that project to 
and release GABA in the VTA or the LH (Figure 3.10h-j). 
BNST CRF neurons contribute to SSRI-induced increases in fear 
 To probe the translational relevance of these BNST microcircuits, we adopted a pharmacological 
approach using SSRIs. SSRIs represent one of the most widely used classes of drugs for psychiatric 
disorders.  One limitation of SSRIs is that acute administration can lead to negative behavioral 
states(Gorman et al., 1987; Westenberg & den Boer, 1989), a finding that is recapitulated in rodent 
models(Burghardt et al., 2007; Dekeyne et al., 2000; Belzung et al., 2001; Javelot et al., 2011; Liu et al., 
2010; Mombereau et al., 2010).  Importantly, the BNST has been demonstrated to be an anatomical site 
of action for some of the aversive actions of SSRIs in rodents(Ravinder et al., 2013).  This provided the 
opportunity to test our model that 5-HT in the BNST drives aversive behavior through inhibition of BNST 
outputs to the VTA. We observed that an acute systemic injection of the SSRI fluoxetine increased 
GABAergic transmission on to VTA projecting neurons in the BNST (Figure 3.11a-d). We then 
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interrogated the role of CRFBNST neurons in acute fluoxetine-enhanced anxiety using CrfCRE mice 
transduced in the BNST with the Cre-inducible Gi-coupled DREADD.  We found that acute fluoxetine 
potentiated anxiety-like behavior, and this effect was blocked by chemogenetic inhibition of CRFBNST 
neurons (Figure 3.11e-h).  
To evaluate directly whether endogenous 5-HT acts on CRFBNST neurons to enhance cued fear 
memory, we used the same chemogenetic approach to silence CRFBNST neurons during fluoxetine 
treatment and subsequent fear conditioning (Figure 3.11i). Chemogenetic inhibition of CRFBNST neurons 
also significantly attenuated fluoxetine-induced enhancement of cued fear recall, providing proof of 
concept that augmentation of 5-HT via acute SSRI treatment recruits CRFBNST neurons to enhance fear-
related behavior (Figure 3.11j-k). Next, using connectivity based chemogenetic approaches; we tested 
whether inhibition of BNST outputs to the VTA and LH is a critical component of 5-HT→BNST-induced 
aversive states. We observed that activation of Gq signaling in VTA- and LH-projecting BNST neurons, 
targeted by HSV-Cre-eYFP infused in the VTA and LH and Cre-dependent Gq-coupled DREADD infused 
in the BNST (HSVCre::hM3DqBNST), significantly attenuated fluoxetine enhancement of cued fear recall 
(Figure 3.11l-o). Together, these data provide compelling evidence that acute fluoxetine engenders 
aversive behavior by recruiting CRF neurons in the BNST that in turn inhibit putative GABAergic 
(anxiolytic and stress buffering) outputs from the BNST to the VTA and LH. Pharmacological interventions 
that target this circuit may improve adverse symptoms during the initial weeks of SSRI treatment. Based 
on the critical role for CRFBNST neurons in fluoxetine induced aversive behavior, we examined the impact 
of a systemic CRF1R antagonist on SSRI enhancement of cued fear recall. Notably, blocking the CRF 
system reduced this aversive state and abolished the increase in sIPSCs in LH-projecting neurons in the 
BNST during bath application of 5-HT (Figure 3.12). This provides translational evidence that CRF1R 
antagonists given in concert with SSRIs could be a promising treatment for anxiety disorders. 
Taken together, these data reveal a discrete 5-HT responsive circuit in the BNST that underlies 
pathological anxiety and fear associated with a hyperserotonergic state (Figure 3.13). SSRIs are currently 
a first-line treatment for anxiety and panic disorders but can acutely exacerbate symptoms, resulting in 
poor therapeutic compliance. Our results strongly implicate 5-HT engagement of a local BNST inhibitory 
microcircuit in acute SSRI induced aversive behaviors in rodents, and could potentially be involved in the 
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early adverse events seen in clinical populations, emphasizing the need to identify compounds that 
selectively target both genetically-defined and pathway-specific cell populations.   
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3.4 Figures
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Figure 3.1: Optogenetic identification of a 5-HT DRN→BNST projection that elicits anxiety and 
fear-related behavior. (a) Experimental timeline for c-fos labeling of 5-HTDRN→BNST neurons following an 
aversive footshock stimulus. (b) Representative images of fluorogold (blue), tryptophan hydroxylase 
(violet), and c-fos (green) staining in the DRN for 13 mice. Scale bars: 100 µm. (c-f) Histograms depicting 
the number of double and triple labeled neurons in the DRN of naïve and shocked mice. (c) There were 
no significant differences in the number of BNST projecting 5-HTDRN neurons between groups. (d-f) 
Footshock lead to significant elevations in the number of c-fos+ (“activated”) 5-HT neurons (t11=2.975, 
p<0.05, Student’s unpaired two-tailed t-test, n=7 naïve and n=6 shock mice), c-fos+, fluorogold labeled 
neurons (t11=2.836, p<0.05, Student’s unpaired two-tailed t-test, n=7 naïve and n=6 shock mice), and 
triple labeled neurons (t11=2.374, p<0.05, Student’s unpaired two-tailed t-test, n=7 naïve and n=6 shock 
mice). (g) Experimental configuration for light-evoked FSCV experiments in SertCre::ChR2DRN→BNST mice 
(h) Coronal images showing ChR2-YFP expression in soma of the DRN and axons of the BNST. Scale 
bars: 500 µm. (i) Representative color plot of 5-HT release to optical stimulation (blue bar, 20 Hz 20 
pulses) for 3 mice (j) Representative cyclic voltammogram at peak 5-HT (blue dashed line panel E) for 3 
mice. (k) Representative Current vs. Time trace at baseline  (black) and following 10 µM fluoxetine (red) 
for 3 mice. (l) Clearance half-life of 5-HT at baseline (white bar) and following 10 µM fluoxetine (red bar). 
(t2=8.43, p<0.05, Student’s paired two-tailed t-test, n = 3 slices from 3 mice) (m) SertCre mice were 
transduced in the DRN and implanted with bilateral optical fibers in the BNST. (n) Schematic of fear 
conditioning procedures in SertCre::ChR2DRN→BNST mice. (o-q) Photostimulation during fear acquisition had 
no effect on freezing behavior during fear learning but increased freezing during cued (t17=2.436, p<0.05, 
Student’s unpaired two-tailed t-test, n=10 control, n=9 ChR2) and contextual fear recall (t17=2.271, 
p<0.05, Student’s unpaired two-tailed t-test, n=10 control, n=9 ChR2). (r) Light delivery to the BNST 
reduced open arm time in the EPM (t15=2.79, p<0.05, Student’s unpaired two-tailed t-test, n=8 control, 
n=9 ChR2) and (s) increased latency to feed in the NSF (t17=2.19, p<0.05, Student’s unpaired two-tailed t-
test, n=9 control, n=10 ChR2). (t) Action potentials generated by photostimulation in the DRN (5 Hz (top), 
10 Hz (middle), 20 Hz (bottom), 473 nm). (u) Depolarization in cells (t8=5.20, p<0.01, One-sample t-test, 
n=9 cells from 4 mice) after photostimulation in the BNST (5 Hz, 10 s, 473 nm) and blockade of this 
response by 5 µM RS 102221 (t4=2.5, p>0.05, One-sample t-test, n=5 cells from 2 mice). Data are mean 
± s.e.m. *P<0.05; **P<0.01; ***P<0.001. 
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Figure 3.2: In vivo recordings in BNST neurons during fear conditioning reveal opposite patterns of 
activation during acquisition and recall. (a) Representative neuron firing rate and (b) population Z score 
of the firing rate for BNST neurons (n=45 cells from 7 mice) 30 s before conditioned stimulus (tone), during 
the conditioned stimulus, and 30 seconds after the unconditioned stimulus. (c) Percentage time spent 
freezing during fear acquisition, cued fear recall and contextual fear recall. (d) Electrode placements for 
BNST recordings. (e) Raw firing rates during freezing (blue) versus movement (red) epochs were averaged 
across all putative principal neurons (firing rate <10Hz). Acquisition: Cells in BNST exhibited greater 
average firing rates during freezing epochs compared to movement epochs during CS3 (t44=2.88, p<0.01, 
Student’s unpaired two-tailed t-test), 4 (t44=3.14, p<0.01, Student’s unpaired two-tailed t-test), and 5 
(t44=4.4, p<0.001, Student’s unpaired two-tailed t-test) (n=45 cells from 7 mice). CS Recall: Average firing 
rates during freezing epochs decreased over CS presentations such that firing during block 5 was 
significantly less than block 1 (t41=3.44, p=0.001, Student’s unpaired two-tailed t-test). Freezing firing rates 
during block 5 were also significantly less than movement epochs during block 5 (t41=4.03, p<0.001, 
Student’s unpaired two-tailed t-test) (n=42 cells from 7 mice).  CX test: Average firing rate was significantly 
greater during movement versus freezing epochs during minutes 1 (t44=4.83, p<0.001, Student’s unpaired 
two-tailed t-test), 2 (t44=3.17, p<0.01, Student’s unpaired two-tailed t-test), and 5 (t44=4.36, p<0.001, 
Student’s unpaired two-tailed t-test) (n=45 cells from 7 mice). (f) Freezing-related changes in firing rates 
during the CS were determined by measuring the ratio of average firing rates during freezing versus 
movement epochs for each session. Acquisition: Activity during freezing epochs increased significantly 
relative to movement epochs during CS4 (t45=3.26, p<0.01, Student’s unpaired two-tailed t-test) and CS5 
(t45=2.17, p<0.05, Student’s unpaired two-tailed t-test) (n=46 cells from 7 mice). CS Recall: Freezing 
significantly suppressed activity relative to movement epochs during the last two CS presentations (t47=5.29, 
p=<0.001, Student’s unpaired two-tailed t-test) (n=48 cells from 7 mice) CX test: Freezing significantly 
suppressed activity during minutes 1 (t44=6.06, p<0.001, Student’s unpaired two-tailed t-test), 2 (t44=2.92, 
p<0.01, Student’s unpaired two-tailed t-test), and 5 (t44=3.55, p=.001, Student’s unpaired two-tailed t-test) 
(n=45 cells from 7 mice). (g) Plots showing correlation between freezing behavior and firing rate of BNST 
neurons across sessions and for all sessions. Data are mean ± s.e.m. *P<0.05 **P<0.01; ***P<0.001. Scale 
bar = 100 µm. 
  
 74  
 
 
Figure 3.3: Effects of optogenetic stimulation of 5HT inputs to the BNST on feeding, anxiety and 
locomotion. (a-c) SertCre::ChR2DRN→BNST mice exhibited reduced probability (t15=2.67, p<0.05, Student’s 
unpaired two-tailed t-test, n=8 control, n=9 ChR2) and latency (t15=1.003, p>0.05, Student’s unpaired two-
tailed t-test, n=8 control, n=9 ChR2) to enter the open arms of the EPM without exhibiting locomotor 
deficits. (d) Photostimulation of 5-HTDRN→BNST terminals had no effect on locomotor activity in the open 
field (n=9 control, n=11 ChR2) or (e) home cage feeding (n=4 control, n=6 ChR2). Data are mean ± 
s.e.m. *P<0.05. 
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Figure 3.4: Chemogenetic activation of 5-HT2CR expressing neurons in the BNST increases 
anxiety-like behavior. (a) Confocal images of coronal BNST slices obtained from htr2cCre mice following 
double fluorescence in situ hybridization for 5-HT2CR and cre.  Yellow arrows indicate cells in which there 
is colocalization, red arrows indicate cells in which only Cre is expressed and green arrows indicate cells 
in which only 5-HT2CR is expressed.  (b) Pie chart representing the distribution of genetic markers in 
BNST neurons. (c) Experimental configuration in Htr2ccre::hM3DqBNST mice. (d) Coronal images showing 
cfos induction in 5-HT2CR expressing neurons in the BNST of Htr2cCre::hM3DqBNST or 
Htr2cCre::mCherryBNST mice following CNO injection. (e) Bath application of CNO depolarized 5HT2CR-
expressing neurons expressing hM3Dq in slice (n=3 cells from 3 mice). (f) Chemogenetic stimulation of 5-
HT2CR expressing neurons in BNST increased latency to feed in the NSF (t11=2.591, p<0.05, Student’s 
unpaired two-tailed t-test, n=6; mCherry, n=7 hM3Dq). (g) Chemogenetic activation of 5-HT2CR-
expressing BNST neurons had no effect on home cage feeding (n=5 mCherry, n=6 hM3Dq). (h) Confocal 
images from Htr2cCre::mCherryBNST mice showing mCherry expression in 5-HT2CR-expressing soma in the 
BNST and fibers in the LH and VTA. Data are mean ± s.e.m. *P<0.05. Scale bar = 100 µm. 
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Figure 3.5: Electrophysiological characterization of 5-HT responses and 5-HT receptor expression 
in BNST CRF neurons (a) A pie chart showing the distribution of CRFBNST neurons that were 
depolarized, hyperpolarized, or had no response to 5-HT (n=8 cells from 4 mice). (b) Coronal images of 
the BNST showing colocalization of 5-HT2CRs with CRF mRNA using double fluorescence in situ 
hybridization and (c-d) histograms showing the % of 5-HT2C neurons that express CRF and the % of CRF 
neurons that express 5-HT2CRs in the BNST (n=3 slices from 3 mice). (e) Recording configuration in 
CRFBNST neurons. (f) Slice electrophysiology in BNST of Crf reporter mice showing depolarization of all 
(VTA-projecting and non-projecting) CRF neurons following bath application of the 5-HT2 receptor agonist 
mCPP (n=12 cells from 6 mice) and blockade of this response by the 5-HT2C receptor antagonist RS 
102221 (n=5 cells from 3 mice). (g) Change in membrane potential induced by mCPP (t12=2.18, p<0.05, 
One-sample t-test, n=12 cells from 6 mice) is blocked by a 5-HT2CR antagonist (n=5 cells from 3 mice). 
(h) mCPP selectively depolarizes non-VTA projecting CRFBNST neurons (n=3 cells from 2 mice non VTA-
projecting CRF, n=5 cells from 4 mice VTA-projecting CRF). Data are mean ± s.e.m. *P<0.05. 
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Figure 3.6: Serotonin activates a local population of BNST CRF neurons that inhibits outputs to 
the midbrain.  (a) Recording scheme for CRF reporter mice injected with retrograde tracer beads in the 
VTA. (b) 5-HT depolarizes local CRF neurons (t5=7.06 , p<0.001, One-sample t-test, n=6 cells from 4 
mice) in the BNST while hyperpolarizing CRFBNST→VTA neurons (t6=4.64, p<0.01, One-sample t-test, n=7 
cells from 6 mice). Non VTA projecting CRF neurons are hyperpolarized by 5-HT in the presence of the 5-
HT2CR antagonist RS102221 (t4=4.74, p<0.01, One-sample t-test, n=5 cells from 3 mice) (ci-ii) Schematic 
depicting infusions and recording configuration for CrfCre::ChR2BNST mice injected with retrograde tracer 
beads in the VTA.  (ciii) Representative trace of light-evoked IPSC in beaded (i.e. VTA projecting), non-
ChR2 expressing neurons in the BNST of CrfCre::ChR2 mice with retrograde tracer beads in the VTA (n=8 
cells from 3 mice) and blockade of this response by GABAzine (F11,33=53.16, p<0.001, Repeated 
Measures One-way ANOVA, n=4 cells from 3 mice). (d) Recording scheme for C57BL/6 mice with 
retrograde tracer beads in the VTA or LH (e) Representative traces of sIPSCs in BNST neurons that 
project to the VTA before and after 5-HT application for 5 cells from 4 mice (f) Bar graphs showing 
magnitude of 5-HT effect on average sIPSC frequency in BNST neurons that project to the VTA 
(t4=3.257, p<0.05, One-sample t-test, n=5 cells from 4 mice) and in BNST neurons that project to the LH 
(t5=3.027, p<0.05, One-sample t-test, n=6 cells from 3 mice) and blockade of these responses by TTX 
and RS 102221. Effects on amplitude were non-significant. (g) Experimental scheme for experiments with 
CrfCre::Intrsect-ChR2BNSTmice. (h-i,) 5-HT significantly depolarizes non-projecting CRF (“Intrsect”) neurons 
in the BNST (t6=2.501, p < 0.05, One-sample t-test, n=7 cells from 5 mice) and produces a significant 
change in membrane potential in CRF Intrsect neurons compared to all CRF neurons (t26=2.08, p<0.05, 
Student’s unpaired two-tailed t-test, n=21 cells from 14 mice for experiments in all CRF neurons and n=7 
cells from 5 mice for CrfCre::Intrsect-ChR2BNST experiments). Data are mean ± s.e.m. *P<0.05; **P<0.01; 
***P<0.001. # donates P<0.05 for the Student’s unpaired two-tailed t-test between all CRF neurons and 
CRF Intrsect neurons in panel 2h. 
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Figure 3.7: 5-HT activates inhibitory microcircuits in the BNST that modulate outputs to the LH. (a) 
Recording configuration in CRF reporter mice infused with retrograde tracer beads in the LH. (b) Average 
traces of 5-HT induced depolarization in LH projecting vs non-projecting neurons (c) Histograms showing 
5-HT induced depolarization in non-LH projecting BNST neurons (t4=4.425, p<0.05, One-sample t-test, 
n=5 cells from 3 mice) and hyperpolarization in LH-projecting neurons (t5=2.789, p<0.05, One-sample t-
test, n=6 cells from 3 mice). (d) Confocal image of retrogradely CTB-labeled VTA (red) and LH (green) 
outputs in a CRF-L10a reporter (blue). (e-f) Pie charts depicting the percentage of LH-projecting only, 
VTA-projecting only, collateralizing, and CTB-negative (unlabeled) CRF in neurons in the dorsal and 
ventral aspects of the BNST (n=6 hemispheres from 3 mice). (g) Experimental schematic depicting viral 
infusions into the BNST and retrograde tracer bead infusions into the LH of CrfCre::ChR2BNST mice. (h) 
Recording configuration in CrfCre::ChR2BNST mice with LH tracer beads (i) Representative trace of light 
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evoked IPSCs in LH projecting neurons (n=7 cells from 4 mice) and blockade of this light evoked 
response by GABAzine (n=2 cells from 2 mice). (j) Recording configuration in VTA projecting neurons in 
the BNST of C57BL/6 mice. (k-l) 5-HT has no effect on miniature IPSC frequency or amplitude in 
BNST→VTA projecting neurons (n=7 from 4 mice). (m-n) 5-HT has no effect on sIPSC frequency or 
amplitude in the presence of the 5-HT2CR antagonist RS102221 (n=5 cells from 4 mice). (o) Recording 
configuration in LH projecting neurons in the BNST of C57BL/6 mice (p) Representative traces showing 
an increase in sIPSC frequency in the presence of 5-HT for 6 cells from 3 mice (q-r) 5-HT increases 
sIPSC frequency but not amplitude in BNST→LH projecting neurons (F11,55=11.65, p<0.01, Repeated 
measures one-way ANOVA, n=6 cells from 3 mice). (s-t) 5-HT has no effect on miniature IPSC frequency 
or amplitude (n=5 cells from 3 mice). (u-v) 5-HT has no effect on sIPSC frequency or amplitude in the 
presence of RS102221 (n=6 cells from 4 mice). Data are mean ± s.e.m. *P<0.05. 
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Figure 3.8: 5-HT does not alter GABAergic transmission in CRF neurons nor does it directly excite 
non-CRF VTA projecting neurons in the BNST. (a) Recording configuration in CRFBNST neurons in a 
CRF reporter. (b-c) 5-HT has no effect on sIPSC frequency or amplitude in the total population of CRF 
neurons (n=5 cells from 3 mice). (d) Recording configuration in non-CRF, VTA projecting neurons in the 
BNST and average trace of 5-HT effect on membrane potential in non-CRF, VTA projecting neurons in 
the presence of TTX. (e) Histogram summarizing 5-HT effects on membrane potential in local and VTA 
projecting CRF neurons and local CRF neurons in the presence of the 5-HT2C receptor antagonist 
RS102221 (same data shown in Figure 3.6b) juxtaposed with the lack of effect of 5-HT on membrane 
potential in non-CRF, VTA projecting neurons (t4=0.9381, ns, One-sample t-test, n=5 cells from 3 mice). 
Data are mean ± s.e.m. **P<0.01; ***P<0.001. 
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Figure 3.9: The 5-HT2 agonist mCPP increases GABAergic but not glutamatergic transmission in 
the BNST. (a-b) mCPP increases sIPSC frequency (F15,30=1.863, p<0.001, Repeated measures one-way 
ANOVA, n=3 cells from 3 mice) but not amplitude in the BNST of C57BL/6 mice. (c-d) mCPP has no 
effect on sEPSC frequency or amplitude in the BNST of C57BL/6 mice (n=5 cells from 3 mice). Data are 
mean ± s.e.m. *P<0.05. 
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Figure 3.10: Optogenetic and Intrsectional characterization of 5-HT-CRF circuits in the BNST and 
outputs to the midbrain (a) Experimental design and recording configuration from SertCre::ChR2DRN→BNST 
mouse with retrograde tracer beads in the VTA. (b) Representative traces for 5 cells from 3 mice 
depicting the increase in sIPSCs in VTA projecting neurons in the BNST following light-evoked 5-HT 
release (c) Histogram summarizing the effect of light evoked 5-HT release on sIPSC frequency in VTA 
projecting neurons  (t4=4.890, p<0.01, One-sample t-test, n=5 cells from 3 mice). (d) Experimental 
configuration in CrfCre::Intrsect-ChR2BNST mice. (e) Representative images from 4 CrfCre::HSV-LSL1-
mCherry-flpoVTA/LH mice and 4 CrfCre::HSV-LSL1-mCherryVTA/LH mice injected with Intrsect-ChR2-eYFP in 
the BNST. (f) Cell counts of eYFP+ neurons from HSV-LSL1-flpo and HSV-LSL1-mCherry injected 
CrfCre::Intrsect-ChR2BNST mice indicating the number of non-projecting CRF neurons compared to the total 
CRF population in the dorsal (top panel; t14=1.959, ns, Student’s unpaired two-tailed t-test, n=4 mice, 8 
hemispheres per group) and ventral aspects of the BNST (bottom panel; t7=2.431, p<0.05, Student’s 
unpaired Welch’s corrected two-tailed t-test, n=4 mice, 8 hemispheres per group)  (g) Recording 
configuration and light evoked IPSC showing local GABA release from non-projecting CRF neurons in the 
BNST. (h) Sterotaxic injection of ChR2 in Crfcre mouse (i-j) Light evoked IPSCs in the VTA and LH 
indicating that CRF projections to these regions are GABAergic. Data are mean ± s.e.m. *P<0.05; 
**P<0.01. 
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Figure 3.11: Acute fluoxetine elicits aversive behavior by engaging inhibitory CRF circuits in the 
BNST. (a) Schematic of recording for in vivo fluoxetine experiments in CRF reporter mice. (b) 
Representative traces of sIPSCs in VTA projecting neurons in the BNST for 5 experiments in 2 saline-
treated mice and 7 experiments in 2 fluoxetine-treated mice. (c-d) Bar graphs showing that fluoxetine 
increases in sIPSC frequency (t10=2.55, p<0.05, Student’s unpaired two-tailed t-test, n=5 cells from 2 saline-
treated mice, n=7 cells from 2 fluoxetine-treated mice), but not amplitude (t10=0.4752, p>0.05, Student’s 
unpaired two-tailed t-test, n=5 cells from 2 saline mice, n=7 cells from 2 fluoxetine mice) in VTA projecting 
neurons in the BNST. (e) Experimental configuration for assessment of anxiety in fluoxetine-treated 
CrfCre::hM4DiBNST mice and a coronal slice of the BNST expressing hM4Di-mCherry. Scale bar: 100 µm. (f) 
Confirmatory electrophysiology in the BNST showing hyperpolarization of hM4Di-mCherry-expressing cells 
following bath application of CNO (t5=4.32, p<0.01, One-sample t-test, n=6 cells from 4 mice) (g-h) 
Chemogenetic silencing of CRF neurons attenuates fluoxetine-induced anxiety like behavior on the elevated 
zero maze (F1,30=7.086, p<0.05, Two-way ANOVA, n=10 fluoxetine/hM4Di and n=8 for all other groups) 
without any concomitant locomotor effects. (i) Experimental configuration for fear conditioning experiments 
in CrfCre::hM4DiBNST mice. (j-k) Chemogenetic silencing of CRFBNST neurons had no effect on freezing 
behavior during fear learning but prevented fluoxetine enhancement of cued fear recall (F1,17=8.73, p<0.01, 
Two-way ANOVA, n=6 mCherry/vehicle and n=5 per group for all other groups). (l) Experimental 
configuration for assessment of the role of BNST outputs to the VTA and LH in fluoxetine-induced aversive 
behavior. (m) Confocal image of the BNST from HSVCre::hM3DqBNST mice. Scale bars: 500 µm.. (n-o) 
Chemogenetic activation of BNST neurons that project to the midbrain did not impact fear acquisition but 
attenuated fluoxetine induced enhancement of cued fear recall (F1,27=7.541, p<0.05, Two-way ANOVA, n=7 
vehicle/hM3D and n=8 for all other groups). Data are mean ± s.e.m. *P<0.05; **P<0.01; ***P<0.001. 
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Figure 3.12: Pharmacological blockade of CRF1 receptors reduces fluoxetine induced aversive 
behavior and 5-HT enhancement of GABAergic transmission in the BNST. (a) Experimental 
schedule of injections and behavior. (b) CRF1R antagonist does not modify fear acquisition but reduces 
fluoxetine enhancement of cued fear recall (F1,20=13.70, p<0.01, Two-way ANOVA, n=6 per group). (c) 
Recording configuration in BNST neurons that project to the LH in C57BL/6 mice. (d) Bath application of a 
CRF1R antagonist blocks the 5-HT induced increase in sIPSC frequency in LH projecting neurons in the 
BNST (F10,30=0.2213, ns, Repeated measures one-way ANOVA, n=4 cells from 2 mice). (e) There was a 
reduction in sIPSC amplitude during 5-HT bath application and CRF1R blockade (F10,30=2.941, p<0.05, 
Repeated measures one-way ANOVA, n=4 cells from 2 mice). Data are mean ± s.e.m. **P<0.01. 
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Figure 3.13: Model of a serotonin-sensitive inhibitory microcircuit in the BNST that modulates 
anxiety and aversive learning. Serotonin inputs to the BNST activate 5-HT2CRs expressed in non-
projecting “local” CRF neurons. These “local” CRF neurons promote anxiety and fear by inhibiting 
anxiolytic outputs to the VTA and LH that are putatively GABAergic. Another discrete subset of CRF 
neurons, which are inhibited by 5-HT, send direct, inhibitory projections to the VTA and LH. These 
CRFBNST output neurons are GABAergic and putatively anxiolytic and stress buffering. Blue dashed lines 
indicate hypothesized additional synapses between CRFBNST neurons. Dashed red line indicates a 
putatively GABAergic synapse. 
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CHAPTER 4: DISCUSSION 
4.1 Potential interactions accounting for GPCR-mediated effects on anxiety 
 Recent neurobiological technology advances have provided an unprecedented toolbox for 
untangling the complex neurocircuitry involved in generating emotional behavior. Here, we used 
transgenic mouse lines and combinatorial chemogenetic and optogenetic approaches to identify discrete 
cell populations and projections involved in the expression of anxiety-like behavior. The work presented 
here focused on circuits within the BNST, as its chemical and anatomical heterogeneity make it a prime 
candidate for using these innovative tools to dissociate the specific contributions of cells and circuits to 
anxiety. Our findings revealed GPCR-mediated signaling pathways that are sufficient to drive anxiety-
related behavior, and alter the expression of a learned fear. Ultimately, identification of endogenous 
GPCRs located within these circuits will yield more effective pharmacological targets to alleviate 
pathological anxiety.  
 Results presented in Chapter 2 demonstrate that activation of Gq-coupled signaling within 
GABAergic neurons of the BNST induces anxiety-like behavior in the elevated plus maze and light-dark 
box. We did not see changes in the amount of time spent in the center of the open field box, another 
measure of anxiety, indicating that there may be context-specificity to the effects. It would be interesting 
to parse how Gq-coupled signaling in BNST VGAT neurons also alters anxiety-like behavior in assays 
independent of novelty-induced exploration. For example, data from other groups show the involvement 
of the BNST in other emotion and novelty-related behaviors, such as social interaction. Further, 
projections from the BNST to the lateral hypothalamus (LH) can directly drive feeding-related behavior, 
and this result is driven by GABAergic neurons of the ventral BNST (Jennings, Rizzi, et al., 2013). As the 
BNST has direct projections to hindbrain nuclei known to be involved in the regulation of autonomic 
function, such as the parabrachial nucleus (PBN) and locus coeruleus (LC), it would be useful to see how 
activation of discrete signaling cascades contribute to the non-emotional aspects of anxiety. Previous 
reports indicate that manipulations of the BNST can alter autonomic activity, including respiration rate and 
heart rate, though there appears to be topographical differences to the direction of these effects (Kim et 
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al., 2013; Crestani et al., 2013). Our studies did not assess how broad stimulation of Gq-induced anxiety 
behavior alters the autonomic components of anxiety. This would be of interest given that recent work has 
demonstrated that direct stimulation of BNST outputs can drive anxiety-like behavior in a manner that is 
independent of the associated changes in autonomic activity (Kim et al., 2013).  
 In BNST VGAT neurons, DREADD-induced changes in anxiety were selective to the Gq-coupled 
DREADD, as neither Gi-coupled nor Gs-coupled DREADD receptor activation in the BNST evoked acute 
changes in anxiety-like behavior. This is particularly interesting, given that previous research using 
pharmacological inhibition of the BNST, or optogenetic inhibition of the dorsolateral BNST, can reduce 
anxiety-like behavior in exploratory-based assays (Kim et al., 2013). However, it is known that stress 
exposure increases c-fos expression in the BNST, and I presented in Chapter 3 elevated BNST activity 
during shock exposure, so it remains possible that our assays were not stressful enough to engage BNST 
function. If this were the case, suppression of low BNST activity may be insufficient to observe changes in 
anxiety-like behavior. Similar results were previously observed with respect to BNST-induced effects on 
heart rate. Inhibition of BNST synaptic activity using CoCl2 had no effect on baseline heart rate, but 
pretreatment with CoCl2 blocked increases in heart rate induced by intravenuous injection of 
phenylephrine (Crestani et al., 2010). Interestingly, these data suggest an inhibitory role of broad BNST 
activation on cardiac activity, but nonetheless represent that baseline inhibition of the BNST was 
insufficient to alter a cardiovascular phenotype. Given this, I suspect that inhibition of BNST VGAT neuron 
activity using a Gi-coupled DREADD during a stress-inducing stimulus may blunt subsequent increases in 
anxiety-like behavior.  
Critically, the effects we observed in our experiments using DREADD-based approaches rely on 
activation of postsynaptic GPCR signaling. This does not suggest that any peptide bound to a Gi-coupled 
receptor located within the BNST will be sufficient to reduce anxiety-like behavior. Heterogeneity in 
localization of receptors is important to take into account. For example, the canonically anti-stress peptide 
neuropeptide Y (NPY) binds to a family of Gi-coupled receptors (Y1-Y5), some of which are located within 
the BNST. However, genetic deletion of Y2 receptors in various nuclei associated with stress can reduce 
anxiety-like behavior (Tasan et al., 2011). While Y2 receptor deletion in the BNST does not alter anxiety, 
Y2 receptor deletion in the CeA reduces anxiety, which could be mediated by alterations in presynaptic 
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activity in CeA afferents to the BNST (Tasan et al., 2011). NPY in the BNST suppresses GABA release 
through activity at presynaptic Y2 receptors (Kash & Winder, 2006). Thus, while Y2 receptors are present 
within the BNST and are coupled to Gi signaling pathways, activation of Y2 receptors could produce a 
disinhibition of the BNST through a reduction in inhibitory signaling. Further, NPY interacts with CRF-
expressing cells of the BNST to suppress alcohol intake in mice (Pleil et al., 2015). These results highlight 
the importance of identifying postsynaptic signaling pathways and endogenous receptors that can be 
targeted to manipulate these defined pathways.  
The opposing functions of CRF and NPY in the BNST could partially explain the lack of changes 
in anxiety-related behavior following stimulation of Gs-coupled DREADDs in the BNST. In particular, CRF 
and NPY signaling can produce opposing effects on inhibitory transmission in the BNST and interactions 
between these two peptide systems modulate alcohol consumption in rodents and non-human primates 
(Kash & Winder, 2006; Pleil et al., 2015). In a study assessing the activity of agouti-related peptide 
(AgRP) neurons of the hypothalamus, activation of the Gq-coupled DREADD induced behavioral changes 
in feeding were mediated by the release of neurotransmitters, while behavioral effects elicited with the 
Gs-coupled DREADD were mediated by the release of neuropeptides (Nakajima et al., 2016). Thus, 
discrete GPCR-mediated signaling pathways contribute to the regulation of neuronal signaling 
mechanisms that ultimately lead to neuropeptide and neurotransmitter release.  Beyond CRF and NPY, 
BNST neurons express other neuropeptides, including dynorphin, nociceptin, PACAP, and 
cholecystokinin (CCK). It is possible that broad stimulation of BNST VGAT neurons results in the release 
of multiple neuropeptides that could occlude effects that would be seen by stimulation of neuropeptide 
populations individually. However, given that the bulk of BNST neurons are GABAergic, broad expression 
of hM3Dq in our study may have biased signaling towards GABA release. Future experiments assessing 
the contribution of Gs-coupled signaling in discrete neuropeptide defined subpopulations of BNST 
neurons to anxiety-related behavior will better dissect the unique involvement of peptide systems. In 
addition to targeting G protein signaling pathways in discrete neuropeptide populations, it would be useful 
to use the single-cell characterization described in Chapter 2, or an RNA sequencing approach, to identify 
the overlap of peptide-expressing cell populations in the BNST. While the numerous genetic and 
pharmacological behavioral studies described above demonstrate the importance of receptors and 
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peptide expression in the BNST contributing to an array of behaviors, it is unclear of the degree of overlap 
of the peptide expressing populations themselves. A rigorous characterization of single-cell expression 
profiles in the BNST will yield valuable insights into the complexities of peptide expressing populations, 
and could also determine how peptide expression profiles are altered by multiple types of stress-inducing 
stimuli. 
In Chapter 3 we demonstrated that chemogenetic inhibition of CRF-expressing cells of the BNST 
disrupts SSRI-induced increases in fear, but we did not assess the contributions of Gq or Gs-induced 
effects on acute anxiety in CRF neurons. However, a recent paper observed that chemogenetic inhibition 
of BNST CRF-expressing neurons with the Gi DREADD following repeated cycles of drinking in the dark 
(DID) reduces anxiety-like behavior in the elevated plus maze, while stimulation with the Gs DREADD 
does not alter anxiety (Pleil et al., 2015). It is important to note, however, that these experiments were 
conducted following chronic alcohol exposure and not under naïve conditions. Chronic exposure to 
alcohol is known to produce an array of changes in excitability and receptor expression of neurons within 
the extended amygdala, which has been extensively characterized in both the CeA and BNST. These 
stress-induced changes in receptor expression could ultimately affect the behavioral consequences of G 
protein-mediated activity. For example, a study demonstrated that while the actions of CRF1R and 
CRF2R binding in the nucleus accumbens are initially rewarding, exposure to severe stress reverses the 
response such that local infusion of CRF receptor agonists to the nucleus accumbens is aversive (Lemos 
et al., 2012).  
 CRF-expressing neurons of the BNST have recently been demonstrated to be directly involved in 
alcohol drinking behaviors. The reduction in alcohol drinking induced by BNST CRF neuron inhibition may 
be mediated through BNST CRF projections to the VTA (Rinker et al., 2015). In this study, antagonism of 
the CRF1 receptors in the VTA reduced alcohol intake, which could be recapitulated with agonism of the 
CRF2 receptor in the BNST. Simultaneous antagonism of CRFR1 and CRFR2 did not affect alcohol 
intake, suggesting that intact signaling through CRFR2 is required for CRFR1-induced effects on alcohol 
consumption. Chemogenetic inhibition of CRF-expressing VTA neurons did not suppress alcohol intake. 
However, chemogenetic inhibition of CRF terminals originating from the BNST through infusion of CNO to 
the VTA was sufficient to blunt alcohol drinking. This study identified a discrete output of BNST CRF 
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neurons to the VTA that may be sufficient to drive alcohol drinking (Rinker et al., 2015). This finding is 
important, as we show in Chapter 3 that BNST CRF neurons have GABAergic projections to the VTA, 
and previous research identified that optogenetic activation of GABAergic projections from the BNST to 
the VTA reduces anxiety-like behavior (Jennings, Sparta, et al., 2013). Given the wealth of literature 
demonstrating stress- or anxiety-induced increases in alcohol intake, one may suspect that stimulation of 
an anxiolytic pathway would suppress alcohol consumption. It is important to consider, however, that 
BNST CRF neurons are only a subset of the GABAergic BNST projections to the VTA, so it remains 
possible the CRF projection subset may alter anxiety-related behavior differently than the GABAergic 
population as a whole. Heterogeneity in the anterior and posterior VTA contributions to alcohol drinking 
further complicate the effects of GABAergic signaling in the VTA on alcohol consumption (Melón & 
Boehm, 2011). Regardless, future work assessing the contributions of GABA or CRF release from BNST 
CRF neurons in driving alcohol drinking or anxiety-like behavior using the Gq and Gs DREADD variants 
will yield better information in the involvement of transmitter and peptide systems in behavioral outcomes. 
Further, as we observe that local CRF neurons can inhibit VTA-projecting neurons in the dorsal BNST, 
which are primarily GABAergic, it is possible that CRF neurons with local inhibitory synapses will 
differentially affect behavior relative to stimulation of CRF neurons that project beyond the BNST. It will be 
interesting to use an intersectional strategy to selectively label CRF neurons using either DREADDs or 
light-gated opsins to target the behavioral contributions of these projection-defined subpopulations.   
 It is important to consider that the investigative approaches described thus far have relied on a 
pre-determined transmitter or peptide to define a neural population of interest. While the selection of the 
transmitter, peptide, or receptor is guided by knowledge of that marker’s function, defining a neural 
population entirely by any one marker provides both benefits and drawbacks. For example, in some 
cases, such as AgRP and pro-opiomelanocortin (POMC) neurons of the arcuate nucleus, peptide defined 
populations can be largely non-overlapping and can drive opposing behavioral effects (Aponte et al., 
2011; Krashes et al., 2011). In this situation, AgRP and POMC expression serves as a good molecular 
marker for targeting molecularly and behaviorally discrete cell populations. A drawback to this approach, 
however, is that stimulation of the entire peptide population may not represent how the neural population 
is activated by the appropriate stimulus. Heterogeneity within a peptide-specific population may still exist. 
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In agreement with this, we observed in Chapter 3 that CRF neurons of the BNST can be differentially 
activated or inhibited by 5-HT, and differences in circuit connectivity suggests that these connections may 
differentially affect behavioral output in a manner that may not be captured by stimulation of the entire 
population. Further, as described above, neurons may express numerous neuropeptides, so defining a 
cellular population by any one peptide may not truly capture the peptide or transmitter that is driving a 
potentially observed behavioral effect. Nonetheless, if stimulation or inhibition of a peptide-defined cell 
type is sufficient to drive a behavior, then targeting a receptor enriched in this population to selectively 
modulate neuronal activity may prove to be a useful therapeutic target. In contrast to defining cells by 
peptide identity, neurons can also be defined by activity-dependent identity through the use of 
intermediate early genes (IEGs). Such an approach has commonly been used in the identification of an 
engram, or neural ensemble that encodes a particular memory (X. Liu et al., 2012; Trouche et al., 2016; 
Ramirez et al., 2015).    
4.2 Gq-induced LTD in the BNST and implications for anxiety treatments 
In addition to using chemogenetics to identify behavioral manifestations upon engagement of 
endogenous signaling pathways, I observed that ex vivo stimulation of the hM3Dq DREADD induced a 
long-term depression (LTD)-like state of electrically evoked excitatory postsynaptic currents (eEPSCs). 
Previous electrophysiological studies conducted within the BNST show that agonists for various Gq-
coupled receptors can induce an LTD of EPSCs, including the α1-adrenergic receptor and the Group 1 
metabotropic glutamate receptors (mGluR) mGluR1 and mGlurR5 (Grueter et al., 2006; Grueter, 
McElligott, & Winder, 2007; Z. A. McElligott & Winder, 2008; Z. A. McElligott et al., 2010). These results 
are in agreement with findings from another study showing that stimulation of hM3Dq-expressing cells in 
the dorsal hippocampus induces an LTD, while hM4Di activation can alter LTP development (López et al., 
2016). In addition to inducing an LTD-like state, noradrenergic signaling in the BNST can depolarize 
neurons via α1-adrenergic receptors and can acutely facilitate spontaneous EPSCs (sEPSCs) (Dumont & 
Williams, 2004; Z. A. McElligott et al., 2010). This facilitation of glutamatergic transmission requires 
activity of CRF1 receptors (Z. A. McElligott et al., 2010). Of note, however, α1 signaling in the BNST can 
facilitate GABA release and increase the frequency of inhibitory postsynaptic currents (IPSCs), possibly 
through depolarization of local inhibitory interneurons of the BNST (Dumont & Williams, 2004).  
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The complex interactions of neurotransmitters and CRF in the BNST are not limited to 
noradrenergic signaling. Dopamine (DA) release in the BNST facilitates glutamatergic signaling in a 
manner that requires CRF1 receptor activation (Kash et al., 2008). Interactions between the DA and CRF 
systems are required for CRF-potentiated startle responses (Meloni et al., 2006). Intriguingly, the 
dopaminergic afferents to the BNST arise from both the VTA and the ventrolateral periaqueductal gray 
(vlPAG) (Meloni et al., 2006). This connectivity positions the BNST as a relay center integrating circuits 
involved in pain, reward, motivation, and emotion. While I did not target projection-defined populations of 
neurons in the BNST, it will be interesting in future experiments to use the single-cell qPCR approach 
described in Chapter 2 to identify how projection-defined neurons of the BNST differ with respect to 
receptor expression. If we are able to identify unique receptor targets on these cells, we may be able to 
modulate defined behaviors while minimizing other behavioral side effects. A similar approach was used 
recently to identify genetic differences between basolateral amygdala (BLA) neurons that project to the 
nucleus accumbens (NAc) and the CeA  (Namburi et al., 2015). Likewise, transgenic mouse lines that use 
an IEG promotor to drive expression of Cre recombinase in a tamoxifen- and activity-dependent manner, 
such as the Fos-Cre or Arc-Cre lines, would allow for targeting of neurons that were active during a 
temporally defined task. These IEG-based lines could be further crossed with a floxed-stop reporter line 
that produces fluorophore expression in Cre-expressing cells, thus allowing fluorophore expression in 
neurons that were active during a discrete time point. Such a strategy would allow for isolation of 
stimulus-responsive neurons, as identified by fluorescence, using FACS or similar sorting approach. 
Sequencing of isolated populations could then identify receptors or signaling targets that are differentially 
expressed in responsive neurons compared with non-responsive neurons. Perhaps manipulations of 
these activity-defined cell types could better prevent subsequent activity and aversive behavioral 
experiences. This and similar strategies have been employed to assess the contributions of neurons in 
the hippocampus and lateral amygdala active during fear conditioning training to driving later fear 
expression (X. Liu et al., 2012; Rashid et al., 2016; Yiu et al., 2014). Generally, subsequent stimulation of 
neuronal populations engaged during fear learning is sufficient to induce fear-related behavior, though it 
can be context-dependent. In keeping with this, the temporal delay between fear training in various 
contexts can alter the degree to which overlapping neurons are recruited to the same fear memory (Cai et 
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al., 2016). The mechanisms underlying the overlap may prove a critical target in preventing the 
development of generalized fear behavior. Ongoing studies will probe the contributions of these defined 
populations to emotional behavior and how perturbation of this plasticity may disrupt the progression to a 
disease state.  
It is of interest that Gq-induced LTD in the BNST requires CB1 receptor activity given the 
potential for cannabinoids as a pharmacotherapy for treating anxiety disorders. The endocannabinoids 
anandamide (AEA) and 2-arachidonoylglycerol (2-AG) both primarily act on the CB1 receptor within the 
brain, while CB2 receptor expression is limited to peripheral structures. Unlike classic neurotransmitter 
release, endocannabinoids are released by the postsynaptic cell and act on presynaptic CB1 receptors to 
dampen presynaptic transmitter release. This form of retrograde transmission generates a negative 
feedback loop. Importantly, AEA is generated from diacylglycerol (DAG), which is created through the 
hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2). This reaction is catalyzed by PLC, which is 
downstream of the Gq signaling pathway. However, a separate synthesis pathway involving 
phospholipase D has also been observed (Freund et al., 2003). This synthesis pathway would suggest 
that activation of the Gq-coupled DREADD in BNST VGAT neurons leads to the generation of 
endocannabinoids, ultimately leading to presynaptic inhibition of transmitter release. As our ex vivo 
electrophysiological results indicate that CB1 receptor inhibition can block the reduction in evoked 
excitatory postsynaptic currents induced by Gq activation, it suggests this finding is mediated through the 
action of endocannabinoids.  
In my study I did not target specific excitatory inputs to the BNST. Possible glutamatergic 
afferents in the BNST arise from the BLA, PFC, and ventral hippocampus. Further, given the broad and 
robust expression of the CB1 receptor throughout the brain, it remains unclear which particular excitatory 
input contributed to the LTD in the postsynaptic cell. Further, endocannabinoid signaling can result in 
depolarization induced suppression of inhibition (DSI), resulting in a reduction of inhibitory transmission 
on the postsynaptic cell. While I only assessed glutamatergic events onto BNST VGAT neurons, it is likely 
that GABAergic transmission was reduced as well. Similarly, I did not target Gq-DREADD expression 
selectively in BNST interneurons or projection neurons. Future studies assessing the contributions of Gq 
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signaling-induced reductions in synaptic transmission on projection-defined BNST neurons will better 
parse the circuits underlying the net increase in anxiety-like behavior. 
The involvement of endocannabinoid release in modulating the activity of BNST neurons is 
interesting given the role of endocannabinoids in the stress response and anxious behavior (Hill & 
Tasker, 2012; Hill et al., 2010). Knockout of the CB1 receptor, or systemic administration of CB1 receptor 
antagonists, blunts the HPA axis response to acute stressors, though in a context dependent manner 
(Patel et al., 2004; Cota et al., 2007). Antagonism of CB1 receptors leads to a rise in c-fos expression in 
the PVN, which contains the CRF-expressing neurons that initiate the HPA stress response. Activation of 
PVN CRF neurons ultimately leads to the release of cortisol in humans, or corticosterone in rodents, from 
the adrenal glands. Endocannabinoid release can activate CB1 receptors on glutamatergic terminals that 
synapse onto PVN CRF-expressing neurons, thereby providing a feedback mechanism to inhibit HPA 
axis activity (Di et al., 2003). While I did not assess CB1 receptor involvement within the BNST in 
contributing to HPA axis activity, the CB1 receptor-mediated LTD induced by Gq activation in the BNST is 
of interest given that the BNST has direct projections to the PVN. It would be of interest to use retrograde 
viruses, such as an HSV-Cre injected into the PVN, followed by a cre-inducible hM3Dq DREADD into the 
BNST, to selectively activate Gq signaling in PVN-projecting BNST neurons. Such a study would provide 
mechanistic insight into how the BNST projection to the PVN contributes to the generation of anxiety 
states and how this functional connectivity is modulated by the release of endocannabinoids.  
Together, our findings are in agreement with previous studies within the BNST demonstrating that 
Gq-induced signaling leads to CB1 receptor-mediated LTD (McElligott et al., 2010; Grueter et al., 2006; 
Glangetas et al., 2013). Prolonged changes in synaptic activity could be associated with the development 
of psychiatric disease. Indeed, altered CB1 receptor signaling has been implicated in anxiety-related 
psychiatric conditions, such as PTSD. A study in patients diagnosed with PTSD showed elevated 
expression of CB1 receptors throughout the brain, while levels of anandamide and cortisol were reduced 
(Neumeister et al., 2013). Although our results suggest that CB1 receptors may be an interesting target 
for modulating the activity of BNST neurons that are sufficient to drive anxiety, targeting CB1 receptors for 
the treatment of anxiety-related conditions poses many challenges. CB1 receptors are broadly and 
densely expressed throughout the brain (Herkenham et al., 1990; Glass et al., 1997), thus, large-scale 
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dampening of synaptic transmission mediated by CB1 receptor activity could produce a variety of 
undesirable side effects. Indeed, a clinical trial assessing the efficacy of rimonabant, a CB1 receptor 
antagonist, in reducing a number of cardiovascular diseases needed to be terminated due to multiple 
psychiatric side effects (Topol et al., 2010). Patients receiving rimonabant reported significantly increased 
gastrointestinal problems, neuropsychiatric conditions, suicidal ideation, and multiple participants 
completed suicide. Other pharmacological manipulations of endocannabinoid signaling, such as reuptake 
blockers, offer alternative approaches that may yield more beneficial results (Griebel & Holmes, 2013; 
Micale et al., 2013).  
4.3 Considerations of brain-wide metabolic mapping during behavioral states 
Interestingly, we observed with DREAMM imaging that activation of Gq-coupled signaling altered 
metabolic activity throughout the brain in regions associated with anxiety in human patients experiencing 
anxiety. Specifically, acute activation of the Gq-DREADD in BNST VGAT neurons of mice resulted in 
enhanced activity within the BNST, the VTA, the BLA and CEA, the PBN, LC, and other areas of the 
hindbrain. While the BNST has direct projections to many of these structures, we also observed elevated 
activity in the regions that do not receive direct BNST innervation, such as the PFC. The PFC sends 
afferents to the BNST, so enhanced activity in the PFC may reflect the engagement of polysynaptic 
feedback loops. It would be interesting to assess in future studies if neurons that project from the PFC to 
the BNST are directly activated following activation of the hM3Dq DREADD in the BNST. This could be 
accomplished by injecting both a retrograde trafficking virus encoding a fluorophore along with a virus 
encoding an hM3Dq DREADD into the BNST. Following CNO-induced activation of the hM3Dq, staining 
for the IEG c-fos or arc could be used to assess changes in activity of the defined populations of the PFC. 
This would be particularly useful given that while DREAMM imaging does provide insights into changes of 
metabolic activity of a region, it is based upon the uptake of glucose, which occurs at both pre- and 
postsynaptic sites. Therefore, I cannot say with certainty whether the changes in metabolic activity 
represent alterations in pre- or postsynaptic responses. Similarly, the genetic identity of a postsynaptic 
cell would be unclear, making it impossible to discern whether cells with increased activity represent local 
interneurons, projecting neurons, or a combination of the two.  
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While there are limitations and caveats for metabolic mapping, a biological map of altered 
metabolic activity throughout the brain provides insights into the circuits engaged during emotional and 
behavioral states. If we are able to generate an endophenotype of the brain-wide metabolic activity of 
disease states, then we may be able to use this readout to assess whether treatments have indeed 
restored normal brain-wide network patterns of activity. Future studies will assess how engagement of the 
other G protein coupled pathways alters metabolic demand throughout the brain. These findings can be 
expanded upon by assessing how perturbations of BNST activity following stressors or withdrawal from 
drugs of abuse and alcohol affect network function. Of particular interest, chronic activation of GPCR 
signaling can induce metabolic changes that differ from acute activity. For example, DREAMM imaging 
results following acute activation of Gq-coupled signaling in DR 5-HT neurons using CNO produces a 
pattern of activity that differs from results observed when Gq signaling was chronically activated by CNO 
availability in drinking water (Urban et al., 2015). Specifically, while acute Gq signaling within DR 5-HT 
neurons elevates metabolic activity in areas of forebrain cortex including somatosensory and motor 
cortices, chronic treatment with CNO results in a reduction in metabolic activity of somatosensory and 
motor cortex (Urban et al., 2015). The driving force behind the differences remains to be determined. It is 
unclear if the broad network effects are the result of prolonged stimulation of 5-HT release from DR 
serotonergic neurons, if Gq-mediated events within 5-HT DR neurons produce long-term changes in 
release, or if there is a combination of long-term plasticity induced alterations throughout the entire 
network resulting in broad functional differences. It will be informative in future studies if chronic CNO 
treatment is coupled with either systemic or local application of particular receptor antagonists to assess 
the contributions of both neurotransmitter modulation and postsynaptic GPCR-based activity on 
subsequent network responses. If using the metabolic map as an endophenotype of a disease state, then 
this approach will provide ways of targeting the unique signaling contributions that generate prolonged 
aberrations of metabolic network patterns. 
4.4 Serotonin interactions with CRF in the BNST to generate anxiety and implications for 
therapeutics 
Using a single-cell qPCR approach to identify endogenous Gq-coupled receptors expressed 
within BNST VGAT neurons, I generated a list of Gq coupled receptors expressed by BNST VGAT 
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neurons (Figure 2.6). We ultimately focused on the 5-HT2C receptor as serotonin has been widely 
implicated in anxiety and emotional disorders, and the colocalization of CRF containing neurons and 5-HT 
terminals in the BNST provided complex interactions between the 5-HT and CRF systems. Although there 
was robust expression of mGluR1 and mGluR5, these receptors are broadly expressed at both pre- and 
postsynaptic sites throughout the brain, so they are unlikely candidates for modulating discrete behaviors 
within a nuclei of interest. It will be interesting for future studies to probe the contributions of M1 receptor 
and neurotensin 2 receptor signaling in the BNST in driving anxiety-like states. We identified that agonism 
of the 5-HT2C receptor of the BNST in vivo was sufficient to induce an increase in startle amplitude, 
indicative of an increase in anxiety-like behavior. This is of high interest as it demonstrates that 5-HT 
signaling through actions at Gq-coupled receptors in the BNST can drive anxiety states. Coupled with the 
data described above, these data generated a locus within the BNST for investigating the role of 5-HT 
signaling on discrete cell types as defined by neurotransmitter and neuropeptide content. 
 In particular, given that selective serotonin reuptake inhibitors (SSRIs) are the most common 
pharmacological treatment for an array of anxiety and depression disorders, it is of interest that we 
identified acute signaling via the 5-HT2C receptor in the BNST is sufficient to promote anxiety-like 
behavior. In Chapter 3 we demonstrate that 5-HT has opposing effects on membrane polarization in 
BNST CRF neurons that is dependent on 5-HT2R expression with respect to connectivity. 5-HT-induced 
depolarization of BNST CRF neurons could be blocked by antagonism of the 5-HT2C receptor. This effect 
was only identified in BNST CRF neurons that do not project to the LH or VTA, thus highlighting the 
anatomical specificity of the effect. Intriguingly, optical stimulation of serotonergic inputs to the BNST 
increased 5-HT release as assessed ex vivo and increased anxiety and fear expression in vivo. These 
findings were critical as they provide a node for 5-HT induced increases in anxiety and fear behavior. 
Further, they identify opposing effects of 5-HT on membrane properties of BNST CRF-expressing cells, 
which are known to be located near serotonergic fibers. 
 These findings build on the long observed connection between serotonergic activity and 
emotional behavior. Following benzodiazepines, which act as an agonist at the GABA-A receptor, the 5-
HT1A receptor partial agonist buspirone became the first pharmacotherapeutical option for patients with 
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generalized anxiety disorder (GAD) (Goldberg & Finnerty, 1979; Rickels et al., 1982; Griebel & Holmes, 
2013). While the therapeutic efficacy of buspirone did not translate to all anxiety-related conditions, such 
as panic disorder, it pointed to the involvement of serotonin receptors as candidate targets for regulating 
emotional disorders. The first-line pharmacotherapeutic for multiple anxiety and depression conditions 
today remains SSRIs that enhancing synaptic levels of 5-HT through inhibition of the presynaptic 
serotonin transporter. 
As previously observed, acute SSRI pretreatment can exacerbate cued fear recall, and we 
identified that systemic treatment with a CRF1 receptor antagonist is sufficient to block SSRI-induced 
potentiation of fear. These data position CRF1 receptor antagonists as a potential pharmacotherapeutic 
option for alleviating the acute aversive effects of SSRIs. Patients taking SSRIs have cited aversive side 
effects, as well as an exacerbation of preexisting symptoms, as contributors to their decisions to abstain 
from continued SSRI treatment. Therefore, coupling CRF1 receptor antagonism to the early stages of 
SSRI-based treatment regimens may aid in reducing aversive side effects and lead to better adherence to 
SSRI treatment schedules.  
 It is worth noting that the CRF1 receptor has been a previous target for alleviation of symptoms in 
patients with anxiety, depression, or addiction, with various results. Early preclinical studies demonstrated 
CRF1 receptor antagonism reduces multiple aversive conditions in rodents and non-human primates 
without changes in HPA axis activity. The first small clinical trial in human subjects with the CRF1 
receptor antagonist R121919 showed a reduction in the Hamilton Depression Rating Scale (HAM-D) in 
some patients suffering from major depressive disorder (MDD) (Zobel et al., 2000). However treatment at 
a variety of doses remained ineffective or worsened symptoms in some patients (Zobel et al., 2000). This 
study was also limited by its lack of a placebo control group, randomization in group assignment, and 
blinding of investigators. A subsequent clinical trial using a different CRF1 receptor antagonist, CP-
316,311, saw no differences in HAM-D scores in patients with MDD relative to a placebo control, while 
the SSRI sertraline improved symptoms (Binneman et al., 2008). Similarly, the CRF1 receptor antagonist 
pexacerfont failed to reduce anxiety relative to a placebo in patients suffering from GAD (Coric et al., 
2010).  
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While clinical trial results aiming to treat anxiety and depression have had discouraging results, 
CRF1 receptor antagonists may still hold promise for the treatment of diseases featuring an exacerbated 
response to discrete stressors that result in elevated CRF levels. That is, if a stressor evokes CRF 
release, then antagonism of CRF receptors may still present a promising avenue for the alleviation of 
stress-induced aversive states. In accordance with this, rats receiving multiple infusions across days of 
the CRF receptor agonist urocortin (Ucn) into the BLA show elevated anxiety-like behavior that persists a 
month following the last Ucn injection. The persistent behavioral changes are accompanied by alterations 
in synaptic transmission within the BLA, including increased excitability and a reduction in inhibitory 
postsynaptic transmission (Rainnie et al., 2004). Co-administration of Ucn and the NMDA receptor 
antagonist AP-5 abolished the behavioral and subsequent inhibitory transmission changes normally 
induced by chronic Ucn treatment (Rainnie et al., 2004). Critically, these data suggest that blockade of 
CRF receptors during periods of elevated CRF release induced by stressors, particularly long-lasting 
stressors that generate sustained CRF release, may be able to prevent the long-term plasticity effects 
that remain in the absence of continued CRF secretion. The blockade of Ucn-induced plasticity through 
inhibition of NMDA receptors is also noteworthy in light of evidence that NMDA receptor antagonism with 
ketamine has shown promise as a way to generate long-lasting improvements in mood in patients 
suffering from major depression (Murrough, 2016; Zarate et al., 2006). 
In keeping with this, a study comparing rodent and human responses to antagonism of CRF1 
receptors with NBI-34041 observed reductions in stress-induced ACTH levels in rodents and reduced 
ACTH and cortisol following a Trier Social Stress Test (TSST) in human subjects (Ising et al., 2007). 
However, intravenuous administration of CRF increased ACTH and cortisol levels despite CRF1 receptor 
antagonism (Ising et al., 2007). Together, these results highlight the importance of CRF1 receptor 
antagonism in reducing stress-evoked increases in behavior that are upstream of increases in stress-
induced CRF release. Basal levels of ACTH and cortisol remain unaltered with CRF receptor antagonism, 
again pointing to the role of these receptors in blocking CRF receptor-induced increases in downstream 
ACTH and cortisol release. These findings are particularly intriguing in light of our finding that CRF1 
receptor antagonism can reduce SSRI-induced increases in learned fear. In Chapter 3 we presented data 
showing that we observed increased electrical activity during fear conditioning within the BNST as 
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assessed by in vivo electrophysiology, and immunohistochemical analysis revealed that that serotonergic 
DR neurons projecting to the BNST had elevated c-fos immunoreactivity relative to non-shocked mice. 
Further, we saw that 5-HT release in the BNST can depolarize a subpopulation of CRF-expressing cells 
through a postsynaptic 5-HT2C receptor-dependent mechanism. Given that the BNST has direct 
projections to the paraventricular nucleus of the hypothalamus (PVN), it would be interesting to assess if 
increases in ACTH or corticosterone levels in mice following shock exposure require activity of BNST 
CRF neurons, and if 5-HT input arising from the DR onto BNST CRF neurons contributes to modulation of 
downstream stress hormone release. Such a study would be of particular relevance given the broad 
disruption of HPA axis activity across mood disorders.  
Although the clinical efficacy of coadministration of CRF1 receptor and SSRIs remains to be 
explored, we have identified that broad suppression of BNST CRF neurons reduces the acute aversive 
effects of SSRI pretreatment and these neurons may yield other promising targets. GPCRs enriched in 
BNST CRF neurons may provide useful targets for blunting the adverse effects of acute elevations of 5-
HT levels. Given that data with DREADDs have demonstrated that Gs-mediated signaling pathways 
contribute to peptide release, functionally opposing this signaling pathway in BNST CRF neurons may 
provide another potential avenue for treatment (Nakajima et al., 2016). Gs-mediated signaling results in 
the downstream activation of adenylyl cyclase and the production of cyclic AMP (cAMP), ultimately 
stimulating protein kinase A (PKA) activity and further downstream phosphorylation events. Conversely, 
Gi-mediated signaling inhibits activity of adenylyl cyclase, thus opposing the actions of Gs-coupled 
GPCRs. In light of this, stimulation of Gi-coupled receptors within BNST CRF neurons, or within neurons 
that express the CRF1 receptor may provide a target to alleviate anxiety and fear that is mediated 
through BNST CRF neuron circuitry. In agreement with this, I show in Chapter 3 that activation of Gi-
coupled signaling using the hM4Di DREADD in BNST CRF neurons blocks SSRI-induced increases in 
fear. Further, NPY is known to functionally oppose the actions of CRF and acts on a family of Gi-coupled 
receptors. Preclinical research has observed promising anxiolytic effects of NPY and its receptors across 
multiple anxiety assays, and NPY over-expressing mice show an anxiolytic phenotype, so modulation of 
NPY signaling may be a useful future target for alleviation of emotional disorders discussed here. Future 
studies assessing how NPY interacts with SSRI-induced changes in anxiety and fear will provide more 
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insight into discrete cells and receptors for alternative alleviations of SSRI-induced adverse treatment 
outcomes.  
Given our findings that 5-HT2C receptor expressing neurons in the BNST contribute to anxiety-
like behavior, it is interesting that a pair of recent studies assessing anxiety and depression in cancer 
patients observed reductions in both of these measures following treatment with the 5-HT2A receptor 
agonist psilocybin (Griffiths et al., 2016; Ross et al., 2016). 5-HT2A receptors, like 5-HT2C receptors, are 
Gq-coupled and are densely expressed in the prefrontal cortex as well as the BNST (Hammack, Guo, et 
al., 2009). In both studies, a single dose of psilocybin, coupled with psychotherapy, reduced scores of 
anxiety and depression as long as six months following treatment. While both studies assessing clinical 
efficacy of psilocybin were limited to patients with cancer, it remains encouraging that select modulation 
of 5-HT receptor activity can produce long-lasting and rapid reductions in anxiety and depression. In a 
separate study assessing the effects of psilocybin on the blood oxygen level-dependent (BOLD) response 
using functional magnetic resonance imaging (fMRI), acute treatment led to reductions in BOLD signals in 
the medial PFC (Carhart-Harris et al., 2012). However, this study was conducted in healthy volunteers, so 
it is unclear if network activity patterns following psilocybin would differ in patients suffering from anxiety 
or depression. As the BNST expresses 5-HT2A receptors and receives glutamatergic afferents from the 
PFC, it would be of interest to assess if the therapeutic benefits of 5-HT2A receptor agonism require 
activity within the BNST. Further, it is unknown whether 5-HT2A receptor expression is limited to BNST 
interneurons or projection neurons. As SSRI treatment enhances synaptic 5-HT levels, thereby increasing 
receptor binding at a variety of 5-HT receptor families, it will be important to discern how 5-HT2A receptor 
activity within the BNST contributes to anxiety-like behavior.  
 Altogether, the work described in this dissertation identifies novel signaling contributions within 
the extended amygdala to anxiety-related behavior and characterizes discrete cell types and projection 
pathways involved in mediating the exacerbation of fear following acute treatment with SSRIs. Untangling 
the precise circuits underlying both these conditions and the effects of phamaracological therapy on the 
physiology of these circuits is critical as SSRIs remain the predominant form of treatment for anxiety and 
depression disorders. Here we have shed light on some of the signaling pathways and interactions 
between 5-HT and CRF within the BNST in generating an anxious state. We have also identified a 
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brainwide map of metabolic activity that correlated with a time point of increased anxiety-like behavior 
following activation of Gq-coupled signaling in GABAergic neurons of the BNST. This biomarker may 
serve as an endophenotype to recognize regions involved in anxiety, and further studied characterizing 
metabolic activity of these same regions at various time points along the progression to pathology may be 
useful in determining what structures to target to restore baseline circuit activity. As we better discern the 
exact contributions of transmitters, peptides, and network function in generating aversive states, we will 
provide targets for more selective, and more efficacious, means of treating an array of psychiatric 
illnesses.    
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